UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
CERTIFIED SHAREHOLDER REPORT OF REGISTERED MANAGEMENT INVESTMENT COMPANIES
Investment Company Act file number:
811-21784
| Name of Fund: | | BlackRock Enhanced Equity Dividend Trust (BDJ) |
| Fund Address: | | 100 Bellevue Parkway, Wilmington, DE 19809 |
Name and address of agent for service: John M. Perlowski, Chief Executive Officer, BlackRock Enhanced Equity Dividend Trust, 50 Hudson Yards, New York, NY 10001
Registrant’s telephone number, including area code: (800)
882-0052,
Option 4
Date of fiscal year end: 12/31/2024
Date of reporting period: 06/30/2024
Item 1 – Reports to Stockholders
(a) The Reports to Shareholders are attached herewith.
BlackRock Energy and Resources Trust (BGR) |
BlackRock Enhanced Capital and Income Fund, Inc. (CII) |
BlackRock Enhanced Equity Dividend |
BlackRock Enhanced Global Dividend |
BlackRock Enhanced International Dividend Trust (BGY) |
BlackRock Health Sciences Term |
BlackRock Health Sciences Trust (BME) |
BlackRock Innovation and Growth Term |
BlackRock Resources & Commodities Strategy Trust (BCX) |
BlackRock Science and Technology Term |
BlackRock Science and Technology Trust (BST) |
BlackRock Utilities, Infrastructure & Power Opportunities Trust (BUI) |
Not FDIC Insured • May Lose Value • No Bank Guarantee |
Supplemental Information
(unaudited)
BlackRock Energy and Resources Trust
’
s (BGR), BlackRock Enhanced Capital and Income Fund, Inc.’s (CII), BlackRock Enhanced Equity Dividend Trust’s (BDJ), BlackRock
Enhanced Global Dividend Trust’s (BOE), BlackRock Enhanced International Dividend Trust’s (BGY), BlackRock Health Sciences Term Trust
’
s (BMEZ), BlackRock Health
Sciences Trust’s (BME), BlackRock Innovation and Growth Term Trust
’
s (BIGZ), BlackRock Resources & Commodities Strategy Trust’s (BCX), BlackRock Science and
Technology Term Trust’s (BSTZ), BlackRock Science and Technology Trust
’
s (BST) and BlackRock Utilities, Infrastructure & Power Opportunities Trust’s (BUI) (collectively, the
"Trusts" or individually, a “Trust”) amounts and sources of distributions reported are estimates and are being provided pursuant to regulatory requirements and are not being
provided for tax reporting purposes. The actual amounts and sources for tax reporting purposes will depend upon each Trust’s investment experience during the remainder of
its fiscal year and may be subject to changes based on tax regulations. Each Trust will provide a Form 1099-DIV each calendar year that will tell you how to report these
distributions for U.S. federal income tax purposes.
| | Total Cumulative Distributions | % Breakdown of the Total Cumulative Distributions for the Fiscal Period |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| Each Trust estimates that it has distributed more than its net income and net realized capital gains; therefore, a portion of the distribution may be a return of capital. A return of capital may occur, for example, when some or all of the shareholder’s investment in a Trust is returned to the shareholder. A return of capital does not necessarily reflect a Trust’s investment performance and should not be confused with “yield” or “income.” When distributions exceed total return performance, the difference will reduce a Trust’s net asset value per share. |
Section 19(a) notices for the Trusts, as applicable, are available on the BlackRock website at
.
The Trusts, acting pursuant to a U.S. Securities and Exchange Commission (“SEC”) exemptive order and with the approval of each Trust’s Board of Trustees (the “Board”),
each has adopted a managed distribution plan, consistent with its investment objectives and policies, to support a level distribution of income, capital gains and/or return of
capital (the “Plan”). In accordance with the Plans, the Trusts currently distribute the following fixed amounts per share on a monthly basis:
The fixed amounts distributed per share are subject to change at the discretion of each Trust’s Board. Under its Plan, each Trust will distribute all available net income to its
shareholders as required by the Internal Revenue Code of 1986, as amended (the “Code”). If sufficient income (inclusive of net income and short-term capital gains) is not
earned on a monthly basis, the Trusts will distribute long-term capital gains and/or return of capital to shareholders in order to maintain a level distribution. Each monthly
distribution to shareholders is expected to be at the fixed amount established by the Board; however, each Trust may make additional distributions from time to time, including
additional capital gain distributions at the end of the taxable year, if required to meet requirements imposed by the Code and/or the Investment Company Act of 1940, as
amended (the “1940 Act”).
Shareholders should not draw any conclusions about a Trust’s investment performance from the amount of these distributions or from the terms of the Plan. Each Trust’s total
return performance is presented in its financial highlights table.
2
2024
BlackRock Semi-Annual Report to Shareholders
Supplemental Information
(unaudited) (continued)
The Board may amend, suspend or terminate a Trust’s Plan at any time without prior notice to the Trust
’
s shareholders if it deems such actions to be in the best interests of the
Trust or its shareholders. The suspension or termination of the Plan could have the effect of creating a trading discount (if the Trust’s stock is trading at or above net asset
value) or widening an existing trading discount. The Trusts are subject to risks that could have an adverse impact on their ability to maintain level distributions. Examples of
potential risks include, but are not limited to, economic downturns impacting the markets, changes in interest rates, decreased market volatility, companies suspending or
decreasing corporate dividend distributions and changes in the Code. Please refer to BDJ, BME, BST and BUI’s prospectuses for a more complete description of each Trust’s
risks.
Supplemental Information
3
Option Over-Writing Strategy
In general, the goal of each of the Trusts is to provide total return through a combination of current income and realized and unrealized gains (capital appreciation). The Trusts
seek to pursue these goals primarily by investing in a portfolio of equity securities and also by employing a strategy of writing (selling) call and put options in an effort to
generate current gains from option premiums and to enhance each Trust’s risk-adjusted return. Each Trust’s objectives cannot be achieved in all market conditions.
Each Trust primarily writes single stock covered call options and may also from time to time write single stock put options. When writing (selling) a covered call option, a Trust
holds an underlying equity security and enters into an option transaction which allows the counterparty to purchase the equity security at an agreed-upon price (“strike price”)
within an agreed-upon time period. The Trust receives cash premiums from the counterparties upon writing (selling) the option, which along with net investment income and net
realized gains, if any, are generally available to support current or future distributions paid by the Trust. During the option term, the counterparty may elect to exercise the option
if the market value of the equity security rises above the strike price, and the Trust is obligated to sell the equity security to the counterparty at the strike price, realizing a gain
or loss. Premiums received increase gains or reduce losses realized on the sale of the equity security. If the option remains unexercised upon its expiration, the Trust realizes
gains equal to the premiums received. Alternatively, an option may be closed out by an offsetting purchase or sale of an option prior to expiration. The Trust realizes a capital
gain from a closing purchase or sale transaction if the premium paid is less than the premium received from writing the option. The Trust realizes a capital loss from a closing
purchase or sale transaction if the premium received is less than the premium paid to purchase the option.
Writing covered call options entails certain risks, which include, but are not limited to, the following: an increase in the value of the underlying equity security above the strike
price can result in the exercise of a written option (sale by a Trust to the counterparty) when the Trust might not otherwise have sold the security; exercise of the option by the
counterparty may result in a sale below the current market value and a gain or loss being realized by the Trust; and limiting the potential appreciation that could be realized on
the underlying equity security to the extent of the strike price of the option. The premium that a Trust receives from writing a covered call option may not be sufficient to offset
the potential appreciation on the underlying equity security above the strike price of the option that could have otherwise been realized by the Trust. As such, an option
over-writing strategy may outperform the general equity market in flat or falling markets but underperform in rising markets.
Option Over-Writing Strategy Illustration
To illustrate these concepts, assume the following: (1) a common stock purchased at and currently trading at $37.15 per share; (2) a three-month call option is written by a Trust
with a strike price of $40 (i.e., 7.7% higher than the current market price); and (3) the Trust receives $2.45, or 6.6% of the common stock’s value, as a premium. If the stock price
remains unchanged, the option expires and there would be a 6.6% return for the three-month period. If the stock were to decline in price by 6.6% (i.e., decline to $34.70 per
share), the option strategy would “break-even” from an economic perspective resulting in neither a gain nor a loss. If the stock were to climb to a price of $40 or above, the
option would be exercised and the stock would return 7.7% coupled with the option premium received of 6.6% for a total return of 14.3%. Under this scenario, the Trust loses
the benefit of any appreciation of the stock above $40, and thus is limited to a 14.3% total return. The premium from writing the call option serves to offset some of the
unrealized loss on the stock in the event that the price of the stock declines, but if the stock were to decline more than 6.6% under this scenario, the Trust’s downside protection
is eliminated and the stock could eventually become worthless.
Each Trust intends to write covered call and other options to varying degrees depending upon market conditions. Please refer to each Trust’s Schedule of Investments and the
Notes to Financial Statements for details of written options.
Derivative Financial Instruments
The Trusts may invest in various derivative financial instruments. These instruments are used to obtain exposure to a security, commodity, index, market, and/or other assets
without owning or taking physical custody of securities, commodities and/or other referenced assets or to manage market, equity, credit, interest rate, foreign currency
exchange rate, commodity and/or other risks. Derivative financial instruments may give rise to a form of economic leverage and involve risks, including the imperfect
correlation between the value of a derivative financial instrument and the underlying asset, possible default of the counterparty to the transaction or illiquidity of the instrument.
Pursuant to Rule 18f-4 under the 1940 Act, among other things, the Trusts must either use derivative financial instruments with embedded leverage in a limited manner or
comply with an outer limit on fund leverage risk based on value-at-risk. The Trusts
’
successful use of a derivative financial instrument depends on the investment adviser’s
ability to predict pertinent market movements accurately, which cannot be assured. The use of these instruments may result in losses greater than if they had not been used,
may limit the amount of appreciation a Trust can realize on an investment and/or may result in lower distributions paid to shareholders. The Trusts
’
investments in these
instruments, if any, are discussed in detail in the Notes to Financial Statements.
Option Over-Writing Strategy / Derivative Financial Instruments
5
Trust Summary
as of June 30, 2024
BlackRock Energy and Resources Trust (BGR)
BlackRock Energy and Resources Trust
investment objective is to provide total return through a combination of current income and long-term capital
appreciation. The Trust seeks to achieve its investment objective by investing, under normal market conditions, at least 80% of its total assets in equity securities of energy and
natural resources companies and equity derivatives with exposure to the energy and natural resources industry. The Trust may invest directly in such securities or synthetically
through the use of derivatives. The Trust seeks to pursue this goal primarily by investing in a portfolio of equity securities and also by employing a strategy of writing (selling)
call and put options.
No assurance can be given that the Trust’s investment objective will be achieved.
Symbol on New York Stock Exchange | |
| |
Current Distribution Rate on Closing Market Price as of June 30, 2024 ($13.22) (a) | |
Current Monthly Distribution per Common Share (b) | |
Current Annualized Distribution per Common Share (b) | |
| Current distribution rate on closing market price is calculated by dividing the current annualized distribution per share by the closing market price. The current distribution rate may consist of income, net realized gains and/or a return of capital. Past performance is not an indication of future results. |
| The distribution rate is not constant and is subject to change. A portion of the distribution may be deemed a return of capital or net realized gain. |
Market Price and Net Asset Value Per Share Summary
Returns for the period ended June 30, 2024 were as follows:
| | Average Annual Total Returns |
| | | | |
| | | | |
Trust at Market Price (a)(b) | | | | |
MSCI World Energy Call Overwrite Index | | | | |
| | | | |
| All returns reflect reinvestment of dividends and/or distributions at actual reinvestment prices. |
| The Trust ’ s discount to NAV narrowed during the period, which accounts for the difference between performance based on market price and performance based on NAV. |
| An index that incorporates an option overlay component on the MSCI World Energy Index with a 33% overwrite level. The benchmark commenced on December 31, 2018 and therefore the benchmark does not have 10-year returns. |
| An index that is designed to capture the large- and mid-cap segments across developed markets countries. All securities in the index are classified in the energy sector as per the Global Industry Classification Standard. |
Performance results may include adjustments made for financial reporting purposes in accordance with U.S. generally accepted accounting principles.
Past performance is not an indication of future results.
The Trust is presenting the performance of one or more indices for informational purposes only. The Trust
is actively managed and does not seek to track or replicate the
performance of any index. The index performance shown is not intended to be indicative of the Trust’s investment strategies, portfolio components or past or future
performance.
More information about the Trust’s historical performance can be found in the “Closed End Funds” section of
.
The following discussion relates to the Trust’s absolute performance based on NAV:
What factors influenced performance?
Energy stocks performed well during the reporting period, reflecting strength in oil prices and a broader rally in the equity market.
Holdings in integrated energy and midstream companies contributed to performance, as sticky inflation, geopolitical risk, and higher oil prices served as tailwinds for these
sectors. Exxon Mobil Corp., a U.S.-based integrated energy firm, was the largest contributor at the individual stock level. The company reported strong earnings, and it
completed its strategic acquisition of Pioneer Resources. Shell PLC, a European-based integrated energy company that benefited from higher oil prices and its divestment of
less profitable projects, also contributed to performance.
The Trust used an options overlay strategy in which calls were written on a portion of the portfolio’s holdings. Given the strength in energy stocks, this strategy detracted from
results during the reporting period.
6
2024
BlackRock Semi-Annual Report to Shareholders
Trust Summary
as of June 30, 2024
(continued)
BlackRock Energy and Resources Trust (BGR)
Schlumberger Ltd., a U.S.-based oilfield services company, detracted from performance. Major oil producers focused on acquiring assets and buying back shares, leading to
a reduction in capital spending. Total Energies SE, a French-based integrated energy firm, also detracted. The company reported weaker-than-expected earnings, citing the
impact of lower gasoline prices on its refining margins.
The Trust
’
s practice of maintaining a specified level of monthly distributions to shareholders did not have a material impact on the Trust
’
s investment strategy.
Describe recent portfolio activity.
The Trust rotated its positioning in the integrated oil and gas and exploration and production industries by shifting assets from European companies to U.S.-based companies.
It also increased its allocation to midstream energy.
Describe portfolio positioning at period end.
As the end of the period, 50.2% of the portfolio was invested in integrated oil and gas, 21.9% in exploration and production industry, 13.2% in distribution, 7.2% in refining and
marketing, 6.9% in oilfield services, and 0.7% in cash.
As of June 30, 2024, the Trust had in place an option overwriting program whereby 32.4% of the underlying equities were overwritten with call options on individual stocks.
These call options were typically written at prices above the prevailing market prices (estimated to be 3.4% out of the money) and for maturities averaging 51 days.
The views expressed reflect the opinions of BlackRock as of the date of this report and are subject to change based on changes in market, economic or other conditions.
These views are not intended to be a forecast of future events and are no guarantee of future results.
Overview of the Trust’s Total Investments
|
| |
| |
| |
| |
| |
| |
| |
Canadian Natural Resources Ltd. | |
| |
| |
| |
|
| |
Oil, Gas & Consumable Fuels | |
Energy Equipment & Services | |
| Excludes short-term securities, short investments and options, if any. |
| For purposes of this report, industry sub-classifications may differ from those utilized for compliance purposes. |
Trust Summary
as of June 30, 2024
BlackRock Enhanced Capital and Income Fund, Inc. (CII)
BlackRock Enhanced Capital and Income Fund, Inc.
investment objective is to provide current income and capital appreciation. The Trust seeks to
achieve its investment objective by investing in a portfolio of equity securities of U.S. and foreign issuers. The Trust may invest directly in such securities or synthetically
through the use of derivatives. The Trust also seeks to achieve its investment objective by employing a strategy of writing (selling) call and put options.
No assurance can be given that the Trust’s investment objective will be achieved.
Symbol on New York Stock Exchange | |
| |
Current Distribution Rate on Closing Market Price as of June 30, 2024 ($19.99) (a) | |
Current Monthly Distribution per Common Share (b) | |
Current Annualized Distribution per Common Share (b) | |
| Current distribution rate on closing market price is calculated by dividing the current annualized distribution per share by the closing market price. Past performance is not an indication |
| The distribution rate is not constant and is subject to change. |
Market Price and Net Asset Value Per Share Summary
Returns for the period ended June 30, 2024 were as follows:
| | Average Annual Total Returns |
| | | | |
| | | | |
Trust at Market Price (a)(b) | | | | |
MSCI USA Call Overwrite Index | | | | |
| | | | |
| All returns reflect reinvestment of dividends and/or distributions at actual reinvestment prices. |
| The Trust ’ s discount to NAV widened during the period, which accounts for the difference between performance based on market price and performance based on NAV. |
| An index that incorporates an option overlay component on the MSCI USA Index with a 55% overwrite level. The benchmark commenced on December 31, 2018 and therefore the benchmark does not have 10-year returns. |
| An index that measures the performance of the large-cap segment of the U.S. equity universe. It is a subset of the Russell 3000 ® Index and includes approximately 1,000 of the largest securities based on a combination of their market capitalization and current index membership. The Russell 1000 ® Index represents approximately 93% of the U.S. market. |
Performance results may include adjustments made for financial reporting purposes in accordance with U.S. generally accepted accounting principles.
Past performance is not an indication of future results.
The Trust is presenting the performance of one or more indices for informational purposes only. The Trust
is actively managed and does not seek to track or replicate the
performance of any index. The index performance shown is not intended to be indicative of the Trust’s investment strategies, portfolio components or past or future
performance.
More information about the Trust’s historical performance can be found in the “Closed End Funds” section of
.
The following discussion relates to the Trust’s relative performance based on NAV:
What factors influenced performance?
The largest contributor to the Trust’s relative performance was security selection in the financials sector, specifically within the capital markets industry. Selection in the
consumer discretionary sector also proved beneficial, most notably the decision to not invest in automobiles. An underweight allocation to the real estate sector and stock
selection in materials also modestly boosted relative performance.
Investment decisions in information technology weighed on relative return, specifically in semiconductors and semiconductor equipment. Stock selection in the consumer
staples sector, specifically in the consumer staples distribution and retail industry, also detracted. Finally, stock selection in energy and communication services modestly
detracted.
The Trust utilized an options overlay strategy in which calls are written on a portion of the portfolio
’
s holdings. The Trust
’
s options overlay strategy detracted from relative
performance for the period.
8
2024
BlackRock Semi-Annual Report to Shareholders
Trust Summary
as of June 30, 2024
(continued)
BlackRock Enhanced Capital and Income Fund, Inc. (CII)
The Trust
’
s practice of maintaining a specified level of monthly distributions did not have a material impact on the Trust
’
s investment strategy.
Describe recent portfolio activity.
As a result of a combination of portfolio trading activity and market price changes, the Trust’s allocations to the information technology and real estate sectors increased over
the period. Conversely, the Trust’s allocations to the financials and consumer staples sectors decreased.
Describe portfolio positioning at period end.
At period end, the Trust’s largest absolute allocations were to information technology, healthcare and communication services. Relative to the benchmark, the Trust’s most
significant overweight exposures were in communication services, healthcare and consumer discretionary. The Trust maintained its most significant relative underweight
exposures to consumer staples, industrials and information technology.
The Trust had an options overwriting program in place under which 50.5% of the underlying equities were overwritten with call options on individual stocks. These call options
were typically written at levels above prevailing market prices (estimated to be 5.0% out of the money) with an average time until expiration of 49 days.
The views expressed reflect the opinions of BlackRock as of the date of this report and are subject to change based on changes in market, economic or other conditions.
These views are not intended to be a forecast of future events and are no guarantee of future results.
Overview of the Trust’s Total Investments
|
| |
| |
| |
| |
| |
| |
| |
| |
| |
Intercontinental Exchange, Inc. | |
| |
| Excludes short-term securities, short investments and options, if any. |
| For purposes of this report, sector sub-classifications may differ from those utilized for compliance purposes. |
Trust Summary
as of June 30, 2024
BlackRock Enhanced Equity Dividend Trust (BDJ)
BlackRock Enhanced Equity Dividend
primary investment objective is to provide current income and current gains, with a secondary investment
objective of long-term capital appreciation. The Trust seeks to achieve its investment objectives by investing in common stocks that pay dividends and have the potential for
capital appreciation and by utilizing an option writing strategy to enhance distributions to its shareholders. The Trust invests, under normal market conditions, at least 80% of
its total assets in dividend paying equities and may invest up to 20% of its total assets in equity securities of issuers that do not pay dividends. The Trust may invest directly in
such securities or synthetically through the use of derivatives.
No assurance can be given that the Trust’s investment objectives will be achieved.
Symbol on New York Stock Exchange | |
| |
Current Distribution Rate on Closing Market Price as of June 30, 2024 ($8.17) (a) | |
Current Monthly Distribution per Common Share (b) | |
Current Annualized Distribution per Common Share (b) | |
| Current distribution rate on closing market price is calculated by dividing the current annualized distribution per share by the closing market price. Past performance is not an indication |
| The distribution rate is not constant and is subject to change. |
Market Price and Net Asset Value Per Share Summary
Returns for the period ended June 30, 2024 were as follows:
| | Average Annual Total Returns |
| | | | |
| | | | |
Trust at Market Price (a)(b) | | | | |
MSCI USA Value Call Overwrite Index | | | | |
| | | | |
| All returns reflect reinvestment of dividends and/or distributions at actual reinvestment prices. |
| The Trust ’ s discount to NAV narrowed during the period, which accounts for the difference between performance based on market price and performance based on NAV. |
| An index that incorporates an option overlay component on the MSCI USA Value Index with a 55% overwrite level. The benchmark commenced on December 31, 2018 and therefore the benchmark does not have 10-year returns. |
| An index that measures the performance of the large-cap value segment of the U.S. equity universe. It includes those Russell 1000 companies with lower price-to-book ratios and lower |
Performance results may include adjustments made for financial reporting purposes in accordance with U.S. generally accepted accounting principles.
Past performance is not an indication of future results.
The Trust is presenting the performance of one or more indices for informational purposes only. The Trust
is actively managed and does not seek to track or replicate the
performance of any index. The index performance shown is not intended to be indicative of the Trust’s investment strategies, portfolio components or past or future
performance.
More information about the Trust’s historical performance can be found in the “Closed End Funds” section of
.
The following discussion relates to the Trust’s relative performance based on NAV:
What factors influenced performance?
The largest contributor to the Trust’s relative performance was security selection in the financials sector, specifically among banks. Stock selection in industrials was another
key contributor to relative performance, most notably in professional services. Selection in the consumer discretionary sector and an underweight allocation to the real estate
sector also proved additive.
The largest detractor was stock selection in the consumer staples sector, specifically in the food products industry. An underweight allocation to information technology, most
notably to the semiconductors and semiconductor equipment industry, also weighed on relative performance. Finally, stock selection in utilities and an underweight allocation
to energy detracted.
The Trust used an options overlay strategy in which calls were written on a portion of the portfolio’s holdings. The options overlay strategy detracted from relative performance.
10
2024
BlackRock Semi-Annual Report to Shareholders
Trust Summary
as of June 30, 2024
(continued)
BlackRock Enhanced Equity Dividend Trust (BDJ)
The Trust’s practice of maintaining a specified level of monthly distributions to shareholders did not have a material impact on the Trust’s investment strategy.
Describe recent portfolio activity.
As the result of a combination of portfolio trading activity and market price movements, the Trust’s allocations to the information technology and communication services
sectors increased over the period. Conversely, the Trust’s allocations to the financials and consumer staples sectors decreased.
Describe portfolio positioning at period end.
At period end, the Trust’s largest absolute allocations were in financials, health care and industrials. Relative to the benchmark, the Trust’s most significant overweight
exposures were in financials, health care and communication services. The most significant underweight exposures were to information technology, real estate, and consumer
staples.
The Trust had in place an option overwriting program under which 48.4% of the underlying equities were overwritten with call options on individual stocks. These call options
were typically written at prices above the prevailing market prices (estimated to be 5.0% out of the money) and for maturities averaging 55 days.
The views expressed reflect the opinions of BlackRock as of the date of this report and are subject to change based on changes in market, economic or other conditions.
These views are not intended to be a forecast of future events and are no guarantee of future results.
Overview of the Trust’s Total Investments
|
| |
| |
| |
American International Group, Inc. | |
First Citizens BancShares, Inc. | |
Fidelity National Information Services, Inc. | |
| |
| |
L3Harris Technologies, Inc. | |
| |
| |
| Excludes short-term securities, short investments and options, if any. |
| For purposes of this report, sector sub-classifications may differ from those utilized for compliance purposes. |
Trust Summary
as of June 30, 2024
BlackRock Enhanced Global Dividend Trust (BOE)
BlackRock Enhanced Global Dividend
primary investment objective is to provide current income and current gains, with a secondary
investment objective of long-term capital appreciation. The Trust seeks to achieve its investment objectives by investing primarily in equity securities issued by companies
located in countries throughout the world and by employing a strategy of writing (selling) call and put options. Under normal circumstances, the Trust invests at least 80% of its
net assets in dividend-paying equity securities and at least 40% of its assets outside of the U.S. (unless market conditions are not deemed favorable by Trust management, in
which case the Trust would invest at least 30% of its assets outside of the U.S.). The Trust may invest in securities of companies of any market capitalization, but intends to
invest primarily in securities of large capitalization companies. The Trust may invest directly in such securities or synthetically through the use of derivatives.
No assurance can be given that the Trust’s investment objectives will be achieved.
Symbol on New York Stock Exchange | |
| |
Current Distribution Rate on Closing Market Price as of June 30, 2024 ($10.61) (a) | |
Current Monthly Distribution per Common Share (b) | |
Current Annualized Distribution per Common Share (b) | |
| Current distribution rate on closing market price is calculated by dividing the current annualized distribution per share by the closing market price. The current distribution rate may consist of income, net realized gains and/or a return of capital. Past performance is not an indication of future results. |
| The distribution rate is not constant and is subject to change. A portion of the distribution may be deemed a return of capital or net realized gain. |
Market Price and Net Asset Value Per Share Summary
Returns for the period ended June 30, 2024 were as follows:
| | Average Annual Total Returns |
| | | | |
| | | | |
Trust at Market Price (a)(b) | | | | |
MSCI ACWI Call Overwrite Index | | | | |
| | | | |
| All returns reflect reinvestment of dividends and/or distributions at actual reinvestment prices. |
| The Trust ’ s discount to NAV narrowed during the period, which accounts for the difference between performance based on market price and performance based on NAV. |
| An index that incorporates an option overlay component on the MSCI ACWI Index with a 45% overwrite level. The benchmark commenced on December 31, 2018 and therefore the benchmark does not have 10-year returns. |
| An index that captures large- and mid-cap representation across certain developed and emerging markets. |
Performance results may include adjustments made for financial reporting purposes in accordance with U.S. generally accepted accounting principles.
Past performance is not an indication of future results.
The Trust is presenting the performance of one or more indices for informational purposes only. The Trust
is actively managed and does not seek to track or replicate the
performance of any index. The index performance shown is not intended to be indicative of the Trust’s investment strategies, portfolio components or past or future
performance.
More information about the Trust’s historical performance can be found in the “Closed End Funds” section of
.
The following discussion relates to the Trust’s relative performance based on NAV:
What factors influenced performance?
An underweight to and stock selection in the information technology sector detracted from relative performance during the period. Stock selection in consumer staples and
communication services also weighed on relative return.
At the individual security level, not owning NVIDIA Corp. detracted the most from relative performance. The technology giant outperformed on continued positive sentiment
surrounding the surge in artificial intelligence (“AI”)-driven demand for its leading-edge chips. As the stock does not align with the Trust’s dividend criteria, the Trust strategically
allocated capital to other companies that are engaged in comparable sectors, many of which also demonstrated strong performance during the period. Shares of Walmart de
Mexico fell following the decisive victory by a left-wing populist candidate in Mexico’s presidential election, raising concerns about the possibility of more extensive reforms to
12
2024
BlackRock Semi-Annual Report to Shareholders
Trust Summary
as of June 30, 2024
(continued)
BlackRock Enhanced Global Dividend Trust (BOE)
the constitution. Telus Corp. was another laggard as the Canadian telecommunications company continued to be impacted by the high interest rate environment given its
substantial long-term debt as it continued to spend capital to expand its fiber network.
Stock selection in the healthcare sector led positive contributions to the Trust’s relative performance, while underweights to real estate and materials also proved additive.
Taiwan Semiconductor Manufacturing Co. Ltd. was the leading individual contributor as revenue from AI processors continued to accelerate. Strength continues to come from
the company’s strategic position in AI chip manufacturing, driving both demand growth and pricing power for leading edge chips. In addition to AI-driven demand, the company
also had an improving outlook across other key markets, including PCs, smartphones, autos and industrial sectors. Applied Materials Inc. reported strong financial results
driven by robust demand for its semiconductor manufacturing equipment and services. The company
’
s performance was bolstered by secular growth trends including AI,
Internet of things and clean energy, which are fuelling the need for advanced chips and driving capacity expansions across the semiconductor industry. Novo Nordisk A/S
continued its strong performance as the pharmaceutical company executed on its established diabetes franchise and capitalized on the weight-loss drug opportunity. The
company’s R&D pipeline also continued to innovate new products that deliverd greater weight loss and additional medical benefits, further expanding the market opportunity.
The Trust utilized an options overlay strategy in which calls are written on a portion of the portfolio
’
s holdings. The Trust
’
s options overlay strategy contributed positively to
relative performance. The Trust’s practice of maintaining a specified level of monthly distributions to shareholders did not have a material impact on the Trust’s investment
strategy.
Describe recent portfolio activity.
During the period, the Trust reduced exposure to the financials, healthcare and industrials sectors. The Trust added exposure to communication services, consumer staples
and information technology.
Describe portfolio positioning at period end.
At the end of the period, the Trust’s largest sector overweights were in industrials, consumer staples and health care. Regionally, the majority of the portfolio was listed in the
U.S., with material exposure also in Europe.
As of June 30, 2024, the Trust had in place an option overwriting program under which 45% of the underlying equities were overwritten with call options. These call options
were typically written at prices above the prevailing market prices (estimated to be 2.4% out of the money) with an average time until expiration of 50 days.
The views expressed reflect the opinions of BlackRock as of the date of this report and are subject to change based on changes in market, economic or other conditions.
These views are not intended to be a forecast of future events and are no guarantee of future results.
Overview of the Trust’s Total Investments
|
| |
| |
Taiwan Semiconductor Manufacturing Co. Ltd. | |
| |
| |
| |
| |
| |
| |
| |
| |
|
Country/Geographic Region | |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| Excludes short-term securities, short investments and options, if any. |
| Includes holdings within countries/geographic regions that are less than 1.0% of total investments. Please refer to the Schedule of Investments for such countries/geographic regions. |
Trust Summary
as of June 30, 2024
BlackRock Enhanced International Dividend Trust (BGY)
BlackRock Enhanced International Dividend Trust
primary investment objective is to provide current income and current gains, with a secondary
objective of long-term capital appreciation. The Trust seeks to achieve its investment objectives by investing primarily in equity securities issued by companies of any market
capitalization located in countries throughout the world and by employing a strategy of writing (selling) call and put options. The Trust invests, under normal circumstances, at
least 80% of its net assets in dividend-paying equity securities issued by non-U.S. companies of any market capitalization, but intends to invest primarily in securities of large
capitalization companies. The Trust may invest directly in such securities or synthetically through the use of derivatives.
No assurance can be given that the Trust’s investment objectives will be achieved.
Symbol on New York Stock Exchange | |
| |
Current Distribution Rate on Closing Market Price as of June 30, 2024 ($5.58) (a) | |
Current Monthly Distribution per Common Share (b) | |
Current Annualized Distribution per Common Share (b) | |
| Current distribution rate on closing market price is calculated by dividing the current annualized distribution per share by the closing market price. The current distribution rate may consist of income, net realized gains and/or a return of capital. Past performance is not an indication of future results. |
| The distribution rate is not constant and is subject to change. A portion of the distribution may be deemed a return of capital or net realized gain. |
Market Price and Net Asset Value Per Share Summary
Returns for the period ended June 30, 2024 were as follows:
| | Average Annual Total Returns |
| | | | |
| | | | |
Trust at Market Price (a)(b) | | | | |
MSCI ACWI ex USA Call Overwrite Index | | | | |
| | | | |
| All returns reflect reinvestment of dividends and/or distributions at actual reinvestment prices. |
| The Trust ’ s discount to NAV narrowed during the period, which accounts for the difference between performance based on market price and performance based on NAV. |
| An index that incorporates an option overlay component on the MSCI ACWI ex USA Index with a 45% overwrite level. The benchmark commenced on December 31, 2018 and therefore the benchmark does not have 10-year returns. |
| An index that captures large- and mid-cap representation across certain developed markets countries (excluding the U.S.) and certain emerging markets countries. |
Performance results may include adjustments made for financial reporting purposes in accordance with U.S. generally accepted accounting principles.
Past performance is not an indication of future results.
The Trust is presenting the performance of one or more indices for informational purposes only. The Trust
is actively managed and does not seek to track or replicate the
performance of any index. The index performance shown is not intended to be indicative of the Trust’s investment strategies, portfolio components or past or future
performance.
More information about the Trust’s historical performance can be found in the “Closed End Funds” section of
.
The following discussion relates to the Trust’s relative performance based on NAV:
What factors influenced performance?
Stock selection in the financials, consumer staples and consumer discretionary sectors detracted from relative performance.
Shares of B3 S.A., the Brazilian stock exchange, underperformed as the company’s quarterly profit fell 9% on weaker volumes as interest rate cut expectations moderated
during the period. Shares of Walmart de Mexico declined following the decisive victory by a left-wing populist candidate in Mexico’s presidential election, raising concerns
about the possibility of more extensive reforms to the constitution. Diageo plc, one of the highest quality franchises in the alcoholic beverage market, also lagged due to analyst
downgrades and short-term headwinds impacting sales across several geographies. The stock appears to be fully pricing in these risks and the Trust continues to hold the
position.
Stock selection in the healthcare, information technology and industrials sectors were the largest contributors to relative performance.
14
2024
BlackRock Semi-Annual Report to Shareholders
Trust Summary
as of June 30, 2024
(continued)
BlackRock Enhanced International Dividend Trust (BGY)
Taiwan Semiconductor Manufacturing Co. Ltd. was the leading individual contributor as revenue from artificial intelligence (“AI”) processors continued to accelerate. Strength
continued to come from the company’s strategic position in AI chip manufacturing, driving both demand growth and pricing power for leading edge chips. In addition to AI-driven
demand, the company also had an improved outlook across other key markets, including PCs, smartphones, autos and industrial sectors. Novo Nordisk A/S continued its
strong performance as the pharmaceutical company executed on its established diabetes franchise and capitalized on the weight-loss drug opportunity. The company’s R&D
pipeline also continued to innovate new products that deliver greater weight loss and additional medical benefits, further expanding the market opportunity. Even with
intensifying competition, Novo Nordisk’s leadership in production capacity and product innovation positioned the company to continue its extraordinary growth trajectory.
ASICS Corp., the global athletic footwear and apparel company, contributed to relative performance as well, reporting strong sales and profitability for fiscal year 2023.
The Trust utilized an options overlay strategy in which calls are written on a portion of the portfolio’s holdings. The Trust’s options overlay strategy contributed to relative
performance for the reporting period. The Trust’s practice of maintaining a specified level of monthly distributions did not have a material impact on the Trust’s investment
strategy.
Describe recent portfolio activity.
During the period, the Trust reduced its exposure to the financials, communication services and materials sectors, while adding to information technology, industrials and
consumer discretionary.
Describe portfolio positioning at period end.
At period end, the Trust’s largest sector overweights were in industrials, health care and consumer staples. Regionally, the majority of portfolio assets comprised securities
listed in Europe, with particularly significant exposure in Europe excluding the United Kingdom.
As of June 30, 2024, the Trust had in place an option overwriting program under which 43% of the underlying equities were overwritten with call options. These call options
were typically written at prices above the prevailing market prices (estimated to be 2.6% out of the money) with an average time until expiration of 51 days.
The views expressed reflect the opinions of BlackRock as of the date of this report and are subject to change based on changes in market, economic or other conditions.
These views are not intended to be a forecast of future events and are no guarantee of future results.
Overview of the Trust’s Total Investments
|
| |
Taiwan Semiconductor Manufacturing Co. Ltd. | |
| |
| |
| |
| |
| |
LVMH Moet Hennessy Louis Vuitton SE | |
| |
| |
| |
|
Country/Geographic Region | |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| Excludes short-term securities, short investments and options, if any. |
Trust Summary
as of June 30, 2024
BlackRock Health Sciences Term Trust (BMEZ)
BlackRock Health Sciences Term
investment objective is to provide total return and income through a combination of current income, current
gains and long-term capital appreciation. Under normal market conditions, the Trust will invest at least 80% of its total assets in equity securities of companies principally
engaged in the health sciences group of industries and equity derivatives with exposure to the health sciences group of industries. Equity derivatives in which the Trust invests
include purchased and sold (written) call and put options on equity securities of companies in the health sciences group of industries.
No assurance can be given that the Trust’s investment objective will be achieved.
Symbol on New York Stock Exchange | |
| |
Current Distribution Rate on Closing Market Price as of June 30, 2024 ($15.36) (a) | |
Current Monthly Distribution per Common Share (b) | |
Current Annualized Distribution per Common Share (b) | |
| Current distribution rate on closing market price is calculated by dividing the current annualized distribution per share by the closing market price. The current distribution rate may consist of income, net realized gains and/or a return of capital. Past performance is not an indication of future results. |
| The monthly distribution per Common Share, declared on August 1, 2024, was decreased to $0.176410 per share. The current distribution rate on closing market price, current monthly distribution per Common Share, and current annualized distribution per Common Share do not reflect the new distribution rate. The new distribution rate is not constant and is subject to change in the future. A portion of the distribution may be deemed a return of capital or net realized gain. |
Market Price and Net Asset Value Per Share Summary
Returns for the period ended June 30, 2024 were as follows:
| | Average Annual Total Returns |
| | | |
| | | |
Trust at Market Price (b)(c) | | | |
MSCI Custom ACWI SMID Growth HC Call Overwrite Index | | | |
| | | |
| BMEZ commenced operations on January 30, 2020. |
| All returns reflect reinvestment of dividends and/or distributions at actual reinvestment prices. |
| The Trust ’ s discount to NAV narrowed during the period, which accounts for the difference between performance based on market price and performance based on NAV. |
| An index representing the Health Care sector stocks within the MSCI ACWI SMID Cap Growth Index and incorporating an option overlay component with a 25% overwrite level. The MSCI ACWI SMID Cap Growth Index captures mid- and small-cap securities exhibiting overall growth style characteristics across certain developed and emerging markets countries. The index commenced on March 31, 2022 and therefore the since inception return presented is for the period March 31, 2022 through the current reporting period. |
| An index that captures large- and mid-cap representation across certain developed and emerging markets. |
Performance results may include adjustments made for financial reporting purposes in accordance with U.S. generally accepted accounting principles.
Past performance is not an indication of future results.
The Trust is presenting the performance of one or more indices for informational purposes only. The Trust
is actively managed and does not seek to track or replicate the
performance of any index. The index performance shown is not intended to be indicative of the Trust’s investment strategies, portfolio components or past or future
performance.
More information about the Trust’s historical performance can be found in the “Closed End Funds” section of
.
The following discussion relates to the Trust’s relative performance based on NAV:
What factors influenced performance?
At the industry level, security selection in the pharmaceuticals and health care providers and services sub-sectors made the largest contributions to relative performance.
Among the Trust’s individual holdings, an out-of-benchmark position in Numab Therapeutics AG was the leading contributor to relative performance. The biotechnology
company’s lead asset, an investigational antibody to treat chronic skin inflammation, was acquired by Johnson & Johnson. An overweight position in the clinical stage
immuno-oncology company Merus NV, which reported positive trial results for a head and neck cancer therapy, was another leading contributor. An out-of-benchmark position
in Eli Lilly & Co. also contributed positively. The pharmaceutical company continued to benefit from robust sales of its GLP-1 medications.
16
2024
BlackRock Semi-Annual Report to Shareholders
Trust Summary
as of June 30, 2024
(continued)
BlackRock Health Sciences Term Trust (BMEZ)
Security selection in the biotechnology sub-sector was the largest detractor from relative performance. An overweight in the biotechnology company Immunocore Holdings
PLC, which reported trial results for its skin cancer antibody that missed expectations, was the largest detractor at the individual stock level. An overweight position in Carbon
Health, a private company, was also a key detractor. A provider of primary care services, the company experienced decreased demand for its COVID-19 testing and
vaccination services. A zero weighting in Tenet Healthcare Corp. detracted, as well. The hospital manager experienced broad volume growth as medical utilization rates
continued to normalize relative to the depressed levels seen during COVID-19.
The Trust used an options overlay strategy in which calls were written on a portion of the portfolio’s holdings. This strategy contributed to relative performance.
The Trust’s practice of maintaining a specified level of monthly distributions to shareholders did not have a material impact on the Trust’s investment strategy.
Describe recent portfolio activity.
The Trust increased its allocation to the biotechnology sub-sector, including companies with positive near-term product catalysts. The Trust also added to its private holding in
Bright Peak Therapeutics. On the other hand, it reduced positions in select pharmaceutical stocks that appreciated.
Describe portfolio positioning at period end.
The Trust held 20 private investments, comprising 8.3% of total assets for a commitment of approximately $156 million.
The investment adviser continued to seek opportunities to harvest the illiquidity premium by taking advantage of the Trust’s closed-end structure by adding holdings in private
investments as capacity increased.
At the end of the period, the Trust held 45% of net asset value in biotechnology, 32% in medical devices & supplies, 12% in health care providers & services, 7% in
pharmaceuticals, and 1% outside of healthcare. These industry weightings were the result of bottom-up stock selection.
As of June 30, 2024 the Trust had in place an option overwriting program whereby 23.2% of the underlying equities were overwritten with call options on individual stocks.
These call options were typically written at prices above the prevailing market prices (estimated to be 3.8% out of the money) and for maturities averaging 53 days.
The views expressed reflect the opinions of BlackRock as of the date of this report and are subject to change based on changes in market, economic or other conditions.
These views are not intended to be a forecast of future events and are no guarantee of future results.
Overview of the Trust’s Total Investments
|
| |
Alnylam Pharmaceuticals, Inc. | |
West Pharmaceutical Services, Inc. | |
| |
| |
| |
| |
Blueprint Medicines Corp. | |
BioMarin Pharmaceutical, Inc. | |
| |
| |
|
| |
| |
Health Care Equipment & Supplies | |
Life Sciences Tools & Services | |
Health Care Providers & Services | |
| |
Semiconductors & Semiconductor Equipment | |
| |
| Excludes short-term securities, short investments and options, if any. |
| For purposes of this report, industry sub-classifications may differ from those utilized for compliance purposes. |
| Includes one or more investment categories that individually represents less than 1.0% of the Trust ’ s total investments. Please refer to the Schedule of Investments for details. |
Trust Summary
as of June 30, 2024
BlackRock Health Sciences Trust (BME)
BlackRock Health Sciences Trust
investment objective is to provide total return through a combination of current income, current gains and long-term
capital appreciation. The Trust seeks to achieve its investment objective by investing, under normal market conditions, at least 80% of its total assets in equity securities of
companies engaged in the health sciences and related industries and equity derivatives with exposure to the health sciences industry. The Trust seeks to pursue this goal
primarily by investing in a portfolio of equity securities and by employing a strategy of writing (selling) call and put options.
No assurance can be given that the Trust’s investment objective will be achieved.
Symbol on New York Stock Exchange | |
| |
Current Distribution Rate on Closing Market Price as of June 30, 2024 ($40.85) (a) | |
Current Monthly Distribution per Common Share (b) | |
Current Annualized Distribution per Common Share (b) | |
| Current distribution rate on closing market price is calculated by dividing the current annualized distribution per share by the closing market price. The current distribution rate may consist of income, net realized gains and/or a return of capital. Past performance is not an indication of future results. |
| The distribution rate is not constant and is subject to change. A portion of the distribution may be deemed a return of capital or net realized gain. |
Market Price and Net Asset Value Per Share Summary
Returns for the period ended June 30, 2024 were as follows:
| | Average Annual Total Returns |
| | | | |
| | | | |
Trust at Market Price (a)(b) | | | | |
MSCI USA Investable Market Index Health Care Call Overwrite Index | | | | |
| | | | |
| All returns reflect reinvestment of dividends and/or distributions at actual reinvestment prices. |
| The Trust ’ s discount to NAV widened during the period, which accounts for the difference between performance based on market price and performance based on NAV. |
| An index that incorporates an option overlay component on the MSCI USA IMI Health Care Index with a 33% overwrite level. The benchmark commenced on December 31, 2018 and therefore the benchmark does not have 10-year returns. |
| An unmanaged index that features companies involved in medical services or health care in the Russell 3000 ® Index, which includes the largest 3,000 U.S. companies as determined by total market capitalization. |
Performance results may include adjustments made for financial reporting purposes in accordance with U.S. generally accepted accounting principles.
Past performance is not an indication of future results.
The Trust is presenting the performance of one or more indices for informational purposes only. The Trust
is actively managed and does not seek to track or replicate the
performance of any index. The index performance shown is not intended to be indicative of the Trust’s investment strategies, portfolio components or past or future
performance.
More information about the Trust’s historical performance can be found in the “Closed End Funds” section of
.
The following discussion relates to the Trust’s relative performance based on NAV:
What factors influenced performance?
At the industry level, security selection in pharmaceuticals and medical devices and supplies were the largest contributors to relative performance.
An overweight position in Boston Scientific Corp. was the top contributor to performance at the individual security level. The medical device company successfully
commercialized new products, including its Farapulse Pulsed Field Ablation System. Additionally, sales in its medical surgery segment continued to be supported by the
normalization of procedural demand following COVID-19. Lack of positions in CVS Health Corp. was also a notable contributor to relative performance. The managed care
provider missed earnings expectations due to elevated utilization rates, and it cut its full-year profit outlook on expectations that medical costs will remain high. An underweight
in Johnson & Johnson also contributed positively. The healthcare giant continued to face a litigation overhang, leading to increased costs.
Security selection in the biotechnology sub-sector was the largest detractor from relative performance. An underweight position in Eli Lilly & Co. was the most notable detractor
among the Trust’s individual holdings, as the company continued to benefit from strong demand for GLP-1 weight loss drugs. An overweight position in Biogen, Inc. was
18
2024
BlackRock Semi-Annual Report to Shareholders
Trust Summary
as of June 30, 2024
(continued)
BlackRock Health Sciences Trust (BME)
another detractor from performance. The biotechnology company missed earnings expectations, citing elevated generic competition for legacy products and a slower-than-expected
launch of novel treatments. An overweight in the medical device company Penumbra, Inc., which was hurt by weaker demand in the international markets, was also
a meaningful detractor.
The Trust made use of options, principally writing call options on individual stocks, to seek enhanced income returns while continuing to participate in the performance of the
underlying equities. The option overlay strategy contributed to results.
The Trust’s practice of maintaining a specified level of monthly distributions to shareholders did not have a material impact on the Trust’s investment strategy.
Describe recent portfolio activity.
The investment adviser increased the Trust’s allocation to the pharmaceuticals sub-sector, adding to companies with strong product pipelines and positive near-term catalysts.
Additionally, it increased the portfolio’s weightings in the medical devices and supplies sub-sectors by adding to select bioprocessing companies on anticipation of heightened
demand from pharmaceutical manufacturers. The Trust’s weighting in the health care providers and services sub-sector declined due to uncertainty around health insurance
reimbursement rates.
Describe portfolio positioning at period end.
The Trust held 31% of net asset value in medical devices & supplies, 25% in biotechnology, 21% in health care providers & services, and 21% in pharmaceuticals. These
industry weightings were a result of bottom-up stock selection.
As of June 30, 2024, the Trust had in place an option overwriting program whereby 35.4% of the underlying equities were overwritten with call options on individual stocks.
These call options were typically written at prices above the prevailing market prices (estimated to be 3.3% out of the money) and for maturities averaging 52 days.
The views expressed reflect the opinions of BlackRock as of the date of this report and are subject to change based on changes in market, economic or other conditions.
These views are not intended to be a forecast of future events and are no guarantee of future results.
Overview of the Trust’s Total Investments
|
| |
| |
| |
| |
| |
| |
| |
Thermo Fisher Scientific, Inc. | |
| |
| |
| |
|
| |
| |
Health Care Equipment & Supplies | |
| |
Health Care Providers & Services | |
Life Sciences Tools & Services | |
| |
| Excludes short-term securities, short investments and options, if any. |
| For purposes of this report, industry sub-classifications may differ from those utilized for compliance purposes. |
| Includes one or more investment categories that individually represents less than 1.0% of the Trust ’ s total investments. Please refer to the Schedule of Investments for details. |
Trust Summary
as of June 30, 2024
BlackRock Innovation and Growth Term Trust (BIGZ)
BlackRock Innovation and Growth Term
investment objective is to provide total return and income through a combination of current income,
current gains and long-term capital appreciation. The Trust will invest primarily in equity securities issued by mid- and small-capitalization companies that the Trust’s adviser
believes have above-average earnings growth potential. In selecting investments for the Trust, the Trust’s adviser focuses on mid- and small-capitalization growth companies
that are “innovative.” These are companies that have introduced, or are seeking to introduce, a new product or service that potentially changes the marketplace. The Trust
utilizes an option writing (selling) strategy in an effort to generate current gains from options premiums and to enhance the Trust’s risk-adjusted returns.
No assurance can be given that the Trust’s investment objective will be achieved.
Symbol on New York Stock Exchange | |
| |
Current Distribution Rate on Closing Market Price as of June 30, 2024 ($7.23) (a) | |
Current Monthly Distribution per Common Share (b) | |
Current Annualized Distribution per Common Share (b) | |
| Current distribution rate on closing market price is calculated by dividing the current annualized distribution per share by the closing market price. The current distribution rate may consist of income, net realized gains and/or a return of capital. Past performance is not an indication of future results. |
| The monthly distribution per Common Share, declared on August 1, 2024, was decreased to $0.087630 per share. The current distribution rate on closing market price, current monthly distribution per Common Share, and current annualized distribution per Common Share do not reflect the new distribution rate. The new distribution rate is not constant and is subject to change in the future. A portion of the distribution may be deemed a return of capital or net realized gain. |
Market Price and Net Asset Value Per Share Summary
Returns for the period ended June 30, 2024 were as follows:
| | Average Annual Total Returns |
| | | |
| | | |
Trust at Market Price (b)(c) | | | |
MSCI USA SMID Growth Call Overwrite Index | | | |
Russell 2500™ Growth Index | | | |
| BIGZ commenced operations on March 29, 2021. |
| All returns reflect reinvestment of dividends and/or distributions at actual reinvestment prices. |
| The Trust ’ s discount to NAV narrowed during the period, which accounts for the difference between performance based on market price and performance based on NAV. |
| A custom benchmark that is made up of the MSCI USA SMID Growth Index, MSCI USA SMID Growth 25% Call Overwrite Cash and MSCI USA SMID Growth 25% Call Overwrite Option. The MSCI USA SMID Growth Index captures mid and small cap representations of securities exhibiting overall growth style characteristics in the U.S. |
| An index that measures the performance of the small to mid-cap growth segment of the U.S. equity universe. It includes those Russell 2500 companies with higher growth earning potential as defined by FTSE Russell ’ s leading style methodology. |
Performance results may include adjustments made for financial reporting purposes in accordance with U.S. generally accepted accounting principles.
Past performance is not an indication of future results.
The Trust is presenting the performance of one or more indices for informational purposes only. The Trust
is actively managed and does not seek to track or replicate the
performance of any index. The index performance shown is not intended to be indicative of the Trust’s investment strategies, portfolio components or past or future
performance.
More information about the Trust’s historical performance can be found in the “Closed End Funds” section of
.
The following discussion relates to the Trust’s relative performance based on NAV:
What factors influenced performance?
Although the headline equity indexes produced robust performance during the reporting period, small- to mid-sized companies lagged considerably.
Stock selection in the communication services sector was the leading contributor to relative performance, with the largest positive effects occurring in the interactive media and
services category. An overweight in Pinterest, Inc. was the largest contributor in this area, followed by a zero weighting in the underperforming stock, Match Group, Inc. Zero
weightings in the materials and utilities sectors also helped results.
20
2024
BlackRock Semi-Annual Report to Shareholders
Trust Summary
as of June 30, 2024
(continued)
BlackRock Innovation and Growth Term Trust (BIGZ)
Security selection in the information technology sector was the largest detractor from relative performance. Most notably, an out-of-benchmark position in Snyk Limited—a
cybersecurity company specializing in cloud computing—was detrimental. Selection in in the diversified consumer services industry within the consumer discretionary sector
also detracted. The shortfall was primarily the result of a position in Ideal Image Development LLC. Security selection in healthcare further dampened returns, due primarily to
an overweight in Repligen Corp.
The Trust used an options overlay strategy in which calls were written on a portion of the portfolio’s holdings. The Trust’s options overlay strategy contributed to performance.
The Trust’s practice of maintaining a specified level of monthly distributions to shareholders did not have a material impact on the Trust’s investment strategy.
Describe recent portfolio activity.
Due to a combination of market movements and portfolio activity, the Trust’s allocations to communication services and industrials increased, while its weightings in consumer
discretionary and communication services decreased. The Trust did not add any new private companies during the reporting period.
Describe portfolio positioning at period end.
The portfolio’s largest sector overweights were in the information technology and consumer discretionary sectors. Its largest underweights were in energy and materials.
As of June 30, 2024, the Trust had in place an option overwriting program whereby 13.0% of the underlying equities were overwritten with call options on individual stocks.
These call options were typically written at prices above the prevailing market prices (estimated to be 6.2% out of the money) and for maturities averaging 60 days.
The views expressed reflect the opinions of BlackRock as of the date of this report and are subject to change based on changes in market, economic or other conditions. These
views are not intended to be a forecast of future events and are no guarantee of future results.
Overview of the Trust’s Total Investments
|
| |
Monolithic Power Systems, Inc. | |
| |
| |
| |
| |
| |
| |
| |
| |
| |
|
| |
| |
Semiconductors & Semiconductor Equipment | |
| |
| |
| |
Life Sciences Tools & Services | |
Hotels, Restaurants & Leisure | |
Health Care Equipment & Supplies | |
Interactive Media & Services | |
| |
| |
Real Estate Management & Development | |
| |
Textiles, Apparel & Luxury Goods | |
| |
Construction & Engineering | |
Diversified Consumer Services | |
| |
| |
Trading Companies & Distributors | |
Wireless Telecommunication Services | |
| |
| |
| Excludes short-term securities, short investments and options, if any. |
| For purposes of this report, industry sub-classifications may differ from those utilized for compliance purposes. |
| Includes one or more investment categories that individually represents less than 1.0% of the Trust ’ s total investments. Please refer to the Schedule of Investments for details. |
Trust Summary
as of June 30, 2024
BlackRock Resources & Commodities Strategy Trust (BCX)
BlackRock Resources & Commodities Strategy Trust
primary investment objective is to seek high current income and current gains, with a
secondary objective of capital appreciation. The Trust will seek to achieve its investment objectives, under normal market conditions, by investing at least 80% of its total assets
in equity securities issued by commodity or natural resources companies, derivatives with exposure to commodity or natural resources companies or investments in securities
and derivatives linked to the underlying price movement of commodities or natural resources. While permitted, the Trust does not currently expect to invest in securities and
derivatives linked to the underlying price movement of commodities or natural resources. The Trust seeks to pursue this goal primarily by investing in a portfolio of equity
securities and also by employing a strategy of writing (selling) call and put options.
No assurance can be given that the Trust’s investment objectives will be achieved.
Symbol on New York Stock Exchange | |
| |
Current Distribution Rate on Closing Market Price as of June 30, 2024 ($9.19) (a) | |
Current Monthly Distribution per Common Share (b) | |
Current Annualized Distribution per Common Share (b) | |
| Current distribution rate on closing market price is calculated by dividing the current annualized distribution per share by the closing market price. The current distribution rate may consist of income, net realized gains and/or a return of capital. Past performance is not an indication of future results. |
| The distribution rate is not constant and is subject to change. A portion of the distribution may be deemed a return of capital or net realized gain. |
Market Price and Net Asset Value Per Share Summary
Returns for the period ended June 30, 2024 were as follows:
| | Average Annual Total Returns |
| | | | |
| | | | |
Trust at Market Price (a)(b) | | | | |
MSCI ACWI Select Liquidity Natural Resources Call Overwrite Index | | | | |
S&P Global Natural Resources Net Index | | | | |
| All returns reflect reinvestment of dividends and/or distributions at actual reinvestment prices. |
| The Trust ’ s discount to NAV narrowed during the period, which accounts for the difference between performance based on market price and performance based on NAV. |
| An index that incorporates an option overlay component on the MSCI ACWI Select Liquidity Natural Resources Index with a 33% overwrite level. The benchmark commenced on December 31, 2018 and therefore the benchmark does not have 10-year returns. |
| An index that includes approximately 90 of the largest publicly-traded companies in the natural resources and commodities businesses that meet specific investability requirements across three primary commodity-related sectors: agribusiness, energy, and metals and mining. |
Performance results may include adjustments made for financial reporting purposes in accordance with U.S. generally accepted accounting principles.
Past performance is not an indication of future results.
The Trust is presenting the performance of one or more indices for informational purposes only. The Trust
is actively managed and does not seek to track or replicate the
performance of any index. The index performance shown is not intended to be indicative of the Trust’s investment strategies, portfolio components or past or future
performance.
More information about the Trust’s historical performance can be found in the “Closed End Funds” section of
.
The following discussion relates to the Trust’s absolute performance based on NAV:
What factors influenced performance?
Natural resources stocks posted flat returns and lagged the broader equity market in the first half of 2024, as the backdrop of high interest rates and slowing global growth
weighed on the demand outlook for commodities.
Holdings in energy companies contributed to performance, as sticky inflation, geopolitical risk, and higher oil prices served as tailwinds for the sector. Exxon Mobil Corp., a
U.S.-based integrated energy firm, was the largest contributor at the individual stock level. The company reported strong earnings, and it completed its strategic acquisition of
Pioneer Resources. Shell PLC, a European-based integrated energy firm that benefited from higher oil prices and its divestment of less profitable projects, also contributed to
performance.
22
2024
BlackRock Semi-Annual Report to Shareholders
Trust Summary
as of June 30, 2024
(continued)
BlackRock Resources & Commodities Strategy Trust (BCX)
Positions in the metals and mining sub-sector detracted from performance as a group due to mixed economic data in China and anticipation of reduced real estate
development in the country. Vale SA, a Brazil-based mining company, was a leading single-stock detractor as the concerns about China weighed on the price of iron ore. The
agribusiness firm Archer Daniels Midland Co., which faced an accounting scandal and pressure on margins due to an oversupply of grain commodities, also detracted.
The Trust used an options overlay strategy in which calls were written on a portion of the portfolio’s holdings. This strategy contributed to results during the reporting period.
The Trust
’
s practice of maintaining a specified level of monthly distributions to shareholders did not have a material impact on the Trust
’
s investment strategy.
Describe recent portfolio activity.
The Trust initiated positions in exploration and production oil and gas companies with exposure to U.S. shale, Hess Corp. and Diamondback Energy, Inc. It also added to
existing holdings in two diversified mining companies, Teck Resources Ltd. and Anglo American PLC, as well as the gold miner, Barrick Gold Corp. The Trust reduced its
weightings in several integrated oil and gas companies and the nitrogen fertilizer manufacturer CF Industries Holdings, Inc. It also exited its positions in Vale SA, Agco Corp.,
and Archer Daniels Midland Co.
Describe portfolio positioning at period end.
The portfolio had weightings of 40.3% of the portfolio was invested in the energy sector, 36.3% in mining, and 21.4% in agriculture. The remaining 0.5% was held in cash.
As of June 30, 2024, the Trust had in place an option overwriting program whereby 30.7% of the underlying equities were overwritten with call options on individual stocks.
These call options were typically written at prices above the prevailing market prices (estimated to be 3.6% out of the money) and for maturities averaging 50 days.
The views expressed reflect the opinions of BlackRock as of the date of this report and are subject to change based on changes in market, economic or other conditions.
These views are not intended to be a forecast of future events and are no guarantee of future results.
Overview of the Trust’s Total Investments
|
| |
| |
| |
| |
| |
| |
Wheaton Precious Metals Corp. | |
| |
| |
| |
| |
|
| |
Oil, Gas & Consumable Fuels | |
| |
| |
| |
| |
Energy Equipment & Services | |
| |
| |
| Excludes short-term securities, short investments and options, if any. |
| For purposes of this report, industry sub-classifications may differ from those utilized for compliance purposes. |
Trust Summary
as of June 30, 2024
BlackRock Science and Technology Term Trust (BSTZ)
BlackRock Science and Technology Term
investment objective is to provide total return and income through a combination of current income,
current gains and long-term capital appreciation. The Trust seeks to achieve its investment objective by investing, under normal market conditions, at least 80% of its total
assets in equity securities issued by U.S. and non-U.S. science and technology companies in any market capitalization range, selected for their rapid and sustainable growth
potential from the development, advancement and use of science and/or technology. The Trust seeks to pursue this goal primarily by investing in a portfolio of equity securities
and also by employing a strategy of writing (selling) call and put options.
No assurance can be given that the Trust’s investment objective will be achieved.
Symbol on New York Stock Exchange | |
| |
Current Distribution Rate on Closing Market Price as of June 30, 2024 ($19.91) (a) | |
Current Monthly Distribution per Common Share (b)(c) | |
Current Annualized Distribution per Common Share (c) | |
| Current distribution rate on closing market price is calculated by dividing the current annualized distribution per share by the closing market price. The current distribution rate may consist of income, net realized gains and/or a return of capital. Past performance is not an indication of future results. |
| The distribution rate is not constant and is subject to change. A portion of the distribution may be deemed a return of capital or net realized gain. |
| The monthly distribution per Common Share, declared on August 1, 2024, was increased to $0.214050 per share. The current distribution rate on closing market price, current monthly distribution per Common Share, and current annualized distribution per Common Share do not reflect the new distribution rate. The new distribution rate is not constant and is subject to change in the future. A portion of the distribution may be deemed a return of capital or net realized gain. |
Market Price and Net Asset Value Per Share Summary
Returns for the period ended June 30, 2024 were as follows:
| | Average Annual Total Returns |
| | | | |
| | | | |
Trust at Market Price (b)(c) | | | | |
MSCI Custom ACWI SMID Growth IT Call Overwrite Index | | | | |
| | | | |
| BSTZ commenced operations on June 27, 2019. |
| All returns reflect reinvestment of dividends and/or distributions at actual reinvestment prices. |
| The Trust ’ s discount to NAV narrowed during the period, which accounts for the difference between performance based on market price and performance based on NAV. |
| An index representing the Information Technology sector stocks within the MSCI ACWI SMID Cap Growth Index and incorporating an option overlay component with a 25% overwrite level. An index that captures mid- and small-cap securities exhibiting overall growth style characteristics across certain developed and emerging markets. The index commenced on March 31, 2022 and therefore the since inception return presented is for the period March 31, 2022 through the current reporting period. |
| An index that captures large- and mid-cap representation across certain developed and emerging markets. |
Performance results may include adjustments made for financial reporting purposes in accordance with U.S. generally accepted accounting principles.
Past performance is not an indication of future results.
The Trust is presenting the performance of one or more indices for informational purposes only. The Trust
is actively managed and does not seek to track or replicate the
performance of any index. The index performance shown is not intended to be indicative of the Trust’s investment strategies, portfolio components or past or future
performance.
More information about the Trust’s historical performance can be found in the “Closed End Funds” section of
.
The following discussion relates to the Trust’s relative performance based on NAV:
What factors influenced performance?
At the industry level, security selection in the semiconductors and information technology services sub-sectors were the largest contributors to relative performance.
24
2024
BlackRock Semi-Annual Report to Shareholders
Trust Summary
as of June 30, 2024
(continued)
BlackRock Science and Technology Term Trust (BSTZ)
Among individual holdings, an out-of-benchmark position in NVIDIA, Inc. was the leading contributor. The stock continued to rise after consecutive earnings releases that
demonstrated robust demand from data center customers. The firm’s graphics processing units (“GPU”s), which enable artificial intelligence (“AI”), have driven robust revenue
growth. An out-of-benchmark position in the South Korean semiconductor stock, SK Hynix Corp., was a notable contributor, as well. The shares rose due to resilient demand
for the company’s high bandwidth memory chips, which are critical components within the AI supply chain. An out-of-benchmark private position in the “buy-now, pay-later”
financial technology company Klarna Bank AB also contributed. The firm reported healthy growth and smaller losses than previously anticipated, causing its valuation to
appreciate.
Security selection in the software and content and infrastructure sub-sectors detracted from relative performance.
An out-of-benchmark position in Snyk Limited was the single largest detractor. The private cybersecurity company’s valuation declined as shares of its publicly traded industry
peers weakened on demand concerns. Not holding a position in the data analytics software company Palantir Technologies, Inc., which suffered from slowing demand from its
government customers, also detracted. An out-of-benchmark private position in the data infrastructure company Databricks detracted, as well. The company’s valuation
declined in sympathy with those of similar public companies due to weak demand from enterprises.
The Trust used an options overlay strategy in which calls were written on a portion of the portfolio’s holdings. The Trust’s options overlay strategy detracted from relative
performance.
The Trust’s practice of maintaining a specified level of monthly distributions did not have a material impact on the Trust’s investment strategy.
Describe recent portfolio activity.
The Trust added to companies that are critical to the AI supply chain, including those in the semiconductors and hardware sub-sectors. It trimmed select software holdings
where near-term demand remained muted. From a regional perspective, it further reduced holdings in Asian equities and added to the United States and Europe, where the
investment adviser identified both attractive fundamentals and near-term catalysts. The Trust did not make any additional investments in private technology companies.
Describe portfolio positioning at period end.
As of June 30, 2024, the Trust held 22 private investments, comprising 28.4% of total assets for a total commitment of approximately $496 million.
The investment adviser continued to seek opportunities to harvest the illiquidity premium by taking advantage of the Trust’s closed-end structure by adding holdings in private
investments as capacity increased.
The Trust held 36% of net asset value in semiconductors, 28% in software, 14% in hardware, 10% in services, 9% in internet, 2% in new industries, and 2% in content &
infrastructure. These industry weightings were the result of bottom-up stock selection.
As of June 30, 2024, the Trust had in place an option overwriting program whereby 18.8% of the underlying equities were overwritten with call options on individual stocks.
These call options were typically written at prices above the prevailing market prices (estimated to be 5.2% out of the money) and for maturities averaging 49 days.
The views expressed reflect the opinions of BlackRock as of the date of this report and are subject to change based on changes in market, economic or other conditions.
These views are not intended to be a forecast of future events and are no guarantee of future results.
Trust Summary
as of June 30, 2024
(continued)
BlackRock Science and Technology Term Trust (BSTZ)
Overview of the Trust’s Total Investments
|
| |
| |
| |
| |
| |
| |
| |
Credo Technology Group Holding Ltd. | |
| |
| |
| |
|
| |
Semiconductors & Semiconductor Equipment | |
| |
| |
Technology Hardware, Storage & Peripherals | |
| |
Interactive Media & Services | |
Electronic Equipment, Instruments & Components | |
| |
Consumer Staples Distribution & Retail | |
| |
| |
| |
Diversified Consumer Services | |
| |
| |
| |
| |
| |
| Excludes short-term securities, short investments and options, if any. |
| For purposes of this report, industry sub-classifications may differ from those utilized for compliance purposes. |
| Includes one or more investment categories that individually represents less than 1.0% of the Trust ’ s total investments. Please refer to the Consolidated Schedule of Investments for details. |
26
2024
BlackRock Semi-Annual Report to Shareholders
Trust Summary
as of June 30, 2024
BlackRock Science and Technology Trust (BST)
BlackRock Science and Technology Trust
investment objective is to provide income and total return through a combination of current income, current
gains and long-term capital appreciation. The Trust seeks to achieve its investment objective by investing, under normal market conditions, at least 80% of its total assets in
equity securities of U.S. and non-U.S. science and technology companies in any market capitalization range, selected for their rapid and sustainable growth potential from the
development, advancement and use of science and/or technology (high growth science and technology stocks), and/or potential to generate current income from
advantageous dividend yields (cyclical science and technology stocks). The Trust seeks to pursue this goal primarily by investing in a portfolio of equity securities and also by
employing a strategy of writing (selling) call and put options.
No assurance can be given that the Trust’s investment objective will be achieved.
Symbol on New York Stock Exchange | |
| |
Current Distribution Rate on Closing Market Price as of June 30, 2024 ($37.66) (a) | |
Current Monthly Distribution per Common Share (b) | |
Current Annualized Distribution per Common Share (b) | |
| Current distribution rate on closing market price is calculated by dividing the current annualized distribution per share by the closing market price. Past performance is not an indication |
| The distribution rate is not constant and is subject to change. |
Market Price and Net Asset Value Per Share Summary
Returns for the period ended June 30, 2024 were as follows:
| | Average Annual Total Returns |
| | | | |
| | | | |
Trust at Market Price (b)(c) | | | | |
MSCI ACWI Information Technology Call Overwrite Index | | | | |
MSCI ACWI Information Technology Index | | | | |
| BST commenced operations on October 30, 2014. |
| All returns reflect reinvestment of dividends and/or distributions at actual reinvestment prices. |
| The Trust ’ s discount to NAV widened during the period, which accounts for the difference between performance based on market price and performance based on NAV. |
| An index that incorporates an option overlay component on the MSCI ACWI IT Index with a 33% overwrite level. since inception. |
| An index that includes large- and mid-cap securities across certain Developed Markets countries and certain Emerging Markets countries. All securities in the index are classified in the Information Technology sector as per the Global Industry Classification Standard. |
Performance results may include adjustments made for financial reporting purposes in accordance with U.S. generally accepted accounting principles.
Past performance is not an indication of future results.
The Trust is presenting the performance of one or more indices for informational purposes only. The Trust
is actively managed and does not seek to track or replicate the
performance of any index. The index performance shown is not intended to be indicative of the Trust’s investment strategies, portfolio components or past or future
performance.
More information about the Trust’s historical performance can be found in the “Closed End Funds” section of
.
The following discussion relates to the Trust’s relative performance based on NAV:
What factors influenced performance?
At the industry level, an underweight in hardware and security selection in the internet sub-sector were the largest contributors to relative performance.
Trust Summary
as of June 30, 2024
(continued)
BlackRock Science and Technology Trust (BST)
An underweight position in Apple, Inc. was the largest contributor to performance at the individual security level. The stock lagged due to regulatory pressures and weak
demand in China, where it faced stiff competition from local smartphone brands. A zero weighting in Intel Corp. also contributed. The shares dropped after the company issued
disappointing guidance that caused investors to question its ability to keep pace in sales of chips to artificial intelligence (“AI”) data centers. An off-benchmark position in the
British semiconductor and software design company, Arm Holdings PLC, was an additional contributor of note. The stock rose as investors anticipated demand growth for the
firm’s AI infrastructure solutions.
Security selection in software and an out-of-benchmark allocation to the internet sub-sector were the largest detractors from relative performance.
An underweight in NVIDIA, Inc. was the most significant detractor among the Trust’s individual holdings. The stock continued to rise following consecutive earnings releases
that demonstrated robust demand from data center customers. The firm’s graphics processing units (“GPU”s), which enable AI, have driven robust revenue growth. An
out-of-benchmark private position in the data infrastructure company Databricks detracted, as well. The company’s valuation declined in sympathy with those of public
companies due to weak demand from enterprises. An out-of-benchmark position in Tesla, Inc. also detracted amid weakening demand for electric vehicles.
The Trust used an options overlay strategy in which calls were written on a portion of the portfolio’s holdings. The Trust’s options overlay strategy detracted from relative
performance.
The Trust’s practice of maintaining a specified level of monthly distributions to shareholders did not have a material impact on the Trust’s investment strategy.
Describe recent portfolio activity.
The Trust added to companies that are critical to the AI supply chain, including those in the semiconductors and hardware sub-sectors. It trimmed select software and services
holdings where near-term demand remained muted. From a regional perspective, it further reduced holdings in Asian equities and added to the United States and Europe,
where the investment adviser identified both attractive fundamentals and near-term catalysts. The Trust made two additional investments in private technology companies.
Describe portfolio positioning at period end.
The Trust held 37% of net asset value in semiconductors, 29% in software, 14% in internet, 12% in hardware, 6% in services, 2% in new industries, and 1% in content &
infrastructure. These industry weightings were the result of bottom-up stock selection.
As of June 30, 2024, the Trust had in place an option overwriting program whereby 28.0% of the underlying equities were overwritten with call options on individual stocks.
These call options were typically written at prices above the prevailing market prices (estimated to be 3.8% out of the money) and for maturities averaging 50 days.
The views expressed reflect the opinions of BlackRock as of the date of this report and are subject to change based on changes in market, economic or other conditions.
These views are not intended to be a forecast of future events and are no guarantee of future results.
Overview of the Trust’s Total Investments
|
| |
| |
| |
| |
| |
Cadence Design Systems, Inc. | |
| |
| |
| |
| |
| |
|
| |
Semiconductors & Semiconductor Equipment | |
| |
Technology Hardware, Storage & Peripherals | |
| |
Interactive Media & Services | |
| |
| |
| |
Diversified Consumer Services | |
| |
| |
Consumer Staples Distribution & Retail | |
| |
| |
| Excludes short-term securities, short investments and options, if any. |
| For purposes of this report, industry sub-classifications may differ from those utilized for compliance purposes. |
| Includes one or more investment categories that individually represents less than 1.0% of the Trust ’ s total investments. Please refer to the Consolidated Schedule of Investments for details. |
28
2024
BlackRock Semi-Annual Report to Shareholders
Trust Summary
as of June 30, 2024
BlackRock Utilities, Infrastructure & Power Opportunities Trust (BUI)
BlackRock Utilities, Infrastructure & Power Opportunities Trust
investment objective is to provide total return through a combination of current
income, current gains and long-term capital appreciation. The Trust seeks to achieve its investment objective by investing, under normal market conditions, at least 80% of its
total assets in equity securities issued by companies that are engaged in the Utilities, Infrastructure and Power Opportunities business segments anywhere in the world and by
employing a strategy of writing (selling) call and put options. The Trust considers the “Utilities” business segment to include products, technologies and services connected to
the management, ownership, operation, construction, development or financing of facilities used to generate, transmit or distribute electricity, water, natural resources or
telecommunications, the “Infrastructure” business segment to include companies that own or operate infrastructure assets or that are involved in the development,
construction, distribution or financing of infrastructure assets and the “Power Opportunities” business segment to include companies with a significant involvement in,
supporting, or necessary to renewable energy technology and development, alternative fuels, energy efficiency, automotive and sustainable mobility and technologies that
enable or support the growth and adoption of new power and energy sources. Under normal circumstances, the Trust invests a substantial amount of its total assets in foreign
issuers, issuers that primarily trade in a market located outside the United States or issuers that do a substantial amount of business outside the United States. The Trust may
invest directly in such securities or synthetically through the use of derivatives.
No assurance can be given that the Trust’s investment objective will be achieved.
Symbol on New York Stock Exchange | |
| |
Current Distribution Rate on Closing Market Price as of June 30, 2024 ($22.15) (a) | |
Current Monthly Distribution per Common Share (b) | |
Current Annualized Distribution per Common Share (b) | |
| Current distribution rate on closing market price is calculated by dividing the current annualized distribution per share by the closing market price. The current distribution rate may consist of income, net realized gains and/or a return of capital. Past performance is not an indication of future results. |
| The distribution rate is not constant and is subject to change. A portion of the distribution may be deemed a return of capital or net realized gain. |
Market Price and Net Asset Value Per Share Summary
Returns for the period ended June 30, 2024 were as follows:
| | Average Annual Total Returns |
| | | | |
| | | | |
Trust at Market Price (a)(b) | | | | |
MSCI World Select Energy, Utilities and Industry Call Overwrite Index | | | | |
| | | | |
| All returns reflect reinvestment of dividends and/or distributions at actual reinvestment prices. |
| The Trust ’ s discount to NAV narrowed during the period, which accounts for the difference between performance based on market price and performance based on NAV. |
| An index that incorporates an option overlay component on the MSCI World Select Energy, Utilities and Industry Index with a 33% overwrite level.The benchmark commenced on December 31, 2018 and therefore the benchmark does not have 10-year returns. |
| An index that captures large- and mid-cap representation across certain developed and emerging markets. |
Performance results may include adjustments made for financial reporting purposes in accordance with U.S. generally accepted accounting principles.
Past performance is not an indication of future results.
The Trust is presenting the performance of one or more indices for informational purposes only. The Trust
is actively managed and does not seek to track or replicate the
performance of any index. The index performance shown is not intended to be indicative of the Trust’s investment strategies, portfolio components or past or future
performance.
More information about the Trust’s historical performance can be found in the “Closed End Funds” section of
.
Trust Summary
as of June 30, 2024
(continued)
BlackRock Utilities, Infrastructure & Power Opportunities Trust (BUI)
The following discussion relates to the Trust’s relative performance based on NAV:
What factors influenced performance?
Positive contributors to the Trust’s performance during the reporting period included companies providing energy efficient solutions to industrial facilities and data centers.
Energy distribution and electric utility companies also contributed positively to performance. NextEra Energy Inc., a U.S.-based provider of clean power, was the largest
individual contributor to return over the period on optimism about rising electricity demand from U.S. data centers and manufacturing plants. Tran Technologies plc, a
U.S. energy efficiency company, also contributed notably to performance as the company saw strong demand for efficient heating, cooling, and ventilation systems.
Exposure to European companies detracted from the Trust’s performance over the period as the region’s economic growth underperformed that of the U.S. Holdings of RWE
AG, a Germany-based electric utility company, detracted as the company announced that its 2024 profits would be lower than expected due to a drop in wholesale energy
prices in European markets. Vestas Wind Systems, a Danish manufacturer of wind turbines, also detracted as the company reported an unexpected loss attributed to supply
chain issues, increased raw material costs, and competition from solar.
The Trust used an options overlay strategy in which calls were written on a portion of the portfolio’s holdings. The Trust’s options overlay strategy contributed to relative
performance in the period.
Describe recent portfolio activity.
The Trust initiated positions in firms that offer energy-efficient solutions for reshoring and grid-related projects, as well as those involved in enhancing energy efficiency in the
U.S. building sector. The Trust added to an existing position in a U.K.-based company specializing in grid infrastructure. The Trust took profits in select companies in the
building products and machinery industries and scaled back its investments in clean power utilities.
Describe portfolio positioning at period end.
At the end of the period, 44.0% of the portfolio was invested in the utilities sector, 35.5% in the industrials sector, and 11.4% in the energy sector. The remainder was invested
in other infrastructure- and power-related sectors.
The Trust had in place an option overwriting program under which 34.9% of the underlying equities were overwritten with call options on individual stocks. These call options
were typically written at prices above the prevailing market prices (estimated to be 2.8% out of the money) and for maturities averaging 53 days.
The views expressed reflect the opinions of BlackRock as of the date of this report and are subject to change based on changes in market, economic or other conditions.
These views are not intended to be a forecast of future events and are no guarantee of future results.
Overview of the Trust’s Total Investments
|
| |
| |
| |
Oil, Gas & Consumable Fuels | |
| |
| |
Independent Power and Renewable Electricity Producers | |
Construction & Engineering | |
Commercial Services & Supplies | |
Semiconductors & Semiconductor Equipment | |
| |
| |
| |
Electronic Equipment, Instruments & Components | |
| Excludes short-term securities, short investments and options, if any. |
| For purposes of this report, industry sub-classifications may differ from those utilized for compliance purposes. |
30
2024
BlackRock Semi-Annual Report to Shareholders
Schedule of Investments
(unaudited)
BlackRock Energy and Resources Trust (BGR)
(Percentages shown are based on Net Assets)
| | | |
|
Energy Equipment & Services — 6.9% | |
Patterson-UTI Energy, Inc. | | | |
| | | |
| | | |
| | | |
| | | |
Weatherford International PLC (a) | | | |
| | | |
Oil, Gas & Consumable Fuels — 92.6% | |
| | | |
| | | |
Canadian Natural Resources Ltd. | | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
PBF Energy, Inc., Class A | | | |
| | | |
Permian Resources Corp., Class A | | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
Total Long-Term Investments — 99.5% | |
| | | |
|
Money Market Funds — 1.1% | |
BlackRock Liquidity Funds, T-Fund, Institutional Shares, | | | |
Total Short-Term Securities — 1.1% | |
Total Investments Before Options Written — 100.6% | |
(Premiums Received: $(2,444,720)) | |
Total Investments, Net of Options Written — 99.9% | |
Other Assets Less Liabilities — 0.1% | |
| |
| Non-income producing security. |
| All or a portion of the security has been pledged as collateral in connection with outstanding OTC derivatives. |
| All or a portion of the security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written. |
| Security is valued using significant unobservable inputs and is classified as Level 3 in the |
| |
| Annualized 7-day yield as of period end. |
For purposes of this report, industry and sector sub-classifications may differ from those utilized by the Trust for compliance purposes.
Investments in issuers considered to be affiliate(s) of the Trust during the six months ended June 30, 2024 for purposes of Section 2(a)(3) of the Investment Company Act of
1940, as amended, were as follows:
| | | | | | | | | |
BlackRock Liquidity Funds, T-Fund, Institutional Shares | | | | | | | | | |
| Represents net amount purchased (sold). |
Derivative Financial Instruments Outstanding as of Period End
Exchange-Traded Options Written
Schedule of Investments
31
Schedule of Investments
(unaudited)
(continued)
BlackRock Energy and Resources Trust (BGR)
Exchange-Traded Options Written (continued)
| | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Canadian Natural Resources Ltd. | | | | | | | |
Canadian Natural Resources Ltd. | | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
PBF Energy, Inc., Class A | | | | | | | |
Permian Resources Corp., Class A | | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Weatherford International PLC | | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Patterson-UTI Energy, Inc. | | | | | | | |
| | | | | | | |
Permian Resources Corp., Class A | | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Weatherford International PLC | | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
32
2024
BlackRock Semi-Annual Report to Shareholders
Schedule of Investments
(unaudited)
(continued)
BlackRock Energy and Resources Trust (BGR)
| | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| Goldman Sachs International | | | | | | | |
| | | | | | | | |
| Morgan Stanley & Co. International PLC | | | | | | | |
| Morgan Stanley & Co. International PLC | | | | | | | |
| | | | | | | | |
| Morgan Stanley & Co. International PLC | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| Goldman Sachs International | | | | | | | |
| | | | | | | | |
| | | | | | | | |
Balances Reported in the Statements of Assets and Liabilities for Options Written
Derivative Financial Instruments Categorized by Risk Exposure
As of period end, the fair values of derivative financial instruments located in the Statements of Assets and Liabilities were as follows:
| | | | | | | |
Liabilities — Derivative Financial Instruments | | | | | | | |
| | | | | | | |
For the period ended June 30, 2024, the effect of derivative financial instruments in the Statements of Operations was as follows:
| | | | | | | |
Net Realized Gain (Loss) from: | | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Net Change in Unrealized Appreciation (Depreciation) on: | | | | | | | |
| | | | | | | |
| Options purchased are included in net realized gain (loss) from investments — unaffiliated. |
Average Quarterly Balances of Outstanding Derivative Financial Instruments
| |
Average value of option contracts purchased | |
Average value of option contracts written | |
| Derivative financial instrument not held at any quarter-end. The risk exposure table serves as an indicator of activity during the period. |
For more information about the Trust’s investment risks regarding derivative financial instruments, refer to the Notes to Financial Statements.
Schedule of Investments
33
Schedule of Investments
(unaudited)
(continued)
BlackRock Energy and Resources Trust (BGR)
Derivative Financial Instruments — Offsetting as of Period End
The Trust’s derivative assets and liabilities (by type) were as follows:
| | |
Derivative Financial Instruments | | |
| | |
Total derivative assets and liabilities in the Statements of Assets and Liabilities | | |
Derivatives not subject to a Master Netting Agreement or similar agreement (“MNA”) | | |
Total derivative assets and liabilities subject to an MNA | | |
The following table presents the Trust’s derivative liabilities by counterparty net of amounts available for offset under an MNA and net of the related collateral pledged by the
Trust:
| | | | | |
| | | | | |
| | | | | |
Goldman Sachs International | | | | | |
| | | | | |
Morgan Stanley & Co. International PLC | | | | | |
| | | | | |
| | | | | |
| | | | | |
| Excess of collateral received/pledged, if any, from the individual counterparty is not shown for financial reporting purposes. |
| Net amount represents the net amount payable due to counterparty in the event of default. Net amount may be offset further by the options written receivable/payable on the Statements of Assets and Liabilities. |
Fair Value Hierarchy as of Period End
Various inputs are used in determining the fair value of financial instruments. For a description of the input levels and information about the Trust’s policy regarding valuation
of financial instruments, refer to the Notes to Financial Statements.
The following table summarizes the Trust’s financial instruments categorized in the fair value hierarchy. The breakdown of the Trust
’
s financial instruments into major categories
is disclosed in the Schedule of Investments above.
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
Energy Equipment & Services | | | | |
Oil, Gas & Consumable Fuels | | | | |
| | | | |
| | | | |
| | | | |
Derivative Financial Instruments (a) | | | | |
| | | | |
| | | | |
| Derivative financial instruments are options written. Options written are shown at value. |
See notes to financial statements.
34
2024
BlackRock Semi-Annual Report to Shareholders
Schedule of Investments
(unaudited)
BlackRock Enhanced Capital and Income Fund, Inc. (CII)
(Percentages shown are based on Net Assets)
| | | |
|
Aerospace & Defense — 1.0% | |
| | | |
Automobile Components — 1.1% | |
| | | |
| |
| | | |
| |
| | | |
| |
| | | |
| |
Intercontinental Exchange, Inc. (b) | | | |
LPL Financial Holdings, Inc. | | | |
| | | |
| |
Air Products and Chemicals, Inc. | | | |
| | | |
| | | |
Communications Equipment — 1.3% | |
| | | |
Consumer Staples Distribution & Retail — 1.8% | |
| | | |
Electronic Equipment, Instruments & Components — 1.7% | |
Zebra Technologies Corp., Class A (a) | | | |
| |
| | | |
TKO Group Holdings, Inc., Class A | | | |
| | | |
Financial Services — 2.6% | |
Berkshire Hathaway, Inc., Class B (a)(b) | | | |
Health Care Providers & Services — 7.3% | |
| | | |
| | | |
| | | |
Tenet Healthcare Corp. (a) | | | |
| | | |
| | | |
Health Care Technology — 0.8% | |
Veeva Systems, Inc., Class A (a) | | | |
Hotels, Restaurants & Leisure — 0.7% | |
| | | |
Household Durables — 2.0% | |
| | | |
| | | |
| |
Fidelity National Financial, Inc., Class A | | | |
Reinsurance Group of America, Inc. (b) | | | |
| | | |
Interactive Media & Services — 10.1% | |
| | | |
Meta Platforms, Inc., Class A (b) | | | |
| | | |
| |
Cognizant Technology Solutions Corp., Class A | | | |
Life Sciences Tools & Services — 3.6% | |
| | | |
| | | |
Thermo Fisher Scientific, Inc. (c) | | | |
| | | |
| |
| | | |
| | | |
Westinghouse Air Brake Technologies Corp. | | | |
| | | |
| |
Comcast Corp., Class A (b) | | | |
Oil, Gas & Consumable Fuels — 3.6% | |
| | | |
| | | |
| | | |
| | | |
| |
Novo Nordisk A/S, Class B, ADR (c) | | | |
| | | |
| | | |
Professional Services — 0.8% | |
Dun & Bradstreet Holdings, Inc. | | | |
Semiconductors & Semiconductor Equipment — 12.3% | |
Advanced Micro Devices, Inc. (a)(d) | | | |
Applied Materials, Inc. (b) | | | |
| | | |
| | | |
| | | |
| | | |
| |
| | | |
| |
| | | |
| |
| | | |
Technology Hardware, Storage & Peripherals — 4.3% | |
| | | |
Schedule of Investments
35
Schedule of Investments
(unaudited)
(continued)
BlackRock Enhanced Capital and Income Fund, Inc. (CII)
(Percentages shown are based on Net Assets)
| | | |
Textiles, Apparel & Luxury Goods — 1.0% | |
Skechers USA, Inc., Class A (a) | | | |
Total Long-Term Investments — 100.6% | |
|
Money Market Funds — 1.1% | |
BlackRock Cash Funds: Institutional, SL Agency Shares, | | | |
BlackRock Liquidity Funds, T-Fund, Institutional Shares, | | | |
Total Short-Term Securities — 1.1% | |
Total Investments Before Options Written — 101.7% | |
(Premiums Received: $(11,273,204)) | |
Total Investments, Net of Options Written — 100.4% | |
Liabilities in Excess of Other Assets — (0.4)% | |
| |
| Non-income producing security. |
| All or a portion of the security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written. |
| All or a portion of this security is on loan. |
| All or a portion of the security has been pledged as collateral in connection with outstanding OTC derivatives. |
| |
| Annualized 7-day yield as of period end. |
| All or a portion of this security was purchased with the cash collateral from loaned |
For purposes of this report, industry and sector sub-classifications may differ from those utilized by the Trust for compliance purposes.
Investments in issuers considered to be affiliate(s) of the Trust during the six months ended June 30, 2024 for purposes of Section 2(a)(3) of the Investment Company Act of
1940, as amended, were as follows:
| | | | | | | | | |
BlackRock Cash Funds: Institutional, SL Agency | | | | | | | | | |
BlackRock Liquidity Funds, T-Fund, Institutional Shares | | | | | | | | | |
SL Liquidity Series, LLC, Money Market Series (c) | | | | | | | | | |
| | | | | | | | | |
| Represents net amount purchased (sold). |
| All or a portion represents securities lending income earned from the reinvestment of cash collateral from loaned securities, net of fees and collateral investment expenses, and other payments to and from borrowers of securities. |
| As of period end, the entity is no longer held. |
Derivative Financial Instruments Outstanding as of Period End
Exchange-Traded Options Written
| | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Meta Platforms, Inc., Class A | | | | | | | |
| | | | | | | |
| | | | | | | |
36
2024
BlackRock Semi-Annual Report to Shareholders
Schedule of Investments
(unaudited)
(continued)
BlackRock Enhanced Capital and Income Fund, Inc. (CII)
Exchange-Traded Options Written (continued)
| | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Meta Platforms, Inc., Class A | | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Advanced Micro Devices, Inc. | | | | | | | |
Air Products and Chemicals, Inc. | | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Berkshire Hathaway, Inc., Class B | | | | | | | |
| | | | | | | |
| | | | | | | |
Cognizant Technology Solutions Corp., Class A | | | | | | | |
Cognizant Technology Solutions Corp., Class A | | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Fidelity National Financial, Inc., Class A | | | | | | | |
| | | | | | | |
| | | | | | | |
Intercontinental Exchange, Inc. | | | | | | | |
| | | | | | | |
LPL Financial Holdings, Inc. | | | | | | | |
LPL Financial Holdings, Inc. | | | | | | | |
| | | | | | | |
Meta Platforms, Inc., Class A | | | | | | | |
Meta Platforms, Inc., Class A | | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Novo Nordisk A/S, Class B, ADR | | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Skechers USA, Inc., Class A | | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
TKO Group Holdings, Inc., Class A | | | | | | | |
Westinghouse Air Brake Technologies Corp. | | | | | | | |
Zebra Technologies Corp., Class A | | | | | | | |
Advanced Micro Devices, Inc. | | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Schedule of Investments
37
Schedule of Investments
(unaudited)
(continued)
BlackRock Enhanced Capital and Income Fund, Inc. (CII)
Exchange-Traded Options Written (continued)
| | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Novo Nordisk A/S, Class B, ADR | | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Berkshire Hathaway, Inc., Class B | | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Meta Platforms, Inc., Class A | | | | | | | |
| | | | | | | |
| | | | | | | |
Novo Nordisk A/S, Class B, ADR | | | | | | | |
| | | | | | | |
| | | | | | | |
Thermo Fisher Scientific, Inc. | | | | | | | |
Zebra Technologies Corp., Class A | | | | | | | |
Air Products and Chemicals, Inc. | | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Intercontinental Exchange, Inc. | | | | | | | |
LPL Financial Holdings, Inc. | | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Skechers USA, Inc., Class A | | | | | | | |
| | | | | | | |
Thermo Fisher Scientific, Inc. | | | | | | | |
| | | | | | | |
Veeva Systems, Inc., Class A | | | | | | | |
Westinghouse Air Brake Technologies Corp. | | | | | | | |
Zebra Technologies Corp., Class A | | | | | | | |
Intercontinental Exchange, Inc. | | | | | | | |
| | | | | | | |
38
2024
BlackRock Semi-Annual Report to Shareholders
Schedule of Investments
(unaudited)
(continued)
BlackRock Enhanced Capital and Income Fund, Inc. (CII)
| | | | | | |
| | | | | | | | |
| Morgan Stanley & Co. International PLC | | | | | | | |
| | | | | | | | |
Dun & Bradstreet Holdings, Inc. | | | | | | | | |
| Goldman Sachs International | | | | | | | |
| | | | | | | | |
Reinsurance Group of America, Inc. | | | | | | | | |
Fidelity National Financial, Inc., Class A | Morgan Stanley & Co. International PLC | | | | | | | |
| Morgan Stanley & Co. International PLC | | | | | | | |
Reinsurance Group of America, Inc. | Goldman Sachs International | | | | | | | |
| Morgan Stanley & Co. International PLC | | | | | | | |
| | | | | | | | |
Balances Reported in the Statements of Assets and Liabilities for Options Written
Derivative Financial Instruments Categorized by Risk Exposure
As of period end, the fair values of derivative financial instruments located in the Statements of Assets and Liabilities were as follows:
| | | | | | | |
Liabilities — Derivative Financial Instruments | | | | | | | |
| | | | | | | |
For the period ended June 30, 2024, the effect of derivative financial instruments in the Statements of Operations was as follows:
| | | | | | | |
Net Realized Gain (Loss) from: | | | | | | | |
| | | | | | | |
Net Change in Unrealized Appreciation (Depreciation) on: | | | | | | | |
| | | | | | | |
Average Quarterly Balances of Outstanding Derivative Financial Instruments
| |
Average value of option contracts written | |
For more information about the Trust’s investment risks regarding derivative financial instruments, refer to the Notes to Financial Statements.
Schedule of Investments
39
Schedule of Investments
(unaudited)
(continued)
BlackRock Enhanced Capital and Income Fund, Inc. (CII)
Derivative Financial Instruments — Offsetting as of Period End
The Trust’s derivative assets and liabilities (by type) were as follows:
| | |
Derivative Financial Instruments | | |
| | |
Total derivative assets and liabilities in the Statements of Assets and Liabilities | | |
Derivatives not subject to a Master Netting Agreement or similar agreement (“MNA”) | | |
Total derivative assets and liabilities subject to an MNA | | |
The following table presents the Trust’s derivative liabilities by counterparty net of amounts available for offset under an MNA and net of the related collateral pledged by the
Trust:
| | | | | |
| | | | | |
| | | | | |
Goldman Sachs International | | | | | |
Morgan Stanley & Co. International PLC | | | | | |
| | | | | |
| Excess of collateral received/pledged, if any, from the individual counterparty is not shown for financial reporting purposes. |
| Net amount represents the net amount payable due to counterparty in the event of default. Net amount may be offset further by the options written receivable/payable on the Statements of Assets and Liabilities. |
Fair Value Hierarchy as of Period End
Various inputs are used in determining the fair value of financial instruments. For a description of the input levels and information about the Trust’s policy regarding valuation
of financial instruments, refer to the Notes to Financial Statements.
The following table summarizes the Trust’s financial instruments categorized in the fair value hierarchy. The breakdown of the Trust
’
s financial instruments into major categories
is disclosed in the Schedule of Investments above.
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
Consumer Staples Distribution & Retail | | | | |
Electronic Equipment, Instruments & Components | | | | |
| | | | |
| | | | |
Health Care Providers & Services | | | | |
| | | | |
Hotels, Restaurants & Leisure | | | | |
| | | | |
| | | | |
Interactive Media & Services | | | | |
| | | | |
Life Sciences Tools & Services | | | | |
| | | | |
| | | | |
40
2024
BlackRock Semi-Annual Report to Shareholders
Schedule of Investments
(unaudited)
(continued)
BlackRock Enhanced Capital and Income Fund, Inc. (CII)
Fair Value Hierarchy as of Period End (continued)
| | | | |
Common Stocks (continued) | | | | |
Oil, Gas & Consumable Fuels | | | | |
| | | | |
| | | | |
Semiconductors & Semiconductor Equipment | | | | |
| | | | |
| | | | |
| | | | |
Technology Hardware, Storage & Peripherals | | | | |
Textiles, Apparel & Luxury Goods | | | | |
| | | | |
| | | | |
| | | | |
Derivative Financial Instruments (a) | | | | |
| | | | |
| | | | |
| Derivative financial instruments are options written. Options written are shown at value. |
See notes to financial statements.
Schedule of Investments
41
Consolidated Schedule of Investments
(unaudited)
BlackRock Enhanced Equity Dividend Trust (BDJ)
(Percentages shown are based on Net Assets)
| | | |
|
| |
L3Harris Technologies, Inc. (b) | | | |
| | | |
| | | |
Automobile Components — 0.4% | |
| | | |
| |
| | | |
| |
| | | |
| | | |
Citizens Financial Group, Inc. | | | |
First Citizens BancShares, Inc., Class A (b) | | | |
| | | |
| | | |
| | | |
| |
| | | |
| | | |
| | | |
| | | |
| |
Alibaba Group Holding Ltd. | | | |
| |
| | | |
Johnson Controls International PLC | | | |
| | | |
| |
| | | |
Goldman Sachs Group, Inc. | | | |
Intercontinental Exchange, Inc. | | | |
Raymond James Financial, Inc. | | | |
UBS Group AG, Registered Shares | | | |
| | | |
| |
Air Products and Chemicals, Inc. | | | |
| | | |
International Flavors & Fragrances, Inc. | | | |
| | | |
Communications Equipment — 1.5% | |
| | | |
Consumer Staples Distribution & Retail — 1.0% | |
| | | |
Containers & Packaging — 1.4% | |
| | | |
Diversified Telecommunication Services — 1.8% | |
| | | |
Verizon Communications, Inc. (b) | | | |
| | | |
Electric Utilities — 3.7% | |
American Electric Power Co., Inc. | | | |
| | | |
| | | |
| | | |
Electric Utilities (continued) | |
| | | |
| | | |
| | | |
| |
| | | |
Financial Services — 4.4% | |
AP Arsenal Co. Invest LP (c)(d) | | | |
Fidelity National Information Services, Inc. (b) | | | |
| | | |
| | | |
| |
| | | |
Health Care Equipment & Supplies — 4.6% | |
Baxter International, Inc. (a) | | | |
Koninklijke Philips NV (d) | | | |
| | | |
| | | |
Health Care Providers & Services — 8.9% | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
Household Durables — 1.7% | |
| | | |
| | | |
| | | |
| | | |
| |
American International Group, Inc. (a) | | | |
Fidelity National Financial, Inc., Class A | | | |
| | | |
| | | |
| | | |
| |
Cognizant Technology Solutions Corp., Class A (a) | | | |
| |
| | | |
Life Sciences Tools & Services — 0.6% | |
Fortrea Holdings, Inc. (d) | | | |
Thermo Fisher Scientific, Inc. | | | |
| | | |
| |
| | | |
| | | |
Stanley Black & Decker, Inc. | | | |
Westinghouse Air Brake Technologies Corp. | | | |
| | | |
| |
Comcast Corp., Class A (a) | | | |
| | | |
| | | |
| | | |
42
2024
BlackRock Semi-Annual Report to Shareholders
Consolidated Schedule of Investments
(unaudited)
(continued)
BlackRock Enhanced Equity Dividend Trust (BDJ)
(Percentages shown are based on Net Assets)
| | | |
| |
| | | |
Oil, Gas & Consumable Fuels — 8.7% | |
| | | |
Enterprise Products Partners LP (a) | | | |
Formentera Partners Fund II LP (c)(e) | | | |
| | | |
| | | |
| | | |
| | | |
Personal Care Products — 0.6% | |
| | | |
| |
| | | |
Bayer AG, Class N, Registered Shares | | | |
| | | |
| | | |
| | | |
| | | |
Professional Services — 3.3% | |
| | | |
SS&C Technologies Holdings, Inc. | | | |
| | | |
| |
Mid-America Apartment Communities, Inc. | | | |
Semiconductors & Semiconductor Equipment — 2.9% | |
Micron Technology, Inc. (b) | | | |
Taiwan Semiconductor Manufacturing Co. Ltd., ADR | | | |
| | | |
| |
| | | |
| |
| | | |
Technology Hardware, Storage & Peripherals — 1.3% | |
Hewlett Packard Enterprise Co. | | | |
| | | |
| | | |
Textiles, Apparel & Luxury Goods — 0.8% | |
| | | |
| | | |
| | | |
| |
British American Tobacco PLC, ADR | | | |
Total Common Stocks — 98.0% | |
| | | |
|
|
Household Products — 0.5% | |
| | | |
| |
Total Preferred Securities — 0.5% | |
Total Long-Term Investments — 98.5% | |
|
Money Market Funds — 2.2% | |
BlackRock Liquidity Funds, T-Fund, Institutional | | | |
Total Short-Term Securities — 2.2% | |
Total Investments Before Options Written — 100.7% | |
(Premiums Received: $(17,968,047)) | |
Total Investments, Net of Options Written — 99.8% | |
Other Assets Less Liabilities — 0.2% | |
| |
| All or a portion of the security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written. |
| All or a portion of the security has been pledged as collateral in connection with outstanding OTC derivatives. |
| Security is valued using significant unobservable inputs and is classified as Level 3 in the |
| Non-income producing security. |
| All or a portion of the security is held by a wholly-owned subsidiary. See Note 1 of the Notes to Consolidated Financial Statements for details on the wholly-owned subsidiary. |
| Investment does not issue shares. |
| |
| Annualized 7-day yield as of period end. |
For purposes of this report, industry and sector sub-classifications may differ from those utilized by the Trust for compliance purposes.
Schedule of Investments
43
Consolidated Schedule of Investments
(unaudited)
(continued)
BlackRock Enhanced Equity Dividend Trust (BDJ)
Investments in issuers considered to be affiliate(s) of the Trust during the six months ended June 30, 2024 for purposes of Section 2(a)(3) of the Investment Company Act of
1940, as amended, were as follows:
| | | | | | | | | |
BlackRock Cash Funds: Institutional, SL Agency | | | | | | | | | |
BlackRock Liquidity Funds, T-Fund, Institutional Shares | | | | | | | | | |
| | | | | | | | | |
| As of period end, the entity is no longer held. |
| Represents net amount purchased (sold). |
| All or a portion represents securities lending income earned from the reinvestment of cash collateral from loaned securities, net of fees and collateral investment expenses, and other payments to and from borrowers of securities. |
Derivative Financial Instruments Outstanding as of Period End
Exchange-Traded Options Written
| | | | | |
| | | | | | | |
American International Group, Inc. | | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Verizon Communications, Inc. | | | | | | | |
| | | | | | | |
American Electric Power Co., Inc. | | | | | | | |
| | | | | | | |
British American Tobacco PLC, ADR | | | | | | | |
| | | | | | | |
Baxter International, Inc. | | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Fidelity National Information Services, Inc. | | | | | | | |
| | | | | | | |
Hewlett Packard Enterprise Co. | | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Verizon Communications, Inc. | | | | | | | |
Air Products and Chemicals, Inc. | | | | | | | |
| | | | | | | |
American International Group, Inc. | | | | | | | |
| | | | | | | |
| | | | | | | |
Baxter International, Inc. | | | | | | | |
British American Tobacco PLC, ADR | | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Citizens Financial Group, Inc. | | | | | | | |
44
2024
BlackRock Semi-Annual Report to Shareholders
Consolidated Schedule of Investments
(unaudited)
(continued)
BlackRock Enhanced Equity Dividend Trust (BDJ)
Exchange-Traded Options Written (continued)
| | | | | |
| | | | | | | |
Cognizant Technology Solutions Corp., Class A | | | | | | | |
Cognizant Technology Solutions Corp., Class A | | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Enterprise Products Partners LP | | | | | | | |
| | | | | | | |
Fidelity National Financial, Inc., Class A | | | | | | | |
Fidelity National Information Services, Inc. | | | | | | | |
First Citizens BancShares, Inc., Class A | | | | | | | |
| | | | | | | |
| | | | | | | |
Goldman Sachs Group, Inc. | | | | | | | |
| | | | | | | |
| | | | | | | |
Intercontinental Exchange, Inc. | | | | | | | |
International Flavors & Fragrances, Inc. | | | | | | | |
Johnson Controls International PLC | | | | | | | |
| | | | | | | |
L3Harris Technologies, Inc. | | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Mid-America Apartment Communities, Inc. | | | | | | | |
| | | | | | | |
Raymond James Financial, Inc. | | | | | | | |
| | | | | | | |
| | | | | | | |
SS&C Technologies Holdings, Inc. | | | | | | | |
Stanley Black & Decker, Inc. | | | | | | | |
| | | | | | | |
Taiwan Semiconductor Manufacturing Co. Ltd., ADR | | | | | | | |
| | | | | | | |
| | | | | | | |
Verizon Communications, Inc. | | | | | | | |
| | | | | | | |
| | | | | | | |
Westinghouse Air Brake Technologies Corp. | | | | | | | |
| | | | | | | |
American Electric Power Co., Inc. | | | | | | | |
British American Tobacco PLC, ADR | | | | | | | |
American International Group, Inc. | | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Enterprise Products Partners LP | | | | | | | |
Fidelity National Information Services, Inc. | | | | | | | |
| | | | | | | |
Hewlett Packard Enterprise Co. | | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Schedule of Investments
45
Consolidated Schedule of Investments
(unaudited)
(continued)
BlackRock Enhanced Equity Dividend Trust (BDJ)
Exchange-Traded Options Written (continued)
| | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Verizon Communications, Inc. | | | | | | | |
| | | | | | | |
American International Group, Inc. | | | | | | | |
| | | | | | | |
| | | | | | | |
Baxter International, Inc. | | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Enterprise Products Partners LP | | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Taiwan Semiconductor Manufacturing Co. Ltd., ADR | | | | | | | |
| | | | | | | |
Thermo Fisher Scientific, Inc. | | | | | | | |
Verizon Communications, Inc. | | | | | | | |
| | | | | | | |
American International Group, Inc. | | | | | | | |
| | | | | | | |
Air Products and Chemicals, Inc. | | | | | | | |
British American Tobacco PLC, ADR | | | | | | | |
| | | | | | | |
Citizens Financial Group, Inc. | | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Enterprise Products Partners LP | | | | | | | |
| | | | | | | |
First Citizens BancShares, Inc., Class A | | | | | | | |
| | | | | | | |
| | | | | | | |
Intercontinental Exchange, Inc. | | | | | | | |
International Flavors & Fragrances, Inc. | | | | | | | |
Johnson Controls International PLC | | | | | | | |
| | | | | | | |
L3Harris Technologies, Inc. | | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Mid-America Apartment Communities, Inc. | | | | | | | |
Raymond James Financial, Inc. | | | | | | | |
| | | | | | | |
| | | | | | | |
SS&C Technologies Holdings, Inc. | | | | | | | |
Stanley Black & Decker, Inc. | | | | | | | |
46
2024
BlackRock Semi-Annual Report to Shareholders
Consolidated Schedule of Investments
(unaudited)
(continued)
BlackRock Enhanced Equity Dividend Trust (BDJ)
Exchange-Traded Options Written (continued)
| | | | | |
| | | | | | | |
| | | | | | | |
Westinghouse Air Brake Technologies Corp. | | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Intercontinental Exchange, Inc. | | | | | | | |
| | | | | | | |
| | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
Citizens Financial Group, Inc. | Morgan Stanley & Co. International PLC | | | | | | | |
| Morgan Stanley & Co. International PLC | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| Morgan Stanley & Co. International PLC | | | | | | | |
Alibaba Group Holding Ltd. | | | | | | | | |
| Morgan Stanley & Co. International PLC | | | | | | | |
| Morgan Stanley & Co. International PLC | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| Morgan Stanley & Co. International PLC | | | | | | | |
| Morgan Stanley & Co. International PLC | | | | | | | |
| | | | | | | | |
UBS Group AG, Registered Shares | Goldman Sachs International | | | | | | | |
| Morgan Stanley & Co. International PLC | | | | | | | |
Bayer AG, Class N, Registered Shares | | | | | | | | |
| Goldman Sachs International | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
Bayer AG, Class N, Registered Shares | | | | | | | | |
| Goldman Sachs International | | | | | | | |
| | | | | | | | |
| Morgan Stanley & Co. International PLC | | | | | | | |
| | | | | | | | |
| Morgan Stanley & Co. International PLC | | | | | | | |
| | | | | | | | |
| Morgan Stanley & Co. International PLC | | | | | | | |
Alibaba Group Holding Ltd. | | | | | | | | |
| Goldman Sachs International | | | | | | | |
| | | | | | | | |
Henkel AG & Co. KGaA, Preference Shares | | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
UBS Group AG, Registered Shares | | | | | | | | |
Alibaba Group Holding Ltd. | | | | | | | | |
Henkel AG & Co. KGaA, Preference Shares | | | | | | | | |
| | | | | | | | |
| | | | | | | | |
Schedule of Investments
47
Consolidated Schedule of Investments
(unaudited)
(continued)
BlackRock Enhanced Equity Dividend Trust (BDJ)
OTC Options Written (continued)
| | | | | | |
| | | | | | | | |
Fidelity National Financial, Inc., Class A | Morgan Stanley & Co. International PLC | | | | | | | |
| Morgan Stanley & Co. International PLC | | | | | | | |
| Morgan Stanley & Co. International PLC | | | | | | | |
| | | | | | | | |
Balances Reported in the Consolidated Statements of Assets and Liabilities for Options Written
Derivative Financial Instruments Categorized by Risk Exposure
As of period end, the fair values of derivative financial instruments located in the Consolidated Statements of Assets and Liabilities were as follows:
| | | | | | | |
Liabilities — Derivative Financial Instruments | | | | | | | |
| | | | | | | |
For the period ended June 30, 2024, the effect of derivative financial instruments in the Consolidated Statements of Operations was as follows:
| | | | | | | |
Net Realized Gain (Loss) from: | | | | | | | |
| | | | | | | |
Net Change in Unrealized Appreciation (Depreciation) on: | | | | | | | |
| | | | | | | |
Average Quarterly Balances of Outstanding Derivative Financial Instruments
| |
Average value of option contracts written | |
For more information about the Trust’s investment risks regarding derivative financial instruments, refer to the Notes to Consolidated Financial Statements.
Derivative Financial Instruments — Offsetting as of Period End
The Trust’s derivative assets and liabilities (by type) were as follows:
| | |
Derivative Financial Instruments | | |
| | |
Total derivative assets and liabilities in the Consolidated Statements of Assets and Liabilities | | |
Derivatives not subject to a Master Netting Agreement or similar agreement (“MNA”) | | |
Total derivative assets and liabilities subject to an MNA | | |
48
2024
BlackRock Semi-Annual Report to Shareholders
Consolidated Schedule of Investments
(unaudited)
(continued)
BlackRock Enhanced Equity Dividend Trust (BDJ)
The following table presents the Trust’s derivative liabilities by counterparty net of amounts available for offset under an MNA and net of the related collateral pledged by the
Trust:
| | | | | |
| | | | | |
| | | | | |
| | | | | |
Goldman Sachs International | | | | | |
| | | | | |
Morgan Stanley & Co. International PLC | | | | | |
| | | | | |
| | | | | |
| | | | | |
| Excess of collateral received/pledged, if any, from the individual counterparty is not shown for financial reporting purposes. |
| Net amount represents the net amount payable due to counterparty in the event of default. Net amount may be offset further by the options written receivable/payable on the Consolidated Statements of Assets and Liabilities. |
Fair Value Hierarchy as of Period End
Various inputs are used in determining the fair value of financial instruments. For a description of the input levels and information about the Trust’s policy regarding valuation
of financial instruments, refer to the Notes to Consolidated Financial Statements.
The following table summarizes the Trust’s financial instruments categorized in the fair value hierarchy. The breakdown of the Trust
’
s financial instruments into major categories
is disclosed in the Consolidated Schedule of Investments above.
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
Consumer Staples Distribution & Retail | | | | |
| | | | |
Diversified Telecommunication Services | | | | |
| | | | |
| | | | |
| | | | |
| | | | |
Health Care Equipment & Supplies | | | | |
Health Care Providers & Services | | | | |
| | | | |
| | | | |
| | | | |
| | | | |
Life Sciences Tools & Services | | | | |
| | | | |
| | | | |
| | | | |
Oil, Gas & Consumable Fuels | | | | |
| | | | |
| | | | |
Schedule of Investments
49
Consolidated Schedule of Investments
(unaudited)
(continued)
BlackRock Enhanced Equity Dividend Trust (BDJ)
Fair Value Hierarchy as of Period End (continued)
| | | | |
Common Stocks (continued) | | | | |
| | | | |
| | | | |
Semiconductors & Semiconductor Equipment | | | | |
| | | | |
| | | | |
Technology Hardware, Storage & Peripherals | | | | |
Textiles, Apparel & Luxury Goods | | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
Derivative Financial Instruments (a) | | | | |
| | | | |
| | | | |
| Derivative financial instruments are options written. Options written are shown at value. |
A reconciliation of Level 3 financial instruments is presented when the Trust had a significant amount of Level 3 investments and derivative financial instruments at the
beginning and/or end of the period in relation to net assets. The following table is a reconciliation of Level 3 investments for which significant unobservable inputs were used in
determining fair value:
| |
| |
Opening balance, as of December 31, 2023 | |
| |
| |
Accrued discounts/premiums | |
| |
Net change in unrealized appreciation (depreciation) (a)(b) | |
| |
| |
Closing balance, as of June 30, 2024 | |
Net change in unrealized appreciation (depreciation) on investments still held at June 30, 2024 (b) | |
| Included in the related net change in unrealized appreciation (depreciation) in the Consolidated Statements of Operations. |
| Any difference between net change in unrealized appreciation (depreciation) and net change in unrealized appreciation (depreciation) on investments still held at June 30, 2024 is generally due to investments no longer held or categorized as Level 3 at period end. |
The following table summarizes the valuation approaches used and unobservable inputs utilized by the BlackRock Valuation Committee (the “Valuation Committee”) to
determine the value of certain of the Trust’s Level 3 financial instruments as of period end.
| A significant change in unobservable input would have resulted in a correlated (inverse) significant change to value. |
See notes to financial statements.
50
2024
BlackRock Semi-Annual Report to Shareholders
Schedule of Investments
(unaudited)
BlackRock Enhanced Global Dividend Trust (BOE)
(Percentages shown are based on Net Assets)
| | | |
|
| |
| | | |
| |
Novo Nordisk A/S, Class B | | | |
| |
| | | |
| | | |
LVMH Moet Hennessy Louis Vuitton SE | | | |
| | | |
| |
AceVector Limited, Series I, (Acquired 08/31/18, Cost: | | | |
| |
Bank Rakyat Indonesia Persero Tbk PT | | | |
| |
Wal-Mart de Mexico SAB de CV | | | |
| |
| | | |
| |
| | | |
| |
Zurich Insurance Group AG, Class N | | | |
| |
Taiwan Semiconductor Manufacturing Co. Ltd. | | | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
Baker Hughes Co., Class A (d) | | | |
| | | |
Citizens Financial Group, Inc. (d) | | | |
| | | |
Intercontinental Exchange, Inc. (e) | | | |
| | | |
Mastercard, Inc., Class A | | | |
Meta Platforms, Inc., Class A | | | |
| | | |
United States (continued) | |
| | | |
Mondelez International, Inc., Class A (e) | | | |
| | | |
Nestle SA, Class N, Registered Shares | | | |
| | | |
| | | |
| | | |
Philip Morris International, Inc. (d)(e) | | | |
Republic Services, Inc. (d) | | | |
| | | |
| | | |
| | | |
Texas Instruments, Inc. (d) | | | |
| | | |
United Parcel Service, Inc., Class B (e) | | | |
UnitedHealth Group, Inc. (d) | | | |
| | | |
| | | |
| | | |
Total Long-Term Investments — 100.1% | |
|
Money Market Funds — 0.3% | |
BlackRock Liquidity Funds, T-Fund, Institutional Shares, | | | |
Total Short-Term Securities — 0.3% | |
Total Investments Before Options Written — 100.4% | |
(Premiums Received: $(7,078,012)) | |
Total Investments, Net of Options Written — 99.4% | |
Other Assets Less Liabilities — 0.6% | |
| |
| Security is valued using significant unobservable inputs and is classified as Level 3 in the |
| Non-income producing security. |
| Restricted security as to resale, excluding 144A securities. The Trust held restricted securities with a current value of $261,914, representing less than 0.05% of its net assets as of period end, and an original cost of $2,637,143. |
| All or a portion of the security has been pledged as collateral in connection with outstanding OTC derivatives. |
| All or a portion of the security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written. |
| |
| Annualized 7-day yield as of period end. |
Schedule of Investments
51
Schedule of Investments
(unaudited)
(continued)
BlackRock Enhanced Global Dividend Trust (BOE)
Investments in issuers considered to be affiliate(s) of the Trust during the six months ended June 30, 2024 for purposes of Section 2(a)(3) of the Investment Company Act of
1940, as amended, were as follows:
| | | | | | | | | |
BlackRock Liquidity Funds, T-Fund, Institutional Shares | | | | | | | | | |
| Represents net amount purchased (sold). |
Derivative Financial Instruments Outstanding as of Period End
Exchange-Traded Options Written
| | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Mastercard, Inc., Class A | | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Mastercard, Inc., Class A | | | | | | | |
Meta Platforms, Inc., Class A | | | | | | | |
| | | | | | | |
Mondelez International, Inc., Class A | | | | | | | |
| | | | | | | |
| | | | | | | |
United Parcel Service, Inc., Class B | | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Baker Hughes Co., Class A | | | | | | | |
| | | | | | | |
Citizens Financial Group, Inc. | | | | | | | |
| | | | | | | |
Intercontinental Exchange, Inc. | | | | | | | |
| | | | | | | |
Meta Platforms, Inc., Class A | | | | | | | |
| | | | | | | |
Mondelez International, Inc., Class A | | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Philip Morris International, Inc. | | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Mondelez International, Inc., Class A | | | | | | | |
52
2024
BlackRock Semi-Annual Report to Shareholders
Schedule of Investments
(unaudited)
(continued)
BlackRock Enhanced Global Dividend Trust (BOE)
Exchange-Traded Options Written (continued)
| | | | | |
| | | | | | | |
| | | | | | | |
Philip Morris International, Inc. | | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Meta Platforms, Inc., Class A | | | | | | | |
| | | | | | | |
| | | | | | | |
United Parcel Service, Inc., Class B | | | | | | | |
| | | | | | | |
Baker Hughes Co., Class A | | | | | | | |
Citizens Financial Group, Inc. | | | | | | | |
| | | | | | | |
Intercontinental Exchange, Inc. | | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Baker Hughes Co., Class A | | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | |
| | | | | | | | |
Citizens Financial Group, Inc. | Morgan Stanley & Co. International PLC | | | | | | | |
| Goldman Sachs International | | | | | | | |
| Goldman Sachs International | | | | | | | |
| Morgan Stanley & Co. International PLC | | | | | | | |
Nestle SA, Class N, Registered Shares | Goldman Sachs International | | | | | | | |
| Morgan Stanley & Co. International PLC | | | | | | | |
| Morgan Stanley & Co. International PLC | | | | | | | |
| Morgan Stanley & Co. International PLC | | | | | | | |
Wal-Mart de Mexico SAB de CV | Morgan Stanley & Co. International PLC | | | | | | | |
Zurich Insurance Group AG, Class N | Goldman Sachs International | | | | | | | |
Taiwan Semiconductor Manufacturing Co. Ltd. | | | | | | | | |
Novo Nordisk A/S, Class B | | | | | | | | |
| Morgan Stanley & Co. International PLC | | | | | | | |
| | | | | | | | |
Wal-Mart de Mexico SAB de CV | Morgan Stanley & Co. International PLC | | | | | | | |
| Morgan Stanley & Co. International PLC | | | | | | | |
| | | | | | | | |
| Morgan Stanley & Co. International PLC | | | | | | | |
LVMH Moet Hennessy Louis Vuitton SE | | | | | | | | |
Novo Nordisk A/S, Class B | | | | | | | | |
| Goldman Sachs International | | | | | | | |
| Morgan Stanley & Co. International PLC | | | | | | | |
| | | | | | | | |
| | | | | | | | |
Schedule of Investments
53
Schedule of Investments
(unaudited)
(continued)
BlackRock Enhanced Global Dividend Trust (BOE)
OTC Options Written (continued)
| | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
Wal-Mart de Mexico SAB de CV | Morgan Stanley & Co. International PLC | | | | | | | |
| | | | | | | | |
| Morgan Stanley & Co. International PLC | | | | | | | |
| Morgan Stanley & Co. International PLC | | | | | | | |
| Morgan Stanley & Co. International PLC | | | | | | | |
| Goldman Sachs International | | | | | | | |
| | | | | | | | |
| Goldman Sachs International | | | | | | | |
Nestle SA, Class N, Registered Shares | | | | | | | | |
| | | | | | | | |
Taiwan Semiconductor Manufacturing Co. Ltd. | | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
Novo Nordisk A/S, Class B | Goldman Sachs International | | | | | | | |
| Morgan Stanley & Co. International PLC | | | | | | | |
Baker Hughes Co., Class A | Morgan Stanley & Co. International PLC | | | | | | | |
| | | | | | | | |
Novo Nordisk A/S, Class B | Goldman Sachs International | | | | | | | |
| | | | | | | | |
Taiwan Semiconductor Manufacturing Co. Ltd. | | | | | | | | |
Taiwan Semiconductor Manufacturing Co. Ltd. | | | | | | | | |
| | | | | | | | |
Balances Reported in the Statements of Assets and Liabilities for Options Written
Derivative Financial Instruments Categorized by Risk Exposure
As of period end, the fair values of derivative financial instruments located in the Statements of Assets and Liabilities were as follows:
| | | | | | | |
Liabilities — Derivative Financial Instruments | | | | | | | |
| | | | | | | |
For the period ended June 30, 2024, the effect of derivative financial instruments in the Statements of Operations was as follows:
| | | | | | | |
Net Realized Gain (Loss) from: | | | | | | | |
| | | | | | | |
Net Change in Unrealized Appreciation (Depreciation) on: | | | | | | | |
| | | | | | | |
54
2024
BlackRock Semi-Annual Report to Shareholders
Schedule of Investments
(unaudited)
(continued)
BlackRock Enhanced Global Dividend Trust (BOE)
Average Quarterly Balances of Outstanding Derivative Financial Instruments
| |
Average value of option contracts written | |
For more information about the Trust’s investment risks regarding derivative financial instruments, refer to the Notes to Financial Statements.
Derivative Financial Instruments — Offsetting as of Period End
The Trust’s derivative assets and liabilities (by type) were as follows:
| | |
Derivative Financial Instruments | | |
| | |
Total derivative assets and liabilities in the Statements of Assets and Liabilities | | |
Derivatives not subject to a Master Netting Agreement or similar agreement (“MNA”) | | |
Total derivative assets and liabilities subject to an MNA | | |
The following table presents the Trust’s derivative liabilities by counterparty net of amounts available for offset under an MNA and net of the related collateral pledged by the
Trust:
| | | | | |
| | | | | |
| | | | | |
Goldman Sachs International | | | | | |
| | | | | |
Morgan Stanley & Co. International PLC | | | | | |
| | | | | |
| Excess of collateral received/pledged, if any, from the individual counterparty is not shown for financial reporting purposes. |
| Net amount represents the net amount payable due to counterparty in the event of default. Net amount may be offset further by the options written receivable/payable on the Statements of Assets and Liabilities. |
Fair Value Hierarchy as of Period End
Various inputs are used in determining the fair value of financial instruments. For a description of the input levels and information about the Trust’s policy regarding valuation
of financial instruments, refer to the Notes to Financial Statements.
The following table summarizes the Trust’s financial instruments categorized in the fair value hierarchy. The breakdown of the Trust
’
s financial instruments into major categories
is disclosed in the Schedule of Investments above.
Schedule of Investments
55
Schedule of Investments
(unaudited)
(continued)
BlackRock Enhanced Global Dividend Trust (BOE)
Fair Value Hierarchy as of Period End (continued)
| | | | |
| | | | |
| | | | |
| | | | |
Derivative Financial Instruments (a) | | | | |
| | | | |
| | | | |
| Derivative financial instruments are options written. Options written are shown at value. |
See notes to financial statements.
56
2024
BlackRock Semi-Annual Report to Shareholders
Schedule of Investments
(unaudited)
BlackRock Enhanced International Dividend Trust (BGY)
(Percentages shown are based on Net Assets)
| | | |
|
| |
B3 SA - Brasil Bolsa Balcao | | | |
| |
Canadian National Railway Co. | | | |
Teck Resources Ltd., Class B (a) | | | |
| | | |
| | | |
| |
Novo Nordisk A/S, Class B | | | |
| |
| | | |
| | | |
LVMH Moet Hennessy Louis Vuitton SE | | | |
| | | |
| |
| | | |
| | | |
MTU Aero Engines AG, Class N | | | |
| | | |
| |
AceVector Limited, Series I, (Acquired 01/25/22, Cost: | | | |
| | | |
| | | |
| |
Bank Rakyat Indonesia Persero Tbk PT | | | |
| |
FinecoBank Banca Fineco SpA | | | |
| |
| | | |
| | | |
| | | |
| |
Wal-Mart de Mexico SAB de CV | | | |
| |
| | | |
| | | |
| | | |
| |
| | | |
United Overseas Bank Ltd. | | | |
| | | |
| |
| | | |
| | | |
| | | |
| |
Zurich Insurance Group AG, Class N | | | |
| | | |
| |
Taiwan Semiconductor Manufacturing Co. Ltd. | | | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| |
Baker Hughes Co., Class A (d)(e) | | | |
Nestle SA, Class N, Registered Shares | | | |
Otis Worldwide Corp. (d)(e) | | | |
| | | |
| | | |
Texas Instruments, Inc. (d)(e) | | | |
Visa, Inc., Class A (d)(e) | | | |
| | | |
Total Long-Term Investments — 100.4% | |
|
Money Market Funds — 0.8% | |
BlackRock Liquidity Funds, T-Fund, Institutional Shares, | | | |
Total Short-Term Securities — 0.8% | |
Total Investments Before Options Written — 101.2% | |
(Premiums Received: $(5,843,174)) | |
Total Investments, Net of Options Written — 100.3% | |
Liabilities in Excess of Other Assets — (0.3)% | |
| |
| Non-income producing security. |
| Security is valued using significant unobservable inputs and is classified as Level 3 in the |
| Restricted security as to resale, excluding 144A securities. The Trust held restricted securities with a current value of $392,132, representing 0.1% of its net assets as of period end, and an original cost of $3,948,600. |
| All or a portion of the security has been pledged as collateral in connection with outstanding OTC derivatives. |
| All or a portion of the security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written. |
| |
| Annualized 7-day yield as of period end. |
Schedule of Investments
57
Schedule of Investments
(unaudited)
(continued)
BlackRock Enhanced International Dividend Trust (BGY)
Investments in issuers considered to be affiliate(s) of the Trust during the six months ended June 30, 2024 for purposes of Section 2(a)(3) of the Investment Company Act of
1940, as amended, were as follows:
| | | | | | | | | |
BlackRock Liquidity Funds, T-Fund, Institutional Shares | | | | | | | | | |
| Represents net amount purchased (sold). |
Derivative Financial Instruments Outstanding as of Period End
Exchange-Traded Options Written
| | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Baker Hughes Co., Class A | | | | | | | |
Canadian National Railway Co. | | | | | | | |
| | | | | | | |
Teck Resources Ltd., Class B | | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Baker Hughes Co., Class A | | | | | | | |
Canadian National Railway Co. | | | | | | | |
| | | | | | | |
Teck Resources Ltd., Class B | | | | | | | |
| | | | | | | |
Baker Hughes Co., Class A | | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | |
| | | | | | | | |
| Goldman Sachs International | | | | | | | |
| Goldman Sachs International | | | | | | | |
United Overseas Bank Ltd. | | | | | | | | |
| Morgan Stanley & Co. International PLC | | | | | | | |
Nestle SA, Class N, Registered Shares | Goldman Sachs International | | | | | | | |
| Morgan Stanley & Co. International PLC | | | | | | | |
| Morgan Stanley & Co. International PLC | | | | | | | |
| Morgan Stanley & Co. International PLC | | | | | | | |
Wal-Mart de Mexico SAB de CV | Morgan Stanley & Co. International PLC | | | | | | | |
Zurich Insurance Group AG, Class N | Goldman Sachs International | | | | | | | |
Taiwan Semiconductor Manufacturing Co. Ltd. | | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
Novo Nordisk A/S, Class B | | | | | | | | |
| Morgan Stanley & Co. International PLC | | | | | | | |
58
2024
BlackRock Semi-Annual Report to Shareholders
Schedule of Investments
(unaudited)
(continued)
BlackRock Enhanced International Dividend Trust (BGY)
OTC Options Written (continued)
| | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| Morgan Stanley & Co. International PLC | | | | | | | |
MTU Aero Engines AG, Class N | | | | | | | | |
United Overseas Bank Ltd. | | | | | | | | |
Wal-Mart de Mexico SAB de CV | Morgan Stanley & Co. International PLC | | | | | | | |
| Morgan Stanley & Co. International PLC | | | | | | | |
| | | | | | | | |
| Morgan Stanley & Co. International PLC | | | | | | | |
| | | | | | | | |
FinecoBank Banca Fineco SpA | | | | | | | | |
| | | | | | | | |
LVMH Moet Hennessy Louis Vuitton SE | | | | | | | | |
B3 SA - Brasil Bolsa Balcao | | | | | | | | |
| Morgan Stanley & Co. International PLC | | | | | | | |
| | | | | | | | |
B3 SA - Brasil Bolsa Balcao | | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
United Overseas Bank Ltd. | | | | | | | | |
Wal-Mart de Mexico SAB de CV | Morgan Stanley & Co. International PLC | | | | | | | |
| | | | | | | | |
| Morgan Stanley & Co. International PLC | | | | | | | |
| Morgan Stanley & Co. International PLC | | | | | | | |
| Morgan Stanley & Co. International PLC | | | | | | | |
| Goldman Sachs International | | | | | | | |
| Goldman Sachs International | | | | | | | |
| Goldman Sachs International | | | | | | | |
| Goldman Sachs International | | | | | | | |
| | | | | | | | |
| | | | | | | | |
FinecoBank Banca Fineco SpA | | | | | | | | |
Nestle SA, Class N, Registered Shares | | | | | | | | |
| | | | | | | | |
Taiwan Semiconductor Manufacturing Co. Ltd. | | | | | | | | |
| | | | | | | | |
| | | | | | | | |
FinecoBank Banca Fineco SpA | | | | | | | | |
| | | | | | | | |
Novo Nordisk A/S, Class B | Goldman Sachs International | | | | | | | |
| Morgan Stanley & Co. International PLC | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
Baker Hughes Co., Class A | Morgan Stanley & Co. International PLC | | | | | | | |
| Goldman Sachs International | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
Novo Nordisk A/S, Class B | Goldman Sachs International | | | | | | | |
| | | | | | | | |
Taiwan Semiconductor Manufacturing Co. Ltd. | | | | | | | | |
| | | | | | | | |
Schedule of Investments
59
Schedule of Investments
(unaudited)
(continued)
BlackRock Enhanced International Dividend Trust (BGY)
Balances Reported in the Statements of Assets and Liabilities for Options Written
Derivative Financial Instruments Categorized by Risk Exposure
As of period end, the fair values of derivative financial instruments located in the Statements of Assets and Liabilities were as follows:
| | | | | | | |
Liabilities — Derivative Financial Instruments | | | | | | | |
| | | | | | | |
For the period ended June 30, 2024, the effect of derivative financial instruments in the Statements of Operations was as follows:
| | | | | | | |
Net Realized Gain (Loss) from: | | | | | | | |
| | | | | | | |
Net Change in Unrealized Appreciation (Depreciation) on: | | | | | | | |
| | | | | | | |
Average Quarterly Balances of Outstanding Derivative Financial Instruments
| |
Average value of option contracts purchased | |
Average value of option contracts written | |
| Derivative financial instrument not held at any quarter-end. The risk exposure table serves as an indicator of activity during the period. |
For more information about the Trust’s investment risks regarding derivative financial instruments, refer to the Notes to Financial Statements.
Derivative Financial Instruments — Offsetting as of Period End
The Trust’s derivative assets and liabilities (by type) were as follows:
| | |
Derivative Financial Instruments | | |
| | |
Total derivative assets and liabilities in the Statements of Assets and Liabilities | | |
Derivatives not subject to a Master Netting Agreement or similar agreement (“MNA”) | | |
Total derivative assets and liabilities subject to an MNA | | |
The following table presents the Trust’s derivative liabilities by counterparty net of amounts available for offset under an MNA and net of the related collateral pledged by the
Trust:
| | | | | |
| | | | | |
| | | | | |
Goldman Sachs International | | | | | |
| | | | | |
60
2024
BlackRock Semi-Annual Report to Shareholders
Schedule of Investments
(unaudited)
(continued)
BlackRock Enhanced International Dividend Trust (BGY)
| | | | | |
| | | | | |
Morgan Stanley & Co. International PLC | | | | | |
| | | | | |
| | | | | |
| | | | | |
| Excess of collateral received/pledged, if any, from the individual counterparty is not shown for financial reporting purposes. |
| Net amount represents the net amount payable due to counterparty in the event of default. Net amount may be offset further by the options written receivable/payable on the Statements of Assets and Liabilities. |
Fair Value Hierarchy as of Period End
Various inputs are used in determining the fair value of financial instruments. For a description of the input levels and information about the Trust’s policy regarding valuation
of financial instruments, refer to the Notes to Financial Statements.
The following table summarizes the Trust’s financial instruments categorized in the fair value hierarchy. The breakdown of the Trust
’
s financial instruments into major categories
is disclosed in the Schedule of Investments above.
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
Derivative Financial Instruments (a) | | | | |
| | | | |
| | | | |
| Derivative financial instruments are options written. Options written are shown at value. |
See notes to financial statements.
Schedule of Investments
61
Schedule of Investments
(unaudited)
BlackRock Health Sciences Term Trust (BMEZ)
(Percentages shown are based on Net Assets)
| | | |
|
| |
4D Molecular Therapeutics, Inc. (a) | | | |
| | | |
| | | |
| | | |
| | | |
Allogene Therapeutics, Inc. (a) | | | |
Alnylam Pharmaceuticals, Inc. (a)(b)(c) | | | |
| | | |
| | | |
| | | |
Apellis Pharmaceuticals, Inc. (a) | | | |
Arcturus Therapeutics Holdings, Inc. (a) | | | |
Arcus Biosciences, Inc. (a)(c) | | | |
| | | |
Arrowhead Pharmaceuticals, Inc. (a) | | | |
Autolus Therapeutics PLC, ADR (a) | | | |
Avidity Biosciences, Inc. (a) | | | |
Beam Therapeutics, Inc. (a) | | | |
| | | |
Bicycle Therapeutics PLC, ADR (a) | | | |
| | | |
| | | |
BioMarin Pharmaceutical, Inc. (a)(d) | | | |
Biomea Fusion, Inc. (a)(c) | | | |
Black Diamond Therapeutics, Inc. (a) | | | |
Blueprint Medicines Corp. (a) | | | |
Bridgebio Pharma, Inc. (a)(c) | | | |
| | | |
| | | |
Connect Biopharma Holdings Ltd., ADR (a) | | | |
| | | |
Denali Therapeutics, Inc. (a) | | | |
Dyne Therapeutics, Inc. (a) | | | |
Everest Medicines Ltd. (a) | | | |
| | | |
| | | |
| | | |
| | | |
| | | |
Halozyme Therapeutics, Inc. (a)(c) | | | |
| | | |
Immunocore Holdings PLC, ADR (a) | | | |
Immunocore Holdings PLC, Series C, ADR (a) | | | |
| | | |
| | | |
Ionis Pharmaceuticals, Inc. (a) | | | |
Keros Therapeutics, Inc. (a) | | | |
Kyverna Therapeutics, Inc. (a)(c) | | | |
Legend Biotech Corp., ADR (a) | | | |
Lexeo Therapeutics, Inc. (a) | | | |
| | | |
| | | |
Monte Rosa Therapeutics, Inc. (a) | | | |
MoonLake Immunotherapeutics (a) | | | |
| | | |
Neurocrine Biosciences, Inc. (a) | | | |
| | | |
Nurix Therapeutics, Inc. (a) | | | |
Nuvalent, Inc., Class A (a)(c) | | | |
ORIC Pharmaceuticals, Inc. (a) | | | |
| | | |
Biotechnology (continued) | |
Perspective Therapeutics, Inc. (a) | | | |
| | | |
Protagonist Therapeutics, Inc. (a) | | | |
PTC Therapeutics, Inc. (a) | | | |
| | | |
Renagade Therapeutics, Series A-2 (a)(e) | | | |
REVOLUTION Medicines, Inc. (a) | | | |
Rhythm Pharmaceuticals, Inc. (a) | | | |
Rocket Pharmaceuticals, Inc. (a)(c) | | | |
| | | |
| | | |
Sage Therapeutics, Inc. (a) | | | |
Sagimet Biosciences, Inc., Class A (a) | | | |
Sarepta Therapeutics, Inc. (a) | | | |
Soleno Therapeutics, Inc. (a) | | | |
Stoke Therapeutics, Inc. (a) | | | |
Tenaya Therapeutics, Inc. (a) | | | |
TScan Therapeutics, Inc. (a) | | | |
Twist Bioscience Corp. (a)(c) | | | |
Ultragenyx Pharmaceutical, Inc. (a) | | | |
United Therapeutics Corp. (a) | | | |
| | | |
Vertex Pharmaceuticals, Inc. (a) | | | |
Vigil Neuroscience, Inc. (a) | | | |
Viking Therapeutics, Inc. (a) | | | |
Voyager Therapeutics, Inc. (a) | | | |
Xenon Pharmaceuticals, Inc. (a) | | | |
| | | |
| | | |
| |
Helix Acquisition Corp. II, Class A (a) | | | |
Health Care Equipment & Supplies — 16.7% | |
Align Technology, Inc. (a)(d) | | | |
| | | |
Boston Scientific Corp. (a) | | | |
| | | |
| | | |
| | | |
| | | |
Edwards Lifesciences Corp. (a) | | | |
| | | |
| | | |
Inspire Medical Systems, Inc. (a)(c) | | | |
Intuitive Surgical, Inc. (a)(b) | | | |
| | | |
| | | |
Nucleix Ltd., (Acquired 04/10/24, Cost: | | | |
| | | |
Orchestra BioMed Holdings, Inc. (a) | | | |
| | | |
| | | |
| | | |
Tandem Diabetes Care, Inc. (a)(c) | | | |
| | | |
Health Care Providers & Services — 9.3% | |
Adicon Holdings Ltd., (Acquired 07/19/23, Cost: | | | |
| | | |
| | | |
| | | |
62
2024
BlackRock Semi-Annual Report to Shareholders
Schedule of Investments
(unaudited)
(continued)
BlackRock Health Sciences Term Trust (BMEZ)
(Percentages shown are based on Net Assets)
| | | |
Health Care Providers & Services (continued) | |
| | | |
Guardant Health, Inc. (a)(c) | | | |
Kindstar Globalgene Technology, Inc. (f) | | | |
| | | |
Molina Healthcare, Inc. (a) | | | |
| | | |
UnitedHealth Group, Inc. (b) | | | |
| | | |
Life Sciences Tools & Services — 14.0% | |
10X Genomics, Inc., Class A (a) | | | |
Bio-Rad Laboratories, Inc., Class A (a) | | | |
| | | |
Charles River Laboratories International, Inc. (a) | | | |
| | | |
| | | |
| | | |
Lonza Group AG, Registered Shares | | | |
Mettler-Toledo International, Inc. (a) | | | |
| | | |
Rapid Micro Biosystems, Inc., Class A (a) | | | |
| | | |
| | | |
West Pharmaceutical Services, Inc. (b)(d) | | | |
| | | |
| |
| | | |
| | | |
Axsome Therapeutics, Inc. (a) | | | |
| | | |
| | | |
Longboard Pharmaceuticals, Inc. (a) | | | |
| | | |
Neumora Therapeutics, Inc. (a)(c) | | | |
Novo Nordisk A/S, Class B | | | |
Nuvation Bio, Inc., Class A (a) | | | |
| | | |
Structure Therapeutics, Inc., ADR (a)(c) | | | |
Tarsus Pharmaceuticals, Inc. (a)(c) | | | |
| | | |
| |
Carbon Health Technologies, Inc., Series D2, (Acquired 02/27/24, Cost: $1,226,000) (a)(e)(g) | | | |
Total Common Stocks — 88.1% | |
| | | |
|
| |
Affinivax, Inc., (Acquired 08/18/22, Cost: $ —) | | | |
Amunix Pharmaceuticals, Inc., (Acquired 02/08/22, | | | |
Total Other Interests — 0.2% | |
| | | |
|
|
| |
| | | |
Adarx Pharamaceuticals, Inc., Series C, (Acquired 08/02/23, Cost: $7,160,001) (g) | | | |
Bright Peak Therapeutics, Inc., Series B, (Acquired 05/14/21, Cost: $8,000,004) (g) | | | |
Cellarity, Inc., Series B, (Acquired 01/15/21, Cost: | | | |
Genesis Therapeutics, Inc., Series B, (Acquired 08/10/23, Cost: $6,999,996) (g) | | | |
Goldfinch Bio, Inc., Series B, (Acquired 06/26/20, | | | |
Kartos Therapeutics, Inc., Series C, (Acquired 08/22/23, Cost: $7,539,875) (g) | | | |
Laronde, Inc., Series B, (Acquired 07/28/21, Cost: | | | |
Mirvie, Inc., Series B, (Acquired 10/15/21, Cost: | | | |
NiKang Therapeutics, Inc., Series C, (Acquired 05/20/21, Cost: $7,999,996) (g) | | | |
OnKure, Inc., Series C, (Acquired 03/24/23, Cost: | | | |
| | | |
Health Care Equipment & Supplies | |
Exo Imaging, Inc., Series C, (Acquired 06/24/21, | | | |
Nucleix Ltd., Series AA, (Acquired 03/25/21, Cost: | | | |
Swift Health Systems, Inc., Series D, (Acquired 08/27/21, Cost: $6,441,930) | | | |
| | | |
Health Care Providers & Services | |
Everly Well, Inc., Series D, (Acquired 11/25/20, Cost: | | | |
Numab Therapeutics AG, Series C, (Acquired 05/07/21, Cost: $7,770,441) | | | |
Quanta Dialysis Technologies Ltd., Series D, (Acquired 06/18/21, Cost: $14,071,890) | | | |
| | | |
Schedule of Investments
63
Schedule of Investments
(unaudited)
(continued)
BlackRock Health Sciences Term Trust (BMEZ)
(Percentages shown are based on Net Assets)
| | | |
Life Sciences Tools & Services — 0.6% | |
| | | |
| |
| | | |
Series B, (Acquired 05/21/20, Cost: $5,000,000) | | | |
Series C, (Acquired 03/10/21, Cost: $3,600,018) | | | |
| | | |
Semiconductors & Semiconductor Equipment — 1.0% | |
PsiQuantum Corp., Series D, (Acquired 05/21/21, Cost: $14,999,996) (a)(e)(g) | | | |
| |
Carbon Health Technologies, Inc., Series D2, (Acquired 02/02/23, Cost: $17,100,000) (a)(e)(g) | | | |
| |
Total Preferred Securities — 8.8% | |
|
| |
| | | |
| | | |
| | | |
Health Care Equipment & Supplies — 0.0% | |
| | | |
| |
|
Health Care Equipment & Supplies — 0.0% | |
Nucleix Ltd., (Acquired 04/10/24, Cost: $0) (a)(e)(g) | | | |
Health Care Providers & Services — 0.0% | |
CareMax, Inc., (Issued/Exercisable 09/15/20, 1 Share for 1 Warrant, Expires 08/06/26, Strike Price USD | | | |
| |
Nuvation Bio, Inc., (Issued/Exercisable 08/17/20, 1 Share for 1 Warrant, Expires 07/07/27, Strike | | | |
| |
Total Long-Term Investments — 97.1% | |
| | | |
|
Money Market Funds — 5.6% | |
BlackRock Cash Funds: Institutional, SL Agency | | | |
BlackRock Liquidity Funds, T-Fund, Institutional | | | |
Total Short-Term Securities — 5.6% | |
Total Investments Before Options Written — 102.7% | |
(Premiums Received: $(14,613,820)) | |
Total Investments, Net of Options Written — 101.7% | |
Liabilities in Excess of Other Assets — (1.7)% | |
| |
| Non-income producing security. |
| All or a portion of the security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written. |
| All or a portion of this security is on loan. |
| All or a portion of the security has been pledged as collateral in connection with outstanding OTC derivatives. |
| Security is valued using significant unobservable inputs and is classified as Level 3 in the |
| Security exempt from registration pursuant to Rule 144A under the Securities Act of 1933, as amended. These securities may be resold in transactions exempt from registration to qualified institutional investors. |
| Restricted security as to resale, excluding 144A securities. The Trust held restricted securities with a current value of $167,672,702, representing 9.0% of its net assets as of period end, and an original cost of $203,104,730. |
| Other interests represent beneficial interests in liquidation trusts and other reorganization |
| |
| Annualized 7-day yield as of period end. |
| All or a portion of this security was purchased with the cash collateral from loaned |
For purposes of this report, industry and sector sub-classifications may differ from those utilized by the Trust for compliance purposes.
64
2024
BlackRock Semi-Annual Report to Shareholders
Schedule of Investments
(unaudited)
(continued)
BlackRock Health Sciences Term Trust (BMEZ)
Investments in issuers considered to be affiliate(s) of the Trust during the six months ended June 30, 2024 for purposes of Section 2(a)(3) of the Investment Company Act of
1940, as amended, were as follows:
| | | | | | | | | |
BlackRock Cash Funds: Institutional, SL Agency | | | | | | | | | |
BlackRock Liquidity Funds, T-Fund, Institutional | | | | | | | | | |
SL Liquidity Series, LLC, Money Market Series (c) | | | | | | | | | |
| | | | | | | | | |
| Represents net amount purchased (sold). |
| All or a portion represents securities lending income earned from the reinvestment of cash collateral from loaned securities, net of fees and collateral investment expenses, and other payments to and from borrowers of securities. |
| As of period end, the entity is no longer held. |
Derivative Financial Instruments Outstanding as of Period End
Exchange-Traded Options Written
| | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Alnylam Pharmaceuticals, Inc. | | | | | | | |
| | | | | | | |
Arcturus Therapeutics Holdings, Inc. | | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
BioMarin Pharmaceutical, Inc. | | | | | | | |
Bio-Rad Laboratories, Inc., Class A | | | | | | | |
| | | | | | | |
Blueprint Medicines Corp. | | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Charles River Laboratories International, Inc. | | | | | | | |
| | | | | | | |
| | | | | | | |
Edwards Lifesciences Corp. | | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Halozyme Therapeutics, Inc. | | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Schedule of Investments
65
Schedule of Investments
(unaudited)
(continued)
BlackRock Health Sciences Term Trust (BMEZ)
Exchange-Traded Options Written (continued)
| | | | | |
| | | | | | | |
Inspire Medical Systems, Inc. | | | | | | | |
Legend Biotech Corp., ADR | | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Mettler-Toledo International, Inc. | | | | | | | |
Mettler-Toledo International, Inc. | | | | | | | |
| | | | | | | |
Neurocrine Biosciences, Inc. | | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
REVOLUTION Medicines, Inc. | | | | | | | |
Rhythm Pharmaceuticals, Inc. | | | | | | | |
Rhythm Pharmaceuticals, Inc. | | | | | | | |
Rocket Pharmaceuticals, Inc. | | | | | | | |
| | | | | | | |
Soleno Therapeutics, Inc. | | | | | | | |
| | | | | | | |
Structure Therapeutics, Inc., ADR | | | | | | | |
| | | | | | | |
Tandem Diabetes Care, Inc. | | | | | | | |
Tarsus Pharmaceuticals, Inc. | | | | | | | |
| | | | | | | |
Ultragenyx Pharmaceutical, Inc. | | | | | | | |
United Therapeutics Corp. | | | | | | | |
| | | | | | | |
Vertex Pharmaceuticals, Inc. | | | | | | | |
| | | | | | | |
West Pharmaceutical Services, Inc. | | | | | | | |
Xenon Pharmaceuticals, Inc. | | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Sarepta Therapeutics, Inc. | | | | | | | |
| | | | | | | |
Vertex Pharmaceuticals, Inc. | | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
10X Genomics, Inc., Class A | | | | | | | |
| | | | | | | |
Alnylam Pharmaceuticals, Inc. | | | | | | | |
Arcturus Therapeutics Holdings, Inc. | | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
66
2024
BlackRock Semi-Annual Report to Shareholders
Schedule of Investments
(unaudited)
(continued)
BlackRock Health Sciences Term Trust (BMEZ)
Exchange-Traded Options Written (continued)
| | | | | |
| | | | | | | |
BioMarin Pharmaceutical, Inc. | | | | | | | |
Bio-Rad Laboratories, Inc., Class A | | | | | | | |
| | | | | | | |
Blueprint Medicines Corp. | | | | | | | |
| | | | | | | |
Charles River Laboratories International, Inc. | | | | | | | |
| | | | | | | |
| | | | | | | |
Denali Therapeutics, Inc. | | | | | | | |
| | | | | | | |
Edwards Lifesciences Corp. | | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Halozyme Therapeutics, Inc. | | | | | | | |
| | | | | | | |
| | | | | | | |
Inspire Medical Systems, Inc. | | | | | | | |
Ionis Pharmaceuticals, Inc. | | | | | | | |
| | | | | | | |
Legend Biotech Corp., ADR | | | | | | | |
| | | | | | | |
Neurocrine Biosciences, Inc. | | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
REVOLUTION Medicines, Inc. | | | | | | | |
Rhythm Pharmaceuticals, Inc. | | | | | | | |
Rocket Pharmaceuticals, Inc. | | | | | | | |
Soleno Therapeutics, Inc. | | | | | | | |
| | | | | | | |
Structure Therapeutics, Inc., ADR | | | | | | | |
| | | | | | | |
Tandem Diabetes Care, Inc. | | | | | | | |
Tarsus Pharmaceuticals, Inc. | | | | | | | |
| | | | | | | |
Ultragenyx Pharmaceutical, Inc. | | | | | | | |
United Therapeutics Corp. | | | | | | | |
| | | | | | | |
Viking Therapeutics, Inc. | | | | | | | |
| | | | | | | |
West Pharmaceutical Services, Inc. | | | | | | | |
Xenon Pharmaceuticals, Inc. | | | | | | | |
| | | | | | | |
| | | | | | |
| | | | | | | | |
| Goldman Sachs International | | | | | | | |
| | | | | | | | |
| Goldman Sachs International | | | | | | | |
Lonza Group AG, Registered Shares | | | | | | | | |
| Goldman Sachs International | | | | | | | |
Novo Nordisk A/S, Class B | | | | | | | | |
Sartorius AG, Preference Shares | | | | | | | | |
Schedule of Investments
67
Schedule of Investments
(unaudited)
(continued)
BlackRock Health Sciences Term Trust (BMEZ)
OTC Options Written (continued)
| | | | | | |
| | | | | | | | |
| | | | | | | | |
| Morgan Stanley & Co. International PLC | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| Morgan Stanley & Co. International PLC | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
Balances Reported in the Statements of Assets and Liabilities for Options Written
Derivative Financial Instruments Categorized by Risk Exposure
As of period end, the fair values of derivative financial instruments located in the Statements of Assets and Liabilities were as follows:
| | | | | | | |
Liabilities — Derivative Financial Instruments | | | | | | | |
| | | | | | | |
For the period ended June 30, 2024, the effect of derivative financial instruments in the Statements of Operations was as follows:
| | | | | | | |
Net Realized Gain (Loss) from: | | | | | | | |
Forward foreign currency exchange contracts | | | | | | | |
| | | | | | | |
| | | | | | | |
Net Change in Unrealized Appreciation (Depreciation) on: | | | | | | | |
Forward foreign currency exchange contracts | | | | | | | |
| | | | | | | |
| | | | | | | |
Average Quarterly Balances of Outstanding Derivative Financial Instruments
Forward foreign currency exchange contracts: | |
Average amounts purchased — in USD | |
Average amounts sold — in USD | |
| |
Average value of option contracts written | |
| Derivative financial instrument not held at any quarter-end. The risk exposure table serves as an indicator of activity during the period. |
For more information about the Trust’s investment risks regarding derivative financial instruments, refer to the Notes to Financial Statements.
68
2024
BlackRock Semi-Annual Report to Shareholders
Schedule of Investments
(unaudited)
(continued)
BlackRock Health Sciences Term Trust (BMEZ)
Derivative Financial Instruments — Offsetting as of Period End
The Trust’s derivative assets and liabilities (by type) were as follows:
| | |
Derivative Financial Instruments | | |
| | |
Total derivative assets and liabilities in the Statements of Assets and Liabilities | | |
Derivatives not subject to a Master Netting Agreement or similar agreement (“MNA”) | | |
Total derivative assets and liabilities subject to an MNA | | |
The following table presents the Trust’s derivative liabilities by counterparty net of amounts available for offset under an MNA and net of the related collateral pledged by the
Trust:
| | | | | |
| | | | | |
| | | | | |
Goldman Sachs International | | | | | |
Morgan Stanley & Co. International PLC | | | | | |
| | | | | |
| | | | | |
| The amount of derivatives available for offset is limited to the amount of derivative asset and/or liabilities that are subject to an MNA. |
| Excess of collateral received/pledged, if any, from the individual counterparty is not shown for financial reporting purposes. |
| Net amount represents the net amount payable due to counterparty in the event of default. Net amount may be offset further by the options written receivable/payable on the Statements of Assets and Liabilities. |
Fair Value Hierarchy as of Period End
Various inputs are used in determining the fair value of financial instruments. For a description of the input levels and information about the Trust’s policy regarding valuation
of financial instruments, refer to the Notes to Financial Statements.
The following table summarizes the Trust’s financial instruments categorized in the fair value hierarchy. The breakdown of the Trust
’
s financial instruments into major categories
is disclosed in the Schedule of Investments above.
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
Health Care Equipment & Supplies | | | | |
Health Care Providers & Services | | | | |
Life Sciences Tools & Services | | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
Schedule of Investments
69
Schedule of Investments
(unaudited)
(continued)
BlackRock Health Sciences Term Trust (BMEZ)
Fair Value Hierarchy as of Period End (continued)
| | | | |
Derivative Financial Instruments (a) | | | | |
| | | | |
| | | | |
| Derivative financial instruments are options written. Options written are shown at value. |
A reconciliation of Level 3 financial instruments is presented when the Trust had a significant amount of Level 3 investments and derivative financial instruments at the
beginning and/or end of the period in relation to net assets. The following table is a reconciliation of Level 3 investments for which significant unobservable inputs were used in
determining fair value:
| | | | | | |
| | | | | | |
Opening balance, as of December 31, 2023 | | | | | | |
| | | | | | |
| | | | | | |
Accrued discounts/premiums | | | | | | |
| | | | | | |
Net change in unrealized appreciation (depreciation) (a)(b) | | | | | | |
| | | | | | |
| | | | | | |
Closing balance, as of June 30, 2024 | | | | | | |
Net change in unrealized appreciation (depreciation) on investments still held at June 30, 2024 (b) | | | | | | |
| Included in the related net change in unrealized appreciation (depreciation) in the Statements of Operations. |
| Any difference between net change in unrealized appreciation (depreciation) and net change in unrealized appreciation (depreciation) on investments still held at June 30, 2024 is generally due to investments no longer held or categorized as Level 3 at period end. |
The following table summarizes the valuation approaches used and unobservable inputs utilized by the BlackRock Valuation Committee (the “Valuation Committee”) to
determine the value of certain of the Trust’s Level 3 financial instruments as of period end.
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | Market Adjustment Multiple | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | Market Adjustment Multiple | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | Market Adjustment Multiple | | |
| | | | | |
| A significant change in unobservable input would have resulted in a correlated (inverse) significant change to value. |
See notes to financial statements.
70
2024
BlackRock Semi-Annual Report to Shareholders
Schedule of Investments
(unaudited)
BlackRock Health Sciences Trust (BME)
(Percentages shown are based on Net Assets)
| | | |
|
| |
4D Molecular Therapeutics, Inc. (a) | | | |
| | | |
| | | |
Allogene Therapeutics, Inc. (a) | | | |
Alnylam Pharmaceuticals, Inc. (a) | | | |
| | | |
| | | |
Autolus Therapeutics PLC, ADR (a) | | | |
Avidity Biosciences, Inc. (a) | | | |
Beam Therapeutics, Inc. (a) | | | |
| | | |
| | | |
BioMarin Pharmaceutical, Inc. (a) | | | |
Blueprint Medicines Corp. (a) | | | |
Bridgebio Pharma, Inc. (a) | | | |
| | | |
| | | |
| | | |
Denali Therapeutics, Inc. (a) | | | |
Dyne Therapeutics, Inc. (a) | | | |
| | | |
| | | |
| | | |
| | | |
| | | |
Immunocore Holdings PLC, ADR (a) | | | |
| | | |
| | | |
Ionis Pharmaceuticals, Inc. (a) | | | |
Kyverna Therapeutics, Inc. (a) | | | |
Legend Biotech Corp., ADR (a) | | | |
| | | |
| | | |
MoonLake Immunotherapeutics (a) | | | |
| | | |
Neurocrine Biosciences, Inc. (a) | | | |
| | | |
Nurix Therapeutics, Inc. (a) | | | |
Nuvalent, Inc., Class A (a) | | | |
| | | |
Protagonist Therapeutics, Inc. (a) | | | |
PTC Therapeutics, Inc. (a) | | | |
Regeneron Pharmaceuticals, Inc. (a) | | | |
| | | |
REVOLUTION Medicines, Inc. (a) | | | |
Rhythm Pharmaceuticals, Inc. (a) | | | |
Rocket Pharmaceuticals, Inc. (a) | | | |
| | | |
Sage Therapeutics, Inc. (a) | | | |
Sagimet Biosciences, Inc., Class A (a) | | | |
Sarepta Therapeutics, Inc. (a) | | | |
Soleno Therapeutics, Inc. (a) | | | |
Stoke Therapeutics, Inc. (a) | | | |
TScan Therapeutics, Inc. (a) | | | |
Ultragenyx Pharmaceutical, Inc. (a) | | | |
| | | |
Vertex Pharmaceuticals, Inc. (a) | | | |
Viking Therapeutics, Inc. (a) | | | |
| | | |
Biotechnology (continued) | |
Voyager Therapeutics, Inc. (a) | | | |
Xenon Pharmaceuticals, Inc. (a) | | | |
| | | |
| | | |
| |
Helix Acquisition Corp. II, Class A (a) | | | |
Health Care Equipment & Supplies — 22.1% | |
| | | |
Align Technology, Inc. (a) | | | |
Baxter International, Inc. | | | |
| | | |
Boston Scientific Corp. (a) | | | |
| | | |
| | | |
Edwards Lifesciences Corp. (a) | | | |
GE HealthCare Technologies, Inc. (a) | | | |
| | | |
IDEXX Laboratories, Inc. (a) | | | |
Inspire Medical Systems, Inc. (a)(c) | | | |
Intuitive Surgical, Inc. (a) | | | |
| | | |
| | | |
| | | |
Nucleix Ltd., (Acquired 04/10/24, Cost: $200,000) (a)(d)(e) | | | |
| | | |
Orchestra BioMed Holdings, Inc. (a) | | | |
| | | |
| | | |
| | | |
| | | |
Health Care Providers & Services — 20.5% | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
UnitedHealth Group, Inc. (b) | | | |
| | | |
Life Sciences Tools & Services — 8.9% | |
Agilent Technologies, Inc. | | | |
| | | |
| | | |
| | | |
| | | |
Mettler-Toledo International, Inc. (a) | | | |
Nautilus Biotechnology, Inc. (a) | | | |
| | | |
Rapid Micro Biosystems, Inc., Class A (a) | | | |
| | | |
Thermo Fisher Scientific, Inc. | | | |
West Pharmaceutical Services, Inc. | | | |
| | | |
Schedule of Investments
71
Schedule of Investments
(unaudited)
(continued)
BlackRock Health Sciences Trust (BME)
(Percentages shown are based on Net Assets)
| | | |
| |
| | | |
| | | |
| | | |
| | | |
Longboard Pharmaceuticals, Inc. (a) | | | |
| | | |
Novo Nordisk A/S, Class B | | | |
| | | |
| | | |
Structure Therapeutics, Inc., ADR (a)(c) | | | |
| | | |
| | | |
| |
Carbon Health Technologies, Inc., Series D2, (Acquired 02/27/24, Cost: $65,000) (a)(d)(e) | | | |
Total Common Stocks — 97.0% | |
| | | |
|
| |
Affinivax, Inc., (Acquired 08/18/22, Cost: $ —) (d)(e)(g) | | | |
Health Care Providers & Services — 0.0% | |
Afferent Pharmaceuticals, Inc., (Acquired 09/30/15, | | | |
Total Other Interests — 0.0% | |
| | | |
|
|
| |
Adarx Pharamaceuticals, Inc., Series C, (Acquired 08/02/23, Cost: $440,003) | | | |
Cellarity, Inc., Series B, (Acquired 01/15/21, Cost: | | | |
Genesis Therapeutics, Inc., Series B, (Acquired 08/10/23, Cost: $292,001) | | | |
Goldfinch Bio, Inc., Series B, (Acquired 06/26/20, Cost: | | | |
Kartos Therapeutics, Inc., Series C, (Acquired 08/22/23, | | | |
Laronde, Inc., Series B, (Acquired 07/28/21, Cost: | | | |
| | | |
Health Care Equipment & Supplies — 0.2% | |
Exo Imaging, Inc., Series C, (Acquired 06/24/21, Cost: | | | |
| | | |
Health Care Equipment & Supplies (continued) | |
Nucleix Ltd., Series AA, (Acquired 03/25/21, Cost: | | | |
Swift Health Systems, Inc., Series D, (Acquired 08/27/21, | | | |
| | | |
Health Care Providers & Services — 0.1% | |
Quanta Dialysis Technologies Ltd., Series D, (Acquired 06/18/21, Cost: $515,759) | | | |
| |
Insitro, Inc., Series C, (Acquired 03/10/21, Cost: | | | |
| |
Carbon Health Technologies, Inc., Series D2, (Acquired 02/02/23, Cost: $907,000) | | | |
| |
Total Preferred Securities — 0.7% | |
|
| |
| | | |
Health Care Equipment & Supplies — 0.0% | |
| | | |
| |
|
Health Care Equipment & Supplies — 0.0% | |
Nucleix Ltd., (Acquired 04/10/24, Cost: $0) (a)(d)(e) | | | |
Health Care Providers & Services — 0.0% | |
CareMax, Inc., (Issued/Exercisable 09/15/20, 1 Share for 1 Warrant, Expires 08/06/26, Strike Price USD | | | |
| |
Nuvation Bio, Inc., (Issued/Exercisable 08/17/20, 1 Share for 1 Warrant, Expires 07/07/27, Strike Price USD | | | |
| |
Total Long-Term Investments — 97.7% | |
72
2024
BlackRock Semi-Annual Report to Shareholders
Schedule of Investments
(unaudited)
(continued)
BlackRock Health Sciences Trust (BME)
(Percentages shown are based on Net Assets)
| | | |
|
Money Market Funds — 3.2% | |
BlackRock Cash Funds: Institutional, SL Agency Shares, | | | |
BlackRock Liquidity Funds, T-Fund, Institutional Shares, | | | |
Total Short-Term Securities — 3.2% | |
Total Investments Before Options Written — 100.9% | |
(Premiums Received: $(5,544,655)) | |
Total Investments, Net of Options Written — 99.8% | |
Other Assets Less Liabilities — 0.2% | |
| |
| Non-income producing security. |
| All or a portion of the security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written. |
| All or a portion of this security is on loan. |
| Security is valued using significant unobservable inputs and is classified as Level 3 in the |
| Restricted security as to resale, excluding 144A securities. The Trust held restricted securities with a current value of $4,267,111, representing 0.7% of its net assets as of period end, and an original cost of $6,497,887. |
| All or a portion of the security has been pledged as collateral in connection with outstanding OTC derivatives. |
| Other interests represent beneficial interests in liquidation trusts and other reorganization |
| |
| Annualized 7-day yield as of period end. |
| All or a portion of this security was purchased with the cash collateral from loaned |
For purposes of this report, industry and sector sub-classifications may differ from those utilized by the Trust for compliance purposes.
Investments in issuers considered to be affiliate(s) of the Trust during the six months ended June 30, 2024 for purposes of Section 2(a)(3) of the Investment Company Act of
1940, as amended, were as follows:
| | | | | | | | | |
BlackRock Cash Funds: Institutional, SL Agency | | | | | | | | | |
BlackRock Liquidity Funds, T-Fund, Institutional | | | | | | | | | |
SL Liquidity Series, LLC, Money Market Series (c) | | | | | | | | | |
| | | | | | | | | |
| Represents net amount purchased (sold). |
| All or a portion represents securities lending income earned from the reinvestment of cash collateral from loaned securities, net of fees and collateral investment expenses, and other payments to and from borrowers of securities. |
| As of period end, the entity is no longer held. |
Derivative Financial Instruments Outstanding as of Period End
Exchange-Traded Options Written
| | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Baxter International, Inc. | | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Schedule of Investments
73
Schedule of Investments
(unaudited)
(continued)
BlackRock Health Sciences Trust (BME)
Exchange-Traded Options Written (continued)
| | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Thermo Fisher Scientific, Inc. | | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Agilent Technologies, Inc. | | | | | | | |
Alnylam Pharmaceuticals, Inc. | | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Baxter International, Inc. | | | | | | | |
| | | | | | | |
BioMarin Pharmaceutical, Inc. | | | | | | | |
| | | | | | | |
Blueprint Medicines Corp. | | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Edwards Lifesciences Corp. | | | | | | | |
| | | | | | | |
| | | | | | | |
GE HealthCare Technologies, Inc. | | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Inspire Medical Systems, Inc. | | | | | | | |
| | | | | | | |
| | | | | | | |
Legend Biotech Corp., ADR | | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Mettler-Toledo International, Inc. | | | | | | | |
Mettler-Toledo International, Inc. | | | | | | | |
| | | | | | | |
Neurocrine Biosciences, Inc. | | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Regeneron Pharmaceuticals, Inc. | | | | | | | |
| | | | | | | |
REVOLUTION Medicines, Inc. | | | | | | | |
Rhythm Pharmaceuticals, Inc. | | | | | | | |
Rhythm Pharmaceuticals, Inc. | | | | | | | |
Rocket Pharmaceuticals, Inc. | | | | | | | |
Soleno Therapeutics, Inc. | | | | | | | |
| | | | | | | |
Structure Therapeutics, Inc., ADR | | | | | | | |
| | | | | | | |
Ultragenyx Pharmaceutical, Inc. | | | | | | | |
| | | | | | | |
Vertex Pharmaceuticals, Inc. | | | | | | | |
74
2024
BlackRock Semi-Annual Report to Shareholders
Schedule of Investments
(unaudited)
(continued)
BlackRock Health Sciences Trust (BME)
Exchange-Traded Options Written (continued)
| | | | | |
| | | | | | | |
West Pharmaceutical Services, Inc. | | | | | | | |
Xenon Pharmaceuticals, Inc. | | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Sarepta Therapeutics, Inc. | | | | | | | |
| | | | | | | |
Vertex Pharmaceuticals, Inc. | | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Baxter International, Inc. | | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Thermo Fisher Scientific, Inc. | | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Regeneron Pharmaceuticals, Inc. | | | | | | | |
| | | | | | | |
Agilent Technologies, Inc. | | | | | | | |
Alnylam Pharmaceuticals, Inc. | | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
BioMarin Pharmaceutical, Inc. | | | | | | | |
| | | | | | | |
Blueprint Medicines Corp. | | | | | | | |
| | | | | | | |
| | | | | | | |
Denali Therapeutics, Inc. | | | | | | | |
| | | | | | | |
Edwards Lifesciences Corp. | | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Inspire Medical Systems, Inc. | | | | | | | |
Ionis Pharmaceuticals, Inc. | | | | | | | |
| | | | | | | |
Schedule of Investments
75
Schedule of Investments
(unaudited)
(continued)
BlackRock Health Sciences Trust (BME)
Exchange-Traded Options Written (continued)
| | | | | |
| | | | | | | |
| | | | | | | |
Legend Biotech Corp., ADR | | | | | | | |
| | | | | | | |
| | | | | | | |
Neurocrine Biosciences, Inc. | | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
REVOLUTION Medicines, Inc. | | | | | | | |
Rhythm Pharmaceuticals, Inc. | | | | | | | |
Rocket Pharmaceuticals, Inc. | | | | | | | |
Soleno Therapeutics, Inc. | | | | | | | |
| | | | | | | |
Structure Therapeutics, Inc., ADR | | | | | | | |
| | | | | | | |
Thermo Fisher Scientific, Inc. | | | | | | | |
Ultragenyx Pharmaceutical, Inc. | | | | | | | |
| | | | | | | |
Viking Therapeutics, Inc. | | | | | | | |
West Pharmaceutical Services, Inc. | | | | | | | |
Xenon Pharmaceuticals, Inc. | | | | | | | |
| | | | | | | |
| | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| Goldman Sachs International | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| Morgan Stanley & Co. International PLC | | | | | | | |
| | | | | | | | |
Novo Nordisk A/S, Class B | Goldman Sachs International | | | | | | | |
| | | | | | | | |
| | | | | | | | |
Balances Reported in the Statements of Assets and Liabilities for Options Written
76
2024
BlackRock Semi-Annual Report to Shareholders
Schedule of Investments
(unaudited)
(continued)
BlackRock Health Sciences Trust (BME)
Derivative Financial Instruments Categorized by Risk Exposure
As of period end, the fair values of derivative financial instruments located in the Statements of Assets and Liabilities were as follows:
| | | | | | | |
Liabilities — Derivative Financial Instruments | | | | | | | |
| | | | | | | |
For the period ended June 30, 2024, the effect of derivative financial instruments in the Statements of Operations was as follows:
| | | | | | | |
Net Realized Gain (Loss) from: | | | | | | | |
| | | | | | | |
Net Change in Unrealized Appreciation (Depreciation) on: | | | | | | | |
| | | | | | | |
Average Quarterly Balances of Outstanding Derivative Financial Instruments
| |
Average value of option contracts written | |
For more information about the Trust’s investment risks regarding derivative financial instruments, refer to the Notes to Financial Statements.
Derivative Financial Instruments — Offsetting as of Period End
The Trust’s derivative assets and liabilities (by type) were as follows:
| | |
Derivative Financial Instruments | | |
| | |
Total derivative assets and liabilities in the Statements of Assets and Liabilities | | |
Derivatives not subject to a Master Netting Agreement or similar agreement (“MNA”) | | |
Total derivative assets and liabilities subject to an MNA | | |
The following table presents the Trust’s derivative liabilities by counterparty net of amounts available for offset under an MNA and net of the related collateral pledged by the
Trust:
| | | | | |
| | | | | |
| | | | | |
| | | | | |
Goldman Sachs International | | | | | |
| | | | | |
Morgan Stanley & Co. International PLC | | | | | |
| | | | | |
| | | | | |
| Excess of collateral received/pledged, if any, from the individual counterparty is not shown for financial reporting purposes. |
| Net amount represents the net amount payable due to counterparty in the event of default. Net amount may be offset further by the options written receivable/payable on the Statements of Assets and Liabilities. |
Schedule of Investments
77
Schedule of Investments
(unaudited)
(continued)
BlackRock Health Sciences Trust (BME)
Fair Value Hierarchy as of Period End
Various inputs are used in determining the fair value of financial instruments. For a description of the input levels and information about the Trust’s policy regarding valuation
of financial instruments, refer to the Notes to Financial Statements.
The following table summarizes the Trust’s financial instruments categorized in the fair value hierarchy. The breakdown of the Trust
’
s financial instruments into major categories
is disclosed in the Schedule of Investments above.
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
Health Care Equipment & Supplies | | | | |
Health Care Providers & Services | | | | |
Life Sciences Tools & Services | | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
Derivative Financial Instruments (a) | | | | |
| | | | |
| | | | |
| Derivative financial instruments are options written. Options written are shown at value. |
See notes to financial statements.
78
2024
BlackRock Semi-Annual Report to Shareholders
Schedule of Investments
(unaudited)
BlackRock Innovation and Growth Term Trust (BIGZ)
(Percentages shown are based on Net Assets)
| | | |
|
Aerospace & Defense — 5.6% | |
Axon Enterprise, Inc. (a)(b)(c) | | | |
| | | |
| | | |
Air Freight & Logistics — 0.6% | |
| | | |
Automobile Components — 0.9% | |
Fox Factory Holding Corp. (c) | | | |
| |
Halozyme Therapeutics, Inc. (c)(d) | | | |
| |
AZEK Co., Inc., Class A (c) | | | |
| |
| | | |
Tradeweb Markets, Inc., Class A (b) | | | |
| | | |
Construction & Engineering — 2.2% | |
Comfort Systems USA, Inc. | | | |
Diversified Consumer Services | |
| | | |
Grammarly, Inc., (Acquired 11/17/21, Cost: | | | |
| | | |
Electrical Equipment — 2.8% | |
Vertiv Holdings Co., Class A | | | |
| |
Liberty Media Corp.-Liberty Formula One, Class C (c) | | | |
| |
| | | |
Ground Transportation — 2.9% | |
| | | |
Health Care Equipment & Supplies | |
| | | |
| | | |
Inspire Medical Systems, Inc. (d) | | | |
| | | |
| | | |
Health Care Providers & Services — 0.6% | |
Surgery Partners, Inc. (c) | | | |
Hotels, Restaurants & Leisure | |
DraftKings, Inc., Class A | | | |
Planet Fitness, Inc., Class A (b) | | | |
| | | |
| |
Innovative Industrial Properties, Inc. | | | |
Rexford Industrial Realty, Inc. | | | |
| | | |
Interactive Media & Services | |
Patreon, Inc., (Acquired 08/19/21, Cost: | | | |
| | | |
| | | |
| | | |
| |
DigitalOcean Holdings, Inc. | | | |
| | | |
| | | |
| | | |
Life Sciences Tools & Services — 5.3% | |
| | | |
| | | |
Charles River Laboratories International, Inc. (c) | | | |
| | | |
West Pharmaceutical Services, Inc. | | | |
| | | |
| |
AutoStore Holdings Ltd. (c)(d)(g) | | | |
Professional Services — 0.1% | |
Paylocity Holding Corp. (c) | | | |
Real Estate Management & Development — 2.8% | |
| | | |
Semiconductors & Semiconductor Equipment — 9.8% | |
| | | |
| | | |
| | | |
Lattice Semiconductor Corp. (c) | | | |
Monolithic Power Systems, Inc. (a) | | | |
| | | |
| |
| | | |
Aspen Technology, Inc. (c) | | | |
Bentley Systems, Inc., Class B (d) | | | |
Confluent, Inc., Class A (c)(d) | | | |
CyberArk Software Ltd. (c) | | | |
| | | |
| | | |
| | | |
| | | |
Snorkel AI, Inc., (Acquired 06/30/21, Cost: | | | |
Snyk Ltd., Ordinary Shares, (Acquired 09/02/21, Cost: | | | |
Teya Services Ltd., (Acquired 11/16/21, Cost: | | | |
| | | |
| |
Floor & Decor Holdings, Inc., Class A (c) | | | |
Textiles, Apparel & Luxury Goods — 2.7% | |
| | | |
On Holding AG, Class A (c)(d) | | | |
| | | |
Trading Companies & Distributors — 1.5% | |
Core & Main, Inc., Class A (c)(d) | | | |
Total Common Stocks — 79.0% | |
Schedule of Investments
79
Schedule of Investments
(unaudited)
(continued)
BlackRock Innovation and Growth Term Trust (BIGZ)
(Percentages shown are based on Net Assets)
| | | |
|
|
Aerospace & Defense — 0.1% | |
SkySafe, Inc., Series B, (Acquired 12/02/21, Cost: | | | |
Automobile Components — 2.6% | |
Relativity Space, Inc., Series E, (Acquired 05/27/21, | | | |
| |
Anchor Labs, Inc., Series D, (Acquired 11/24/21, Cost: | | | |
The Production Board LLC, Series A3, (Acquired 06/04/21, Cost: $50,000,001) | | | |
Varo Money, Inc., Series E, (Acquired 08/27/21, Cost: | | | |
| | | |
Diversified Consumer Services — 0.2% | |
Grammarly, Inc., Series 3, (Acquired 11/17/21, Cost: | | | |
Diversified Telecommunication Services — 0.5% | |
Discord, Inc., Series I, (Acquired 09/13/21, Cost: | | | |
| |
Under Canvas, Inc., Class A, (Acquired 08/19/21, Cost: | | | |
| |
Motif Food Works, Inc., Series B, (Acquired 06/08/21, | | | |
Hotels, Restaurants & Leisure | |
Dapper Labs, Inc., Series 7, (Acquired 07/20/21, Cost: | | | |
Underdog Sports, Inc., Series B, (Acquired 01/11/22, | | | |
| | | |
Interactive Media & Services — 0.5% | |
Patreon, Inc., Series D, (Acquired 07/14/21, Cost: | | | |
| |
Via Transportation, Inc., Series G, (Acquired 11/05/21, | | | |
Wagestream Holdings Ltd., Series C Private, (Acquired 02/11/22, Cost: $10,024,684) | | | |
| | | |
Semiconductors & Semiconductor Equipment | |
PsiQuantum Corp., Series D, (Acquired 05/21/21, Cost: | | | |
Rivos, Inc., Series A1, (Acquired 12/03/21, Cost: | | | |
| | | |
| |
AnyRoad, Inc., Series B, (Acquired 12/07/21, Cost: | | | |
Bolt Financial, Inc., Series E, (Acquired 01/18/22, Cost: | | | |
Deepgram, Inc., Series B, (Acquired 10/22/21, Cost: | | | |
Dragos, Inc., Series D, (Acquired 09/28/21, Cost: | | | |
| | | |
| |
Genesys Cloud Services, Inc., (Acquired 11/24/21, | | | |
Open Space Labs, Inc., Series D, (Acquired 01/31/22, | | | |
Snorkel AI, Inc., Series C, (Acquired 06/30/21, Cost: | | | |
Snyk Ltd., Series F, (Acquired 09/02/21, Cost: | | | |
Validere Technologies, Inc., Series B, (Acquired 10/21/21, Cost: $10,000,000) (c) | | | |
| | | |
| |
Super73, Inc., Series C-1, (Acquired 10/25/22, Cost: | | | |
Wireless Telecommunication Services — 1.2% | |
Loft Orbital Solutions, Inc., Series B, (Acquired 10/14/21, Cost: $24,999,992) (c) | | | |
| |
Total Preferred Securities — 21.6% | |
Total Long-Term Investments — 100.6% | |
|
Money Market Funds — 1.4% | |
BlackRock Cash Funds: Institutional, SL Agency | | | |
BlackRock Liquidity Funds, T-Fund, Institutional | | | |
Total Short-Term Securities — 1.4% | |
Total Investments Before Options Written — 102.0% | |
(Premiums Received: $(8,046,400)) | |
Total Investments, Net of Options Written — 101.6% | |
Liabilities in Excess of Other Assets — (1.6)% | |
| |
| All or a portion of the security has been pledged as collateral in connection with outstanding OTC derivatives. |
| All or a portion of the security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written. |
| Non-income producing security. |
| All or a portion of this security is on loan. |
| Security is valued using significant unobservable inputs and is classified as Level 3 in the |
| Restricted security as to resale, excluding 144A securities. The Trust held restricted securities with a current value of $450,930,301, representing 23.8% of its net assets as of period end, and an original cost of $779,086,851. |
| Security exempt from registration pursuant to Rule 144A under the Securities Act of 1933, as amended. These securities may be resold in transactions exempt from registration to qualified institutional investors. |
| |
| Annualized 7-day yield as of period end. |
| All or a portion of this security was purchased with the cash collateral from loaned |
80
2024
BlackRock Semi-Annual Report to Shareholders
Schedule of Investments
(unaudited)
(continued)
BlackRock Innovation and Growth Term Trust (BIGZ)
For purposes of this report, industry and sector sub-classifications may differ from those utilized by the Trust for compliance purposes.
Investments in issuers considered to be affiliate(s) of the Trust during the six months ended June 30, 2024 for purposes of Section 2(a)(3) of the Investment Company Act of
1940, as amended, were as follows:
| | | | | | | | | |
BlackRock Cash Funds: Institutional, SL Agency | | | | | | | | | |
BlackRock Liquidity Funds, T-Fund, Institutional | | | | | | | | | |
SL Liquidity Series, LLC, Money Market Series (c) | | | | | | | | | |
| | | | | | | | | |
| Represents net amount purchased (sold). |
| All or a portion represents securities lending income earned from the reinvestment of cash collateral from loaned securities, net of fees and collateral investment expenses, and other payments to and from borrowers of securities. |
| As of period end, the entity is no longer held. |
Derivative Financial Instruments Outstanding as of Period End
Exchange-Traded Options Written
| | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Bentley Systems, Inc., Class B | | | | | | | |
| | | | | | | |
Charles River Laboratories International, Inc. | | | | | | | |
Comfort Systems USA, Inc. | | | | | | | |
| | | | | | | |
Core & Main, Inc., Class A | | | | | | | |
| | | | | | | |
DigitalOcean Holdings, Inc. | | | | | | | |
DraftKings, Inc., Class A | | | | | | | |
| | | | | | | |
| | | | | | | |
Floor & Decor Holdings, Inc., Class A | | | | | | | |
Fox Factory Holding Corp. | | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Halozyme Therapeutics, Inc. | | | | | | | |
| | | | | | | |
| | | | | | | |
Innovative Industrial Properties, Inc. | | | | | | | |
Inspire Medical Systems, Inc. | | | | | | | |
| | | | | | | |
Lattice Semiconductor Corp. | | | | | | | |
Liberty Media Corp.-Liberty Formula One, Class C | | | | | | | |
Schedule of Investments
81
Schedule of Investments
(unaudited)
(continued)
BlackRock Innovation and Growth Term Trust (BIGZ)
Exchange-Traded Options Written (continued)
| | | | | |
| | | | | | | |
| | | | | | | |
Monolithic Power Systems, Inc. | | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Planet Fitness, Inc., Class A | | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Rexford Industrial Realty, Inc. | | | | | | | |
| | | | | | | |
Tradeweb Markets, Inc., Class A | | | | | | | |
Vertiv Holdings Co., Class A | | | | | | | |
West Pharmaceutical Services, Inc. | | | | | | | |
| | | | | | | |
DraftKings, Inc., Class A | | | | | | | |
| | | | | | | |
| | | | | | | |
Vertiv Holdings Co., Class A | | | | | | | |
| | | | | | | |
DraftKings, Inc., Class A | | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Vertiv Holdings Co., Class A | | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Charles River Laboratories International, Inc. | | | | | | | |
| | | | | | | |
Core & Main, Inc., Class A | | | | | | | |
| | | | | | | |
DigitalOcean Holdings, Inc. | | | | | | | |
DraftKings, Inc., Class A | | | | | | | |
| | | | | | | |
| | | | | | | |
Floor & Decor Holdings, Inc., Class A | | | | | | | |
Fox Factory Holding Corp. | | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Halozyme Therapeutics, Inc. | | | | | | | |
Inspire Medical Systems, Inc. | | | | | | | |
Liberty Media Corp.-Liberty Formula One, Class C | | | | | | | |
| | | | | | | |
Monolithic Power Systems, Inc. | | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Planet Fitness, Inc., Class A | | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Tradeweb Markets, Inc., Class A | | | | | | | |
West Pharmaceutical Services, Inc. | | | | | | | |
| | | | | | | |
82
2024
BlackRock Semi-Annual Report to Shareholders
Schedule of Investments
(unaudited)
(continued)
BlackRock Innovation and Growth Term Trust (BIGZ)
| | | | | | |
| | | | | | | | |
| | | | | | | | |
Bentley Systems, Inc., Class B | | | | | | | | |
Liberty Media Corp.-Liberty Formula One, Class C | | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| Goldman Sachs International | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| Goldman Sachs International | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| Goldman Sachs International | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| Goldman Sachs International | | | | | | | |
| Goldman Sachs International | | | | | | | |
| | | | | | | | |
| Goldman Sachs International | | | | | | | |
| | | | | | | | |
Comfort Systems USA, Inc. | | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| Morgan Stanley & Co. International PLC | | | | | | | |
| | | | | | | | |
| | | | | | | | |
Balances Reported in the Statements of Assets and Liabilities for Options Written
Derivative Financial Instruments Categorized by Risk Exposure
As of period end, the fair values of derivative financial instruments located in the Statements of Assets and Liabilities were as follows:
| | | | | | | |
Liabilities — Derivative Financial Instruments | | | | | | | |
| | | | | | | |
Schedule of Investments
83
Schedule of Investments
(unaudited)
(continued)
BlackRock Innovation and Growth Term Trust (BIGZ)
For the period ended June 30, 2024, the effect of derivative financial instruments in the Statements of Operations was as follows:
| | | | | | | |
Net Realized Gain (Loss) from: | | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Net Change in Unrealized Appreciation (Depreciation) on: | | | | | | | |
| | | | | | | |
| Options purchased are included in net realized gain (loss) from investments — unaffiliated. |
Average Quarterly Balances of Outstanding Derivative Financial Instruments
| |
Average value of option contracts purchased | |
Average value of option contracts written | |
| Derivative financial instrument not held at any quarter-end. The risk exposure table serves as an indicator of activity during the period. |
For more information about the Trust’s investment risks regarding derivative financial instruments, refer to the Notes to Financial Statements.
Derivative Financial Instruments — Offsetting as of Period End
The Trust’s derivative assets and liabilities (by type) were as follows:
| | |
Derivative Financial Instruments | | |
| | |
Total derivative assets and liabilities in the Statements of Assets and Liabilities | | |
Derivatives not subject to a Master Netting Agreement or similar agreement (“MNA”) | | |
Total derivative assets and liabilities subject to an MNA | | |
The following table presents the Trust’s derivative liabilities by counterparty net of amounts available for offset under an MNA and net of the related collateral pledged by the
Trust:
| | | | | |
| | | | | |
| | | | | |
| | | | | |
Goldman Sachs International | | | | | |
| | | | | |
Morgan Stanley & Co. International PLC | | | | | |
| | | | | |
| | | | | |
| Excess of collateral received/pledged, if any, from the individual counterparty is not shown for financial reporting purposes. |
| Net amount represents the net amount payable due to counterparty in the event of default. Net amount may be offset further by the options written receivable/payable on the Statements of Assets and Liabilities. |
84
2024
BlackRock Semi-Annual Report to Shareholders
Schedule of Investments
(unaudited)
(continued)
BlackRock Innovation and Growth Term Trust (BIGZ)
Fair Value Hierarchy as of Period End
Various inputs are used in determining the fair value of financial instruments. For a description of the input levels and information about the Trust’s policy regarding valuation
of financial instruments, refer to the Notes to Financial Statements.
The following table summarizes the Trust’s financial instruments categorized in the fair value hierarchy. The breakdown of the Trust
’
s financial instruments into major categories
is disclosed in the Schedule of Investments above.
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
Construction & Engineering | | | | |
Diversified Consumer Services | | | | |
| | | | |
| | | | |
| | | | |
| | | | |
Health Care Equipment & Supplies | | | | |
Health Care Providers & Services | | | | |
Hotels, Restaurants & Leisure | | | | |
| | | | |
Interactive Media & Services | | | | |
| | | | |
Life Sciences Tools & Services | | | | |
| | | | |
| | | | |
Real Estate Management & Development | | | | |
Semiconductors & Semiconductor Equipment | | | | |
| | | | |
| | | | |
Textiles, Apparel & Luxury Goods | | | | |
Trading Companies & Distributors | | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
Derivative Financial Instruments (a) | | | | |
| | | | |
| | | | |
| Derivative financial instruments are options written. Options written are shown at value. |
A reconciliation of Level 3 financial instruments is presented when the Trust had a significant amount of Level 3 investments and derivative financial instruments at the
beginning and/or end of the period in relation to net assets. The following table is a reconciliation of Level 3 investments for which significant unobservable inputs were used in
determining fair value:
| | | |
| | | |
Opening balance, as of December 31, 2023 | | | |
| | | |
| | | |
Accrued discounts/premiums | | | |
| | | |
Net change in unrealized appreciation (depreciation) (a)(b) | | | |
Schedule of Investments
85
Schedule of Investments
(unaudited)
(continued)
BlackRock Innovation and Growth Term Trust (BIGZ)
| | | |
| | | |
| | | |
Closing balance, as of June 30, 2024 | | | |
Net change in unrealized appreciation (depreciation) on investments still held at June 30, 2024 (b) | | | |
| Included in the related net change in unrealized appreciation (depreciation) in the Statements of Operations. |
| Any difference between net change in unrealized appreciation (depreciation) and net change in unrealized appreciation (depreciation) on investments still held at June 30, 2024 is generally due to investments no longer held or categorized as Level 3 at period end. |
The following table summarizes the valuation approaches used and unobservable inputs utilized by the BlackRock Valuation Committee (the “Valuation Committee”) to
determine the value of certain of the Trust’s Level 3 financial instruments as of period end.
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | Market Adjustment Multiple | | |
| | | | | |
| A significant change in unobservable input would have resulted in a correlated (inverse) significant change to value. |
See notes to financial statements.
86
2024
BlackRock Semi-Annual Report to Shareholders
Schedule of Investments
(unaudited)
BlackRock Resources & Commodities Strategy Trust (BCX)
(Percentages shown are based on Net Assets)
| | | |
|
| |
CF Industries Holdings, Inc. (a) | | | |
| | | |
| | | |
| | | |
Construction Materials — 0.7% | |
| | | |
Containers & Packaging — 9.8% | |
| | | |
| | | |
Graphic Packaging Holding Co. | | | |
Packaging Corp. of America (a) | | | |
| | | |
| | | |
Energy Equipment & Services — 1.7% | |
| | | |
| |
| | | |
Hofseth International, (Acquired 05/26/21, Cost: | | | |
| | | |
| |
| | | |
ArcelorMittal SA, Registered Shares | | | |
| | | |
| | | |
| | | |
| | | |
First Quantum Minerals Ltd. | | | |
Freeport-McMoRan, Inc. (e) | | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
Teck Resources Ltd., Class B | | | |
Wheaton Precious Metals Corp. | | | |
| | | |
Oil, Gas & Consumable Fuels — 38.4% | |
| | | |
Canadian Natural Resources Ltd. | | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
Permian Resources Corp., Class A | | | |
| | | |
| | | |
| | | |
| | | |
Paper & Forest Products — 1.5% | |
Precious Woods Holding AG, Registered Shares (b) | | | |
| | | |
| | | |
Total Common Stocks — 97.8% | |
| | | |
|
|
Allied Gold Corp., 8.75%, 09/07/28 (f)(g) | | | |
Total Corporate Bonds — 0.8% | |
Total Long-Term Investments — 98.6% | |
| | | |
|
Money Market Funds — 2.0% | |
BlackRock Liquidity Funds, T-Fund, Institutional Shares, | | | |
Total Short-Term Securities — 2.0% | |
Total Investments Before Options Written — 100.6% | |
(Premiums Received: $(6,005,423)) | |
Total Investments, Net of Options Written — 100.0% | |
Other Assets Less Liabilities — 0.0% | |
| |
| All or a portion of the security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written. |
| Non-income producing security. |
| Security is valued using significant unobservable inputs and is classified as Level 3 in the |
| Restricted security as to resale, excluding 144A securities. The Trust held restricted securities with a current value of $11,651,775, representing 1.3% of its net assets as of period end, and an original cost of $10,198,056. |
| All or a portion of the security has been pledged as collateral in connection with outstanding OTC derivatives. |
| |
| Security exempt from registration pursuant to Rule 144A under the Securities Act of 1933, as amended. These securities may be resold in transactions exempt from registration to qualified institutional investors. |
| |
| Annualized 7-day yield as of period end. |
For purposes of this report, industry and sector sub-classifications may differ from those utilized by the Trust for compliance purposes.
Schedule of Investments
87
Schedule of Investments
(unaudited)
(continued)
BlackRock Resources & Commodities Strategy Trust (BCX)
Investments in issuers considered to be affiliate(s) of the Trust during the six months ended June 30, 2024 for purposes of Section 2(a)(3) of the Investment Company Act of
1940, as amended, were as follows:
| | | | | | | | | |
BlackRock Cash Funds: Institutional, SL Agency | | | | | | | | | |
BlackRock Liquidity Funds, T-Fund, Institutional | | | | | | | | | |
SL Liquidity Series, LLC, Money Market Series (a) | | | | | | | | | |
| | | | | | | | | |
| As of period end, the entity is no longer held. |
| Represents net amount purchased (sold). |
| All or a portion represents securities lending income earned from the reinvestment of cash collateral from loaned securities, net of fees and collateral investment expenses, and other payments to and from borrowers of securities. |
Derivative Financial Instruments Outstanding as of Period End
Exchange-Traded Options Written
| | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
ArcelorMittal SA, Registered Shares | | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Canadian Natural Resources Ltd. | | | | | | | |
Canadian Natural Resources Ltd. | | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Packaging Corp. of America | | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
88
2024
BlackRock Semi-Annual Report to Shareholders
Schedule of Investments
(unaudited)
(continued)
BlackRock Resources & Commodities Strategy Trust (BCX)
Exchange-Traded Options Written (continued)
| | | | | |
| | | | | | | |
CF Industries Holdings, Inc. | | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
ArcelorMittal SA, Registered Shares | | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Packaging Corp. of America | | | | | | | |
Permian Resources Corp., Class A | | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| Goldman Sachs International | | | | | | | |
| Morgan Stanley & Co. International PLC | | | | | | | |
Graphic Packaging Holding Co. | | | | | | | | |
| Morgan Stanley & Co. International PLC | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| Goldman Sachs International | | | | | | | |
| Morgan Stanley & Co. International PLC | | | | | | | |
| | | | | | | | |
| | | | | | | | |
Graphic Packaging Holding Co. | Morgan Stanley & Co. International PLC | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
Schedule of Investments
89
Schedule of Investments
(unaudited)
(continued)
BlackRock Resources & Commodities Strategy Trust (BCX)
Balances Reported in the Statements of Assets and Liabilities for Options Written
Derivative Financial Instruments Categorized by Risk Exposure
As of period end, the fair values of derivative financial instruments located in the Statements of Assets and Liabilities were as follows:
| | | | | | | |
Liabilities — Derivative Financial Instruments | | | | | | | |
| | | | | | | |
For the period ended June 30, 2024, the effect of derivative financial instruments in the Statements of Operations was as follows:
| | | | | | | |
Net Realized Gain (Loss) from: | | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Net Change in Unrealized Appreciation (Depreciation) on: | | | | | | | |
| | | | | | | |
| Options purchased are included in net realized gain (loss) from investments — unaffiliated. |
Average Quarterly Balances of Outstanding Derivative Financial Instruments
| |
Average value of option contracts purchased | |
Average value of option contracts written | |
| Derivative financial instrument not held at any quarter-end. The risk exposure table serves as an indicator of activity during the period. |
For more information about the Trust’s investment risks regarding derivative financial instruments, refer to the Notes to Financial Statements.
Derivative Financial Instruments — Offsetting as of Period End
The Trust’s derivative assets and liabilities (by type) were as follows:
| | |
Derivative Financial Instruments | | |
| | |
Total derivative assets and liabilities in the Statements of Assets and Liabilities | | |
Derivatives not subject to a Master Netting Agreement or similar agreement (“MNA”) | | |
Total derivative assets and liabilities subject to an MNA | | |
90
2024
BlackRock Semi-Annual Report to Shareholders
Schedule of Investments
(unaudited)
(continued)
BlackRock Resources & Commodities Strategy Trust (BCX)
The following table presents the Trust’s derivative liabilities by counterparty net of amounts available for offset under an MNA and net of the related collateral pledged by the
Trust:
| | | | | |
| | | | | |
| | | | | |
| | | | | |
Goldman Sachs International | | | | | |
Morgan Stanley & Co. International PLC | | | | | |
| | | | | |
| Excess of collateral received/pledged, if any, from the individual counterparty is not shown for financial reporting purposes. |
| Net amount represents the net amount payable due to counterparty in the event of default. Net amount may be offset further by the options written receivable/payable on the Statements of Assets and Liabilities. |
Fair Value Hierarchy as of Period End
Various inputs are used in determining the fair value of financial instruments. For a description of the input levels and information about the Trust’s policy regarding valuation
of financial instruments, refer to the Notes to Financial Statements.
The following table summarizes the Trust’s financial instruments categorized in the fair value hierarchy. The breakdown of the Trust
’
s financial instruments into major categories
is disclosed in the Schedule of Investments above.
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
Energy Equipment & Services | | | | |
| | | | |
| | | | |
Oil, Gas & Consumable Fuels | | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
Derivative Financial Instruments (a) | | | | |
| | | | |
| | | | |
| Derivative financial instruments are options written. Options written are shown at value. |
A reconciliation of Level 3 financial instruments is presented when the Trust had a significant amount of Level 3 investments and derivative financial instruments at the
beginning and/or end of the period in relation to net assets. The following table is a reconciliation of Level 3 investments for which significant unobservable inputs were used in
determining fair value:
| |
| |
Opening balance, as of December 31, 2023 | |
| |
| |
Accrued discounts/premiums | |
| |
Net change in unrealized appreciation (depreciation) (a)(b) | |
Schedule of Investments
91
Schedule of Investments
(unaudited)
(continued)
BlackRock Resources & Commodities Strategy Trust (BCX)
| |
| |
| |
Closing balance, as of June 30, 2024 | |
Net change in unrealized appreciation (depreciation) on investments still held at June 30, 2024 (b) | |
| Included in the related net change in unrealized appreciation (depreciation) in the Statements of Operations. |
| Any difference between net change in unrealized appreciation (depreciation) and net change in unrealized appreciation (depreciation) on investments still held at June 30, 2024 is generally due to investments no longer held or categorized as Level 3 at period end. |
The following table summarizes the valuation approaches used and unobservable inputs utilized by the BlackRock Valuation Committee (the “Valuation Committee”) to
determine the value of certain of the Trust’s Level 3 financial instruments as of period end. The table does not include Level 3 financial instruments with values based upon
unadjusted third-party pricing information in the amount of $645. A significant change in third party information could result in a significantly lower or higher value of such Level 3
financial instruments.
| A significant change in unobservable input would have resulted in a correlated (inverse) significant change to value. |
See notes to financial statements.
92
2024
BlackRock Semi-Annual Report to Shareholders
Consolidated Schedule of Investments
(unaudited)
BlackRock Science and Technology Term Trust (BSTZ)
(Percentages shown are based on Net Assets)
| | | |
|
| |
| | | |
| |
| | | |
Communications Equipment — 1.0% | |
| | | |
| |
| | | |
Diversified Consumer Services — 0.0% | |
Think & Learn Private Ltd., Class J-B, (Acquired 09/30/20, Cost: $7,113,729) (b)(d)(e) | | | |
Electrical Equipment — 0.7% | |
Vertiv Holdings Co., Class A | | | |
Electronic Equipment, Instruments & Components — 3.2% | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| |
| | | |
| | | |
Take-Two Interactive Software, Inc. (b) | | | |
Webtoon Entertainment, Inc. (b) | | | |
| | | |
Industrial Conglomerates — 1.0% | |
| | | |
Interactive Media & Services | |
| | | |
| | | |
| | | |
| |
Automattic, Inc., Series E, (Acquired 02/03/21, Cost: | | | |
Cloudflare, Inc., Class A (b)(c) | | | |
CNEX Labs, Inc., (Acquired 12/14/21, Cost: | | | |
Farmer ’ s Business Network, Inc. (b)(d) | | | |
Klarna Holdings AB, (Acquired 08/07/19, Cost: | | | |
MongoDB, Inc., Class A (b)(c)(f) | | | |
| | | |
| | | |
| |
| | | |
Harmonic Drive Systems, Inc. | | | |
| | | |
| |
| | | |
| | | |
Professional Services — 2.3% | |
| | | |
Wolters Kluwer NV, Class C | | | |
| | | |
Semiconductors & Semiconductor Equipment — 29.2% | |
| | | |
ARM Holdings PLC, ADR (b)(c) | | | |
| | | |
| | | |
| | | |
BE Semiconductor Industries NV | | | |
Credo Technology Group Holding Ltd. (b) | | | |
| | | |
| | | |
| | | |
| | | |
Marvell Technology, Inc. (f) | | | |
Monolithic Power Systems, Inc. | | | |
Mythic AI, Inc., Series C, (Acquired 01/26/21, Cost: | | | |
| | | |
| | | |
| | | |
| | | |
| |
| | | |
| | | |
Databricks, Inc., (Acquired 07/24/20, Cost: | | | |
| | | |
DataRobot, Inc., (Acquired 03/01/21, Cost: | | | |
| | | |
Informatica, Inc., Class A (c) | | | |
| | | |
Manhattan Associates, Inc. | | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
Samsara, Inc., Class A (c) | | | |
SentinelOne, Inc., Class A (c) | | | |
| | | |
| | | |
Snorkel AI, Inc., (Acquired 10/13/20, Cost: | | | |
Snyk Ltd., Ordinary Shares, (Acquired 11/02/20, Cost: | | | |
| | | |
| | | |
| | | |
Technology Hardware, Storage & Peripherals — 5.7% | |
Asia Vital Components Co. Ltd. | | | |
Pure Storage, Inc., Class A (a)(b) | | | |
Super Micro Computer, Inc. (b) | | | |
Consolidated Schedule of Investments
93
Consolidated Schedule of Investments
(unaudited)
(continued)
BlackRock Science and Technology Term Trust (BSTZ)
(Percentages shown are based on Net Assets)
| | | |
Technology Hardware, Storage & Peripherals (continued) | |
| | | |
| | | |
| | | |
Total Common Stocks — 78.0% | |
|
|
Communications Equipment — 0.6% | |
Astranis Space Technologies Corp., Series C (b) | | | |
Consumer Staples Distribution & Retail — 2.2% | |
GrubMarket, Inc., Series D, (Acquired 07/23/20, Cost: | | | |
Diversified Consumer Services | |
FlixMobility GmbH, Series F, (Acquired 07/26/19, Cost: | | | |
Think & Learn Private Ltd., Series F, (Acquired 09/30/20, Cost: $14,251,080) | | | |
| | | |
| |
ResearchGate GmbH, Series D, (Acquired 09/24/20, | | | |
| |
| | | |
Class J-A, (Acquired 07/24/20, Cost: $9,999,857) | | | |
Class J-B, (Acquired 07/24/20, Cost: $5,999,914) | | | |
| | | |
Interactive Media & Services — 1.5% | |
ByteDance Ltd., Series E-1, (Acquired 11/11/20, Cost: | | | |
| |
Deep Instinct Ltd., Series D-2, (Acquired 03/19/21, | | | |
| | | |
(Acquired 09/12/19, Cost: $10,999,988) | | | |
(Acquired 02/18/21, Cost: $9,999,998) | | | |
| | | |
Professional Services — 0.5% | |
Rapyd Financial Network Ltd., Series E, (Acquired 03/31/21, Cost: $13,999,978) (b)(e) | | | |
Semiconductors & Semiconductor Equipment | |
| | | |
Series C, (Acquired 09/09/19, Cost: $9,101,310) | | | |
Series D, (Acquired 05/21/21, Cost: $19,999,969) | | | |
| | | |
| |
| | | |
Series F, (Acquired 10/22/19, Cost: $13,200,019) | | | |
Series G, (Acquired 02/01/21, Cost: $18,500,004) | | | |
DataRobot, Inc., Series F, (Acquired 10/27/20, Cost: | | | |
| | | |
| |
| | | |
Series C, (Acquired 02/20/20, Cost: $33,904,162) | | | |
Series D, (Acquired 04/09/21, Cost: $6,999,979) | | | |
Snorkel AI, Inc., Series B, (Acquired 10/13/20, Cost: | | | |
Snyk Ltd., Seed Preferred, (Acquired 11/02/20, Cost: | | | |
| | | |
Series B, (Acquired 09/19/19, Cost: $6,801,016) | | | |
Series C, (Acquired 09/18/20, Cost: $7,994,787) | | | |
| | | |
| |
Total Preferred Securities — 23.0% | |
Total Long-Term Investments — 101.0% | |
|
Money Market Funds — 1.9% | |
BlackRock Cash Funds: Institutional, SL Agency | | | |
BlackRock Liquidity Funds, T-Fund, Institutional | | | |
Total Short-Term Securities — 1.9% | |
Total Investments Before Options Written — 102.9% | |
(Premiums Received: $(12,707,105)) | |
Total Investments, Net of Options Written — 101.8% | |
Liabilities in Excess of Other Assets — (1.8)% | |
| |
| All or a portion of the security has been pledged as collateral in connection with outstanding OTC derivatives. |
| Non-income producing security. |
| All or a portion of this security is on loan. |
| Security is valued using significant unobservable inputs and is classified as Level 3 in the |
| Restricted security as to resale, excluding 144A securities. The Trust held restricted securities with a current value of $485,176,292, representing 28.0% of its net assets as of period end, and an original cost of $363,733,620. |
| All or a portion of the security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written. |
| All or a portion of the security is held by a wholly-owned subsidiary. See Note 1 of the Notes to Consolidated Financial Statements for details on the wholly-owned subsidiary. |
| |
| Annualized 7-day yield as of period end. |
| All or a portion of this security was purchased with the cash collateral from loaned |
For purposes of this report, industry and sector sub-classifications may differ from those utilized by the Trust for compliance purposes.
94
2024
BlackRock Semi-Annual Report to Shareholders
Consolidated Schedule of Investments
(unaudited)
(continued)
BlackRock Science and Technology Term Trust (BSTZ)
Investments in issuers considered to be affiliate(s) of the Trust during the six months ended June 30, 2024 for purposes of Section 2(a)(3) of the Investment Company Act of
1940, as amended, were as follows:
| | | | | | | | | |
BlackRock Cash Funds: Institutional, SL Agency | | | | | | | | | |
BlackRock Liquidity Funds, T-Fund, Institutional | | | | | | | | | |
SL Liquidity Series, LLC, Money Market Series (c) | | | | | | | | | |
| | | | | | | | | |
| Represents net amount purchased (sold). |
| All or a portion represents securities lending income earned from the reinvestment of cash collateral from loaned securities, net of fees and collateral investment expenses, and other payments to and from borrowers of securities. |
| As of period end, the entity is no longer held. |
Derivative Financial Instruments Outstanding as of Period End
Exchange-Traded Options Written
| | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Take-Two Interactive Software, Inc. | | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Credo Technology Group Holding Ltd. | | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Informatica, Inc., Class A | | | | | | | |
Manhattan Associates, Inc. | | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Monolithic Power Systems, Inc. | | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Pure Storage, Inc., Class A | | | | | | | |
| | | | | | | |
| | | | | | | |
Consolidated Schedule of Investments
95
Consolidated Schedule of Investments
(unaudited)
(continued)
BlackRock Science and Technology Term Trust (BSTZ)
Exchange-Traded Options Written (continued)
| | | | | |
| | | | | | | |
SentinelOne, Inc., Class A | | | | | | | |
| | | | | | | |
Take-Two Interactive Software, Inc. | | | | | | | |
| | | | | | | |
Vertiv Holdings Co., Class A | | | | | | | |
Cloudflare, Inc., Class A | | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
SentinelOne, Inc., Class A | | | | | | | |
Super Micro Computer, Inc. | | | | | | | |
| | | | | | | |
Vertiv Holdings Co., Class A | | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
SentinelOne, Inc., Class A | | | | | | | |
Take-Two Interactive Software, Inc. | | | | | | | |
| | | | | | | |
| | | | | | | |
Vertiv Holdings Co., Class A | | | | | | | |
| | | | | | | |
| | | | | | | |
Credo Technology Group Holding Ltd. | | | | | | | |
Credo Technology Group Holding Ltd. | | | | | | | |
| | | | | | | |
Informatica, Inc., Class A | | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Monolithic Power Systems, Inc. | | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| Goldman Sachs International | | | | | | | |
| | | | | | | | |
| | | | | | | | |
96
2024
BlackRock Semi-Annual Report to Shareholders
Consolidated Schedule of Investments
(unaudited)
(continued)
BlackRock Science and Technology Term Trust (BSTZ)
OTC Options Written (continued)
| | | | | | |
| | | | | | | | |
| Goldman Sachs International | | | | | | | |
| Morgan Stanley & Co. International PLC | | | | | | | |
| | | | | | | | |
| Morgan Stanley & Co. International PLC | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
Pure Storage, Inc., Class A | | | | | | | | |
| Morgan Stanley & Co. International PLC | | | | | | | |
| | | | | | | | |
| Morgan Stanley & Co. International PLC | | | | | | | |
| Morgan Stanley & Co. International PLC | | | | | | | |
| Morgan Stanley & Co. International PLC | | | | | | | |
| Morgan Stanley & Co. International PLC | | | | | | | |
| Morgan Stanley & Co. International PLC | | | | | | | |
Harmonic Drive Systems, Inc. | | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| Morgan Stanley & Co. International PLC | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| Morgan Stanley & Co. International PLC | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| Goldman Sachs International | | | | | | | |
Wolters Kluwer NV, Class C | Goldman Sachs International | | | | | | | |
| | | | | | | | |
BE Semiconductor Industries NV | | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| Goldman Sachs International | | | | | | | |
Pure Storage, Inc., Class A | | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
Balances Reported in the Consolidated Statements of Assets and Liabilities for Options Written
Consolidated Schedule of Investments
97
Consolidated Schedule of Investments
(unaudited)
(continued)
BlackRock Science and Technology Term Trust (BSTZ)
Derivative Financial Instruments Categorized by Risk Exposure
As of period end, the fair values of derivative financial instruments located in the Consolidated Statements of Assets and Liabilities were as follows:
| | | | | | | |
Liabilities — Derivative Financial Instruments | | | | | | | |
| | | | | | | |
For the period ended June 30, 2024, the effect of derivative financial instruments in the Consolidated Statements of Operations was as follows:
| | | | | | | |
Net Realized Gain (Loss) from: | | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Net Change in Unrealized Appreciation (Depreciation) on: | | | | | | | |
| | | | | | | |
| Options purchased are included in net realized gain (loss) from investments — unaffiliated. |
Average Quarterly Balances of Outstanding Derivative Financial Instruments
| |
Average value of option contracts purchased | |
Average value of option contracts written | |
| Derivative financial instrument not held at any quarter-end. The risk exposure table serves as an indicator of activity during the period. |
For more information about the Trust’s investment risks regarding derivative financial instruments, refer to the Notes to Consolidated Financial Statements.
Derivative Financial Instruments — Offsetting as of Period End
The Trust’s derivative assets and liabilities (by type) were as follows:
| | |
Derivative Financial Instruments | | |
| | |
Total derivative assets and liabilities in the Consolidated Statements of Assets and Liabilities | | |
Derivatives not subject to a Master Netting Agreement or similar agreement (“MNA”) | | |
Total derivative assets and liabilities subject to an MNA | | |
The following table presents the Trust’s derivative liabilities by counterparty net of amounts available for offset under an MNA and net of the related collateral pledged by the
Trust:
| | | | | |
| | | | | |
| | | | | |
| | | | | |
Goldman Sachs International | | | | | |
| | | | | |
Morgan Stanley & Co. International PLC | | | | | |
98
2024
BlackRock Semi-Annual Report to Shareholders
Consolidated Schedule of Investments
(unaudited)
(continued)
BlackRock Science and Technology Term Trust (BSTZ)
| Excess of collateral received/pledged, if any, from the individual counterparty is not shown for financial reporting purposes. |
Fair Value Hierarchy as of Period End
Various inputs are used in determining the fair value of financial instruments. For a description of the input levels and information about the Trust’s policy regarding valuation
of financial instruments, refer to the Notes to Consolidated Financial Statements.
The following table summarizes the Trust’s financial instruments categorized in the fair value hierarchy. The breakdown of the Trust
’
s financial instruments into major categories
is disclosed in the Consolidated Schedule of Investments above.
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
Diversified Consumer Services | | | | |
| | | | |
Electronic Equipment, Instruments & Components | | | | |
| | | | |
| | | | |
Interactive Media & Services | | | | |
| | | | |
| | | | |
| | | | |
| | | | |
Semiconductors & Semiconductor Equipment | | | | |
| | | | |
Technology Hardware, Storage & Peripherals | | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
Derivative Financial Instruments (a) | | | | |
| | | | |
| | | | |
| Derivative financial instruments are options written. Options written are shown at value. |
A reconciliation of Level 3 financial instruments is presented when the Trust had a significant amount of Level 3 investments and derivative financial instruments at the
beginning and/or end of the period in relation to net assets. The following table is a reconciliation of Level 3 investments for which significant unobservable inputs were used in
determining fair value:
| | | |
| | | |
Opening balance, as of December 31, 2023 | | | |
| | | |
| | | |
Accrued discounts/premiums | | | |
| | | |
Consolidated Schedule of Investments
99
Consolidated Schedule of Investments
(unaudited)
(continued)
BlackRock Science and Technology Term Trust (BSTZ)
| | | |
Net change in unrealized appreciation (depreciation) (a)(b) | | | |
| | | |
| | | |
Closing balance, as of June 30, 2024 | | | |
Net change in unrealized appreciation (depreciation) on investments still held at June 30, 2024 (b) | | | |
| Included in the related net change in unrealized appreciation (depreciation) in the Consolidated Statements of Operations. |
| Any difference between net change in unrealized appreciation (depreciation) and net change in unrealized appreciation (depreciation) on investments still held at June 30, 2024 is generally due to investments no longer held or categorized as Level 3 at period end. |
The following table summarizes the valuation approaches used and unobservable inputs utilized by the BlackRock Valuation Committee (the “Valuation Committee”) to
determine the value of certain of the Trust’s Level 3 financial instruments as of period end. The table does not include Level 3 financial instruments with values based upon
unadjusted third-party pricing information in the amount of $12. A significant change in third party information could result in a significantly lower or higher value of such Level 3
financial instruments.
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | Market Adjustment Multiple | | |
| | | | | |
| A significant change in unobservable input would have resulted in a correlated (inverse) significant change to value. |
See notes to financial statements.
100
2024
BlackRock Semi-Annual Report to Shareholders
Consolidated Schedule of Investments
(unaudited)
BlackRock Science and Technology Trust (BST)
(Percentages shown are based on Net Assets)
| | | |
|
| |
| | | |
| |
| | | |
| | | |
| | | |
| |
| | | |
Communications Equipment — 1.4% | |
| | | |
| | | |
| | | |
| | | |
Diversified Consumer Services | |
Grammarly, Inc., (Acquired 11/17/21, Cost: | | | |
Think & Learn Private Ltd., Class J-B, (Acquired 09/30/20, Cost: $1,524,948) | | | |
| | | |
Electrical Equipment — 0.4% | |
Vertiv Holdings Co., Class A | | | |
| |
| | | |
| | | |
Take-Two Interactive Software, Inc. (a) | | | |
Webtoon Entertainment, Inc. (a) | | | |
| | | |
Financial Services — 1.8% | |
Mastercard, Inc., Class A | | | |
Ground Transportation — 0.6% | |
Uber Technologies, Inc. (a) | | | |
Industrial Conglomerates — 0.7% | |
| | | |
Interactive Media & Services — 4.0% | |
| | | |
Meta Platforms, Inc., Class A | | | |
Patreon, Inc., (Acquired 08/19/21, Cost: | | | |
| | | |
| |
Automattic, Inc., Series E, (Acquired 02/03/21, Cost: | | | |
Farmer ’ s Business Network, Inc. (b) | | | |
Klarna Holdings AB, (Acquired 08/07/19, Cost: | | | |
| | | |
| | | |
Professional Services — 1.0% | |
| | | |
Semiconductors & Semiconductor Equipment — 33.6% | |
Advanced Micro Devices, Inc. (a)(d) | | | |
ARM Holdings PLC, ADR (a)(e) | | | |
| | | |
| | | |
Semiconductors & Semiconductor Equipment (continued) | |
| | | |
| | | |
Credo Technology Group Holding Ltd. (a) | | | |
| | | |
| | | |
| | | |
Monolithic Power Systems, Inc. | | | |
| | | |
| | | |
Taiwan Semiconductor Manufacturing Co. Ltd., ADR | | | |
| | | |
| |
| | | |
Cadence Design Systems, Inc. (a)(f) | | | |
Constellation Software, Inc./Canada | | | |
Crowdstrike Holdings, Inc., Class A (a) | | | |
Databricks, Inc., (Acquired 07/24/20, Cost: | | | |
Datadog, Inc., Class A (a) | | | |
DataRobot, Inc., (Acquired 03/01/21, Cost: | | | |
Informatica, Inc., Class A (a) | | | |
| | | |
| | | |
| | | |
Palo Alto Networks, Inc. (a) | | | |
| | | |
| | | |
Snorkel AI, Inc., (Acquired 06/30/21, Cost: | | | |
Snyk Ltd., Ordinary Shares, (Acquired 09/02/21, Cost: | | | |
Teya Services Ltd., (Acquired 12/17/21, Cost: | | | |
| | | |
| | | |
| |
AceVector Limited, Series I, (Acquired 08/31/18, Cost: | | | |
Technology Hardware, Storage & Peripherals — 9.0% | |
| | | |
Dell Technologies, Inc., Class C | | | |
| | | |
Western Digital Corp. (a)(e) | | | |
| | | |
Total Common Stocks — 86.2% | |
Consolidated Schedule of Investments
101
Consolidated Schedule of Investments
(unaudited)
(continued)
BlackRock Science and Technology Trust (BST)
(Percentages shown are based on Net Assets)
| | | |
|
Financial Services — 0.0% |
Wyre, Inc., (Acquired: 12/14/21, Cost: $8,000,000), | | | |
Total Convertible Notes — 0.0% | |
| | | |
|
|
| |
Solugen, Inc., Series C, (Acquired 09/02/21, Cost: | | | |
Consumer Staples Distribution & Retail — 1.2% | |
Grubmarket, Inc., Series E, (Acquired 10/18/21, Cost: | | | |
Diversified Consumer Services | |
FlixMobility GmbH, Series F, (Acquired 07/26/19, Cost: | | | |
Grammarly, Inc., Series 3, (Acquired 11/17/21, Cost: | | | |
Think & Learn Private Ltd., Series F, (Acquired 09/30/20, | | | |
| | | |
Diversified Telecommunication Services — 0.3% | |
Discord, Inc., Series I, (Acquired 09/13/21, Cost: | | | |
| |
| | | |
Class J-A, (Acquired 07/24/20, Cost: $2,499,716) | | | |
Class J-B, (Acquired 07/24/20, Cost: $1,499,830) | | | |
Class L, (Acquired 09/15/21, Cost: $9,999,695) | | | |
| | | |
Interactive Media & Services | |
ByteDance Ltd., Series E-1, (Acquired 11/11/20, Cost: | | | |
Patreon, Inc., Series D, (Acquired 07/14/21, Cost: | | | |
| | | |
| |
Deep Instinct Ltd., Series D-2, (Acquired 03/19/21, Cost: | | | |
MNTN Digital, Inc., Series D, (Acquired 11/05/21, Cost: | | | |
| | | |
(Acquired 09/12/19, Cost: $4,000,013) | | | |
(Acquired 02/18/21, Cost: $1,999,989) | | | |
| | | |
| |
| | | |
Series A, (Acquired 01/18/22, Cost: $10,000,000) | | | |
Series SEED, (Acquired 07/14/21, Cost: $5,000,000) | | | |
| | | |
Professional Services — 0.3% | |
Ant Group Co., Ltd., Series C (a) | | | |
Semiconductors & Semiconductor Equipment | |
| | | |
Series C, (Acquired 09/09/19, Cost: $3,200,234) | | | |
Series D, (Acquired 05/21/21, Cost: $5,000,025) | | | |
| | | |
Series A1, (Acquired , Cost: $7,203,709) (c) | | | |
| | | |
| | | |
| | | |
| |
Bolt Financial, Inc., Series E, (Acquired 01/18/22, Cost: | | | |
| | | |
| | | |
Series F, (Acquired 10/22/19, Cost: $3,999,999) | | | |
Series G, (Acquired 02/01/21, Cost: $4,500,001) | | | |
DataRobot, Inc., Series F, (Acquired 10/27/20, Cost: | | | |
Prosimo, Inc., Series B, (Acquired 11/04/21, Cost: | | | |
SambaNova Systems, Inc., Series C, (Acquired 02/20/20, Cost: $9,972,125) (c) | | | |
Snorkel AI, Inc., Series C, (Acquired 06/30/21, Cost: | | | |
Snyk Ltd., Series F, (Acquired 09/02/21, Cost: | | | |
| | | |
Series B, (Acquired 09/19/19, Cost: $3,198,416) | | | |
Series C, (Acquired 09/18/20, Cost: $1,303,260) | | | |
| | | |
| |
Total Preferred Securities — 15.2% | |
|
| |
Constellation Software, Inc., (Issued 08/29/23, 1 Share for 1 Warrant, Expires 03/31/40, Strike Price CAD | | | |
| |
Total Long-Term Investments — 101.4% | |
102
2024
BlackRock Semi-Annual Report to Shareholders
Consolidated Schedule of Investments
(unaudited)
(continued)
BlackRock Science and Technology Trust (BST)
(Percentages shown are based on Net Assets)
| | | |
|
Money Market Funds — 0.7% | |
BlackRock Cash Funds: Institutional, SL Agency | | | |
BlackRock Liquidity Funds, T-Fund, Institutional Shares, | | | |
Total Short-Term Securities — 0.7% | |
Total Investments Before Options Written — 102.1% | |
(Premiums Received: $(13,405,948)) | |
Total Investments, Net of Options Written — 100.6% | |
Liabilities in Excess of Other Assets — (0.6)% | |
| |
| Non-income producing security. |
| Security is valued using significant unobservable inputs and is classified as Level 3 in the |
| Restricted security as to resale, excluding 144A securities. The Trust held restricted securities with a current value of $221,241,652, representing 16.4% of its net assets as of period end, and an original cost of $279,825,622. |
| All or a portion of the security has been pledged as collateral in connection with outstanding OTC derivatives. |
| All or a portion of this security is on loan. |
| All or a portion of the security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written. |
| All or a portion of the security is held by a wholly-owned subsidiary. See Note 1 of the Notes to Consolidated Financial Statements for details on the wholly-owned subsidiary. |
| |
| Annualized 7-day yield as of period end. |
| All or a portion of this security was purchased with the cash collateral from loaned |
For purposes of this report, industry and sector sub-classifications may differ from those utilized by the Trust for compliance purposes.
Investments in issuers considered to be affiliate(s) of the Trust during the six months ended June 30, 2024 for purposes of Section 2(a)(3) of the Investment Company Act of
1940, as amended, were as follows:
| | | | | | | | | |
BlackRock Cash Funds: Institutional, SL Agency Shares | | | | | | | | | |
BlackRock Liquidity Funds, T-Fund, Institutional Shares | | | | | | | | | |
SL Liquidity Series, LLC, Money Market Series (c) | | | | | | | | | |
| | | | | | | | | |
| Represents net amount purchased (sold). |
| All or a portion represents securities lending income earned from the reinvestment of cash collateral from loaned securities, net of fees and collateral investment expenses, and other payments to and from borrowers of securities. |
| As of period end, the entity is no longer held. |
Derivative Financial Instruments Outstanding as of Period End
Exchange-Traded Options Written
| | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Mastercard, Inc., Class A | | | | | | | |
Meta Platforms, Inc., Class A | | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Mastercard, Inc., Class A | | | | | | | |
Meta Platforms, Inc., Class A | | | | | | | |
Consolidated Schedule of Investments
103
Consolidated Schedule of Investments
(unaudited)
(continued)
BlackRock Science and Technology Trust (BST)
Exchange-Traded Options Written (continued)
| | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Take-Two Interactive Software, Inc. | | | | | | | |
| | | | | | | |
Advanced Micro Devices, Inc. | | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Cadence Design Systems, Inc. | | | | | | | |
Credo Technology Group Holding Ltd. | | | | | | | |
Crowdstrike Holdings, Inc., Class A | | | | | | | |
| | | | | | | |
Informatica, Inc., Class A | | | | | | | |
| | | | | | | |
| | | | | | | |
Mastercard, Inc., Class A | | | | | | | |
| | | | | | | |
Meta Platforms, Inc., Class A | | | | | | | |
Meta Platforms, Inc., Class A | | | | | | | |
| | | | | | | |
| | | | | | | |
Monolithic Power Systems, Inc. | | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Taiwan Semiconductor Manufacturing Co. Ltd., ADR | | | | | | | |
Take-Two Interactive Software, Inc. | | | | | | | |
| | | | | | | |
Advanced Micro Devices, Inc. | | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Mastercard, Inc., Class A | | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Taiwan Semiconductor Manufacturing Co. Ltd., ADR | | | | | | | |
| | | | | | | |
| | | | | | | |
Vertiv Holdings Co., Class A | | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
104
2024
BlackRock Semi-Annual Report to Shareholders
Consolidated Schedule of Investments
(unaudited)
(continued)
BlackRock Science and Technology Trust (BST)
Exchange-Traded Options Written (continued)
| | | | | |
| | | | | | | |
| | | | | | | |
Crowdstrike Holdings, Inc., Class A | | | | | | | |
Meta Platforms, Inc., Class A | | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Taiwan Semiconductor Manufacturing Co. Ltd., ADR | | | | | | | |
Take-Two Interactive Software, Inc. | | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Vertiv Holdings Co., Class A | | | | | | | |
| | | | | | | |
Cadence Design Systems, Inc. | | | | | | | |
Credo Technology Group Holding Ltd. | | | | | | | |
Credo Technology Group Holding Ltd. | | | | | | | |
Informatica, Inc., Class A | | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Monolithic Power Systems, Inc. | | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| Goldman Sachs International | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| Morgan Stanley & Co. International PLC | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| Morgan Stanley & Co. International PLC | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| Goldman Sachs International | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| Goldman Sachs International | | | | | | | |
| Goldman Sachs International | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
Consolidated Schedule of Investments
105
Consolidated Schedule of Investments
(unaudited)
(continued)
BlackRock Science and Technology Trust (BST)
Balances Reported in the Consolidated Statements of Assets and Liabilities for Options Written
Derivative Financial Instruments Categorized by Risk Exposure
As of period end, the fair values of derivative financial instruments located in the Consolidated Statements of Assets and Liabilities were as follows:
| | | | | | | |
Liabilities — Derivative Financial Instruments | | | | | | | |
| | | | | | | |
For the period ended June 30, 2024, the effect of derivative financial instruments in the Consolidated Statements of Operations was as follows:
| | | | | | | |
Net Realized Gain (Loss) from: | | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Net Change in Unrealized Appreciation (Depreciation) on: | | | | | | | |
| | | | | | | |
| Options purchased are included in net realized gain (loss) from investments — unaffiliated. |
Average Quarterly Balances of Outstanding Derivative Financial Instruments
| |
Average value of option contracts purchased | |
Average value of option contracts written | |
| Derivative financial instrument not held at any quarter-end. The risk exposure table serves as an indicator of activity during the period. |
For more information about the Trust’s investment risks regarding derivative financial instruments, refer to the Notes to Consolidated Financial Statements.
Derivative Financial Instruments — Offsetting as of Period End
The Trust’s derivative assets and liabilities (by type) were as follows:
| | |
Derivative Financial Instruments | | |
| | |
Total derivative assets and liabilities in the Consolidated Statements of Assets and Liabilities | | |
Derivatives not subject to a Master Netting Agreement or similar agreement (“MNA”) | | |
Total derivative assets and liabilities subject to an MNA | | |
106
2024
BlackRock Semi-Annual Report to Shareholders
Consolidated Schedule of Investments
(unaudited)
(continued)
BlackRock Science and Technology Trust (BST)
The following table presents the Trust’s derivative liabilities by counterparty net of amounts available for offset under an MNA and net of the related collateral pledged by the
Trust:
| | | | | |
| | | | | |
| | | | | |
Goldman Sachs International | | | | | |
| | | | | |
Morgan Stanley & Co. International PLC | | | | | |
| | | | | |
| | | | | |
| Excess of collateral received/pledged, if any, from the individual counterparty is not shown for financial reporting purposes. |
| Net amount represents the net amount payable due to counterparty in the event of default. Net amount may be offset further by the options written receivable/payable on the Consolidated Statements of Assets and Liabilities. |
Fair Value Hierarchy as of Period End
Various inputs are used in determining the fair value of financial instruments. For a description of the input levels and information about the Trust’s policy regarding valuation
of financial instruments, refer to the Notes to Consolidated Financial Statements.
The following table summarizes the Trust’s financial instruments categorized in the fair value hierarchy. The breakdown of the Trust
’
s financial instruments into major categories
is disclosed in the Consolidated Schedule of Investments above.
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
Diversified Consumer Services | | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
Interactive Media & Services | | | | |
| | | | |
| | | | |
Semiconductors & Semiconductor Equipment | | | | |
| | | | |
| | | | |
Technology Hardware, Storage & Peripherals | | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
Derivative Financial Instruments (a) | | | | |
| | | | |
| | | | |
| Derivative financial instruments are options written. Options written are shown at value. |
Consolidated Schedule of Investments
107
Consolidated Schedule of Investments
(unaudited)
(continued)
BlackRock Science and Technology Trust (BST)
A reconciliation of Level 3 financial instruments is presented when the Trust had a significant amount of Level 3 investments and derivative financial instruments at the
beginning and/or end of the period in relation to net assets. The following table is a reconciliation of Level 3 investments for which significant unobservable inputs were used in
determining fair value:
| | | | | |
| | | | | |
Opening balance, as of December 31, 2023 | | | | | |
| | | | | |
| | | | | |
| | | | | |
Accrued discounts/premiums | | | | | |
| | | | | |
Net change in unrealized appreciation (depreciation) (c)(d) | | | | | |
| | | | | |
| | | | | |
Closing balance, as of June 30, 2024 | | | | | |
Net change in unrealized appreciation (depreciation) on investments still held at June 30, 2024 (d) | | | | | |
| |
| Certain Level 3 investments were re-classified between Common Stocks and Preferred Stocks. |
| Included in the related net change in unrealized appreciation (depreciation) in the Consolidated Statements of Operations. |
| Any difference between net change in unrealized appreciation (depreciation) and net change in unrealized appreciation (depreciation) on investments still held at June 30, 2024 is generally due to investments no longer held or categorized as Level 3 at period end. |
The following table summarizes the valuation approaches used and unobservable inputs utilized by the BlackRock Valuation Committee (the “Valuation Committee”) to
determine the value of certain of the Trust’s Level 3 financial instruments as of period end. The table does not include Level 3 financial instruments with values based upon
unadjusted third-party pricing information in the amount of $1. A significant change in third party information could result in a significantly lower or higher value of such Level 3
financial instruments.
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | Market Adjustment Multiple | | |
| | | | | |
| | | | | |
| | | | | |
| A significant change in unobservable input would have resulted in a correlated (inverse) significant change to value. |
See notes to financial statements.
108
2024
BlackRock Semi-Annual Report to Shareholders
Schedule of Investments
(unaudited)
BlackRock Utilities, Infrastructure & Power Opportunities Trust (BUI)
(Percentages shown are based on Net Assets)
| | | |
|
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| |
| | | |
| | | |
| | | |
Commercial Services & Supplies — 4.7% | |
| | | |
| | | |
| | | |
Construction & Engineering — 5.1% | |
| | | |
| | | |
| | | |
Electric Utilities — 24.1% | |
American Electric Power Co., Inc. (a) | | | |
| | | |
EDP - Energias de Portugal SA | | | |
| | | |
| | | |
NextEra Energy, Inc. (a)(b) | | | |
| | | |
| | | |
| | | |
| | | |
Electrical Equipment — 10.3% | |
| | | |
| | | |
| | | |
| | | |
| | | |
Vestas Wind Systems A/S (c) | | | |
| | | |
Electronic Equipment, Instruments & Components — 1.2% | |
| | | |
| | | |
| | | |
Ground Transportation — 2.6% | |
Canadian Pacific Kansas City Ltd. | | | |
| | | |
| | | |
Independent Power and Renewable Electricity Producers — 5.6% | |
| | | |
| | | |
| | | |
| | | |
| | | |
| |
| | | |
| | | |
| | | |
| | | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
Public Service Enterprise Group, Inc. (b) | | | |
| | | |
| | | |
Oil, Gas & Consumable Fuels — 11.5% | |
| | | |
Hess Midstream LP, Class A | | | |
| | | |
| | | |
| | | |
| | | |
| | | |
Semiconductors & Semiconductor Equipment — 4.6% | |
| | | |
| | | |
Canadian Solar, Inc. (c)(d) | | | |
| | | |
ON Semiconductor Corp. (c) | | | |
| | | |
| | | |
Total Long-Term Investments — 99.2% | |
|
Money Market Funds — 1.2% | |
BlackRock Cash Funds: Institutional, SL Agency Shares, | | | |
BlackRock Liquidity Funds, T-Fund, Institutional Shares, | | | |
Total Short-Term Securities — 1.2% | |
Total Investments Before Options Written — 100.4% | |
(Premiums Received: $(4,204,297)) | |
Total Investments, Net of Options Written — 99.9% | |
Other Assets Less Liabilities — 0.1% | |
| |
| All or a portion of the security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written. |
| All or a portion of the security has been pledged as collateral in connection with outstanding OTC derivatives. |
| Non-income producing security. |
| All or a portion of this security is on loan. |
| |
| Annualized 7-day yield as of period end. |
| All or a portion of this security was purchased with the cash collateral from loaned |
For purposes of this report, industry and sector sub-classifications may differ from those utilized by the Trust for compliance purposes.
Schedule of Investments
109
Schedule of Investments
(unaudited)
(continued)
BlackRock Utilities, Infrastructure & Power Opportunities Trust (BUI)
Investments in issuers considered to be affiliate(s) of the Trust during the six months ended June 30, 2024 for purposes of Section 2(a)(3) of the Investment Company Act of
1940, as amended, were as follows:
| | | | | | | | | |
BlackRock Cash Funds: Institutional, SL Agency Shares | | | | | | | | | |
BlackRock Liquidity Funds, T-Fund, Institutional Shares | | | | | | | | | |
SL Liquidity Series, LLC, Money Market Series (c) | | | | | | | | | |
| | | | | | | | | |
| Represents net amount purchased (sold). |
| All or a portion represents securities lending income earned from the reinvestment of cash collateral from loaned securities, net of fees and collateral investment expenses, and other payments to and from borrowers of securities. |
| As of period end, the entity is no longer held. |
Derivative Financial Instruments Outstanding as of Period End
Exchange-Traded Options Written
| | | | | |
| | | | | | | |
American Electric Power Co., Inc. | | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Canadian Pacific Kansas City Ltd. | | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Hess Midstream LP, Class A | | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
American Electric Power Co., Inc. | | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
110
2024
BlackRock Semi-Annual Report to Shareholders
Schedule of Investments
(unaudited)
(continued)
BlackRock Utilities, Infrastructure & Power Opportunities Trust (BUI)
Exchange-Traded Options Written (continued)
| | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Canadian Pacific Kansas City Ltd. | | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Hess Midstream LP, Class A | | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | |
| | | | | | | | |
| Morgan Stanley & Co. International PLC | | | | | | | |
| Morgan Stanley & Co. International PLC | | | | | | | |
| | | | | | | | |
| Goldman Sachs International | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| Morgan Stanley & Co. International PLC | | | | | | | |
Public Service Enterprise Group, Inc. | | | | | | | | |
| | | | | | | | |
| Morgan Stanley & Co. International PLC | | | | | | | |
EDP - Energias de Portugal SA | Morgan Stanley & Co. International PLC | | | | | | | |
| | | | | | | | |
| Morgan Stanley & Co. International PLC | | | | | | | |
| | | | | | | | |
| Morgan Stanley & Co. International PLC | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
Public Service Enterprise Group, Inc. | | | | | | | | |
| | | | | | | | |
| | | | | | | | |
EDP - Energias de Portugal SA | Morgan Stanley & Co. International PLC | | | | | | | |
| | | | | | | | |
| Morgan Stanley & Co. International PLC | | | | | | | |
EDP - Energias de Portugal SA | Morgan Stanley & Co. International PLC | | | | | | | |
| Morgan Stanley & Co. International PLC | | | | | | | |
EDP - Energias de Portugal SA | Morgan Stanley & Co. International PLC | | | | | | | |
Schedule of Investments
111
Schedule of Investments
(unaudited)
(continued)
BlackRock Utilities, Infrastructure & Power Opportunities Trust (BUI)
OTC Options Written (continued)
| | | | | | |
| | | | | | | | |
| Morgan Stanley & Co. International PLC | | | | | | | |
| | | | | | | | |
| Morgan Stanley & Co. International PLC | | | | | | | |
Public Service Enterprise Group, Inc. | Morgan Stanley & Co. International PLC | | | | | | | |
| Goldman Sachs International | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| Goldman Sachs International | | | | | | | |
| Goldman Sachs International | | | | | | | |
EDP - Energias de Portugal SA | | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
Balances Reported in the Statements of Assets and Liabilities for Options Written
Derivative Financial Instruments Categorized by Risk Exposure
As of period end, the fair values of derivative financial instruments located in the Statements of Assets and Liabilities were as follows:
| | | | | | | |
Liabilities — Derivative Financial Instruments | | | | | | | |
| | | | | | | |
For the period ended June 30, 2024, the effect of derivative financial instruments in the Statements of Operations was as follows:
| | | | | | | |
Net Realized Gain (Loss) from: | | | | | | | |
| | | | | | | |
Net Change in Unrealized Appreciation (Depreciation) on: | | | | | | | |
| | | | | | | |
Average Quarterly Balances of Outstanding Derivative Financial Instruments
| |
Average value of option contracts written | |
For more information about the Trust’s investment risks regarding derivative financial instruments, refer to the Notes to Financial Statements.
112
2024
BlackRock Semi-Annual Report to Shareholders
Schedule of Investments
(unaudited)
(continued)
BlackRock Utilities, Infrastructure & Power Opportunities Trust (BUI)
Derivative Financial Instruments — Offsetting as of Period End
The Trust’s derivative assets and liabilities (by type) were as follows:
| | |
Derivative Financial Instruments | | |
| | |
Total derivative assets and liabilities in the Statements of Assets and Liabilities | | |
Derivatives not subject to a Master Netting Agreement or similar agreement (“MNA”) | | |
Total derivative assets and liabilities subject to an MNA | | |
The following table presents the Trust’s derivative liabilities by counterparty net of amounts available for offset under an MNA and net of the related collateral pledged by the
Trust:
| | | | | |
| | | | | |
| | | | | |
| | | | | |
Goldman Sachs International | | | | | |
| | | | | |
Morgan Stanley & Co. International PLC | | | | | |
| | | | | |
| | | | | |
| | | | | |
| Excess of collateral received/pledged, if any, from the individual counterparty is not shown for financial reporting purposes. |
| Net amount represents the net amount payable due to counterparty in the event of default. Net amount may be offset further by the options written receivable/payable on the Statements of Assets and Liabilities. |
Fair Value Hierarchy as of Period End
Various inputs are used in determining the fair value of financial instruments. For a description of the input levels and information about the Trust’s policy regarding valuation
of financial instruments, refer to the Notes to Financial Statements.
The following table summarizes the Trust’s financial instruments categorized in the fair value hierarchy. The breakdown of the Trust
’
s financial instruments into major categories
is disclosed in the Schedule of Investments above.
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
Commercial Services & Supplies | | | | |
Construction & Engineering | | | | |
| | | | |
| | | | |
Electronic Equipment, Instruments & Components | | | | |
| | | | |
Independent Power and Renewable Electricity Producers | | | | |
| | | | |
| | | | |
Oil, Gas & Consumable Fuels | | | | |
Semiconductors & Semiconductor Equipment | | | | |
| | | | |
| | | | |
| | | | |
Schedule of Investments
113
Schedule of Investments
(unaudited)
(continued)
BlackRock Utilities, Infrastructure & Power Opportunities Trust (BUI)
Fair Value Hierarchy as of Period End (continued)
| | | | |
Derivative Financial Instruments (a) | | | | |
| | | | |
| | | | |
| Derivative financial instruments are options written. Options written are shown at value. |
See notes to financial statements.
114
2024
BlackRock Semi-Annual Report to Shareholders
Statements of Assets and Liabilities
(unaudited)
June 30, 2024
| | | | |
| | | | |
Investments, at value — unaffiliated (b)(c) | | | | |
Investments, at value — affiliated (d) | | | | |
Foreign currency, at value (e) | | | | |
| | | | |
| | | | |
| | | | |
Securities lending income — affiliated | | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
Collateral on securities loaned | | | | |
Options written, at value (f) | | | | |
| | | | |
| | | | |
| | | | |
| | | | |
Deferred capital gain tax | | | | |
Income dividend distributions | | | | |
| | | | |
Trustees ’ and Officer ’ s fees | | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
Commitments and contingent liabilities | | | | |
| | | | |
| | | | |
| | | | |
Accumulated earnings (loss) | | | | |
| | | | |
| | | | |
(a) Consolidated Statement of Assets and Liabilities. |
(b) Investments, at cost — unaffiliated | | | | |
(c) Securities loaned, at value | | | | |
(d) Investments, at cost — affiliated | | | | |
(e) Foreign currency, at cost | | | | |
| | | | |
| | | | |
| | | | |
| | | | |
See notes to financial statements.
Statements of Assets and Liabilities
(unaudited) (continued)
June 30, 2024
| | | | |
| | | | |
Investments, at value — unaffiliated (a)(b) | | | | |
Investments, at value — affiliated (c) | | | | |
| | | | |
Cash pledged as collateral for OTC derivatives | | | | |
Foreign currency, at value (d) | | | | |
| | | | |
| | | | |
| | | | |
Securities lending income — affiliated | | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
Collateral on securities loaned | | | | |
Options written, at value (e) | | | | |
| | | | |
| | | | |
| | | | |
| | | | |
Income dividend distributions | | | | |
| | | | |
IRS compliance fee for foreign withholding tax claims | | | | |
Trustees ’ and Officer ’ s fees | | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
Commitments and contingent liabilities | | | | |
| | | | |
| | | | |
| | | | |
Accumulated earnings (loss) | | | | |
| | | | |
| | | | |
(a) Investments, at cost — unaffiliated | | | | |
(b) Securities loaned, at value | | | | |
(c) Investments, at cost — affiliated | | | | |
(d) Foreign currency, at cost | | | | |
| | | | |
| | | | |
| | | | |
| | | | |
See notes to financial statements.
116
2024
BlackRock Semi-Annual Report to Shareholders
Statements of Assets and Liabilities
(unaudited) (continued)
June 30, 2024
| | | | |
| | | | |
Investments, at value — unaffiliated (b)(c) | | | | |
Investments, at value — affiliated (d) | | | | |
| | | | |
Cash pledged as collateral for OTC derivatives | | | | |
Foreign currency, at value (e) | | | | |
| | | | |
| | | | |
| | | | |
Securities lending income — affiliated | | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
Collateral on securities loaned | | | | |
Options written, at value (f) | | | | |
| | | | |
| | | | |
| | | | |
| | | | |
Deferred capital gain tax | | | | |
Income dividend distributions | | | | |
| | | | |
Trustees ’ and Officer ’ s fees | | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
Commitments and contingent liabilities | | | | |
| | | | |
| | | | |
| | | | |
Accumulated earnings (loss) | | | | |
| | | | |
| | | | |
(a) Consolidated Statement of Assets and Liabilities. |
(b) Investments, at cost — unaffiliated | | | | |
(c) Securities loaned, at value | | | | |
(d) Investments, at cost — affiliated | | | | |
(e) Foreign currency, at cost | | | | |
| | | | |
| | | | |
| | | | |
| | | | |
See notes to financial statements.
Statements of Operations
(unaudited)
Six Months Ended June 30, 2024
| | | | |
| | | | |
| | | | |
| | | | |
Securities lending income — affiliated — net | | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
Total expenses excluding interest expense | | | | |
Interest expense — unaffiliated | | | | |
| | | | |
| | | | |
Fees waived and/or reimbursed by the Manager | | | | |
Total expenses after fees waived and/or reimbursed | | | | |
| | | | |
REALIZED AND UNREALIZED GAIN (LOSS) | | | | |
Net realized gain (loss) from: | | | | |
Investments — unaffiliated | | | | |
| | | | |
Foreign currency transactions | | | | |
| | | | |
| | | | |
| | | | |
Net change in unrealized appreciation (depreciation) on: | | | | |
Investments — unaffiliated | | | | |
| | | | |
Foreign currency translations | | | | |
| | | | |
| | | | |
Net realized and unrealized gain | | | | |
NET INCREASE IN NET ASSETS RESULTING FROM OPERATIONS | | | | |
(a) Consolidated Statement of Operations. |
See notes to financial statements.
118
2024
BlackRock Semi-Annual Report to Shareholders
Statements of Operations
(unaudited) (continued)
Six Months Ended June 30, 2024
| | | | |
| | | | |
| | | | |
| | | | |
Securities lending income — affiliated — net | | | | |
| | | | |
Foreign withholding tax claims | | | | |
IRS compliance fee for foreign withholding tax claims | | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
Total expenses excluding interest expense | | | | |
Interest expense — unaffiliated | | | | |
| | | | |
| | | | |
Fees waived and/or reimbursed by the Manager | | | | |
Total expenses after fees waived and/or reimbursed | | | | |
Net investment income (loss) | | | | |
REALIZED AND UNREALIZED GAIN (LOSS) | | | | |
Net realized gain (loss) from: | | | | |
Investments — unaffiliated | | | | |
| | | | |
Forward foreign currency exchange contracts | | | | |
Foreign currency transactions | | | | |
| | | | |
| | | | |
Net change in unrealized appreciation (depreciation) on: | | | | |
Investments — unaffiliated | | | | |
| | | | |
Forward foreign currency exchange contracts | | | | |
Foreign currency translations | | | | |
| | | | |
| | | | |
Net realized and unrealized gain (loss) | | | | |
NET INCREASE (DECREASE) IN NET ASSETS RESULTING FROM OPERATIONS | | | | |
(a) Net of capital gain tax and capital gain tax refund, if applicable of | | | | |
(b) Net of reduction in deferred foreign capital gain tax of | | | | |
See notes to financial statements.
Statements of Operations
(unaudited) (continued)
Six Months Ended June 30, 2024
| | | | |
| | | | |
| | | | |
| | | | |
Securities lending income — affiliated — net | | | | |
| | | | |
Foreign withholding tax claims | | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
Total expenses excluding interest expense | | | | |
Interest expense — unaffiliated | | | | |
| | | | |
| | | | |
Fees waived and/or reimbursed by the Manager | | | | |
Total expenses after fees waived and/or reimbursed | | | | |
Net investment income (loss) | | | | |
REALIZED AND UNREALIZED GAIN (LOSS) | | | | |
Net realized gain (loss) from: | | | | |
Investments — unaffiliated | | | | |
| | | | |
Foreign currency transactions | | | | |
| | | | |
| | | | |
Net change in unrealized appreciation (depreciation) on: | | | | |
Investments — unaffiliated | | | | |
| | | | |
Foreign currency translations | | | | |
| | | | |
| | | | |
Net realized and unrealized gain | | | | |
NET INCREASE IN NET ASSETS RESULTING FROM OPERATIONS | | | | |
(a) Consolidated Statement of Operations. |
(b) Net of increase in deferred capital gain tax of | | | | |
See notes to financial statements.
120
2024
BlackRock Semi-Annual Report to Shareholders
Statements of Changes in Net Assets
| | |
| | | | |
INCREASE (DECREASE) IN NET ASSETS | | | | |
| | | | |
| | | | |
| | | | |
Net change in unrealized appreciation (depreciation) | | | | |
Net increase in net assets resulting from operations | | | | |
| | | | |
From net investment income and net realized gain | | | | |
| | | | |
Decrease in net assets resulting from distributions to shareholders | | | | |
CAPITAL SHARE TRANSACTIONS | | | | |
Reinvestment of distributions | | | | |
Redemption of shares resulting from share repurchase program (including transaction costs) | | | | |
Net increase (decrease) in net assets derived from capital share transactions | | | | |
| | | | |
Total increase (decrease) in net assets | | | | |
| | | | |
| | | | |
| Distributions for annual periods determined in accordance with U.S. federal income tax regulations. |
| A portion of the distributions from net investment income may be deemed a return of capital or net realized gain at fiscal year-end. |
See notes to financial statements.
Statements of Changes in Net Assets
(continued)
| | |
| | | | |
INCREASE (DECREASE) IN NET ASSETS | | | | |
| | | | |
| | | | |
| | | | |
Net change in unrealized appreciation (depreciation) | | | | |
Net increase in net assets resulting from operations | | | | |
| | | | |
From net investment income and net realized gain | | | | |
| | | | |
Decrease in net assets resulting from distributions to shareholders | | | | |
CAPITAL SHARE TRANSACTIONS | | | | |
Reinvestment of distributions | | | | |
Redemption of shares resulting from share repurchase program (including transaction costs) | | | | |
Net decrease in net assets derived from capital share transactions | | | | |
| | | | |
Total increase in net assets | | | | |
| | | | |
| | | | |
| Consolidated Statement of Changes in Net Assets. |
| Distributions for annual periods determined in accordance with U.S. federal income tax regulations. |
| A portion of the distributions from net investment income may be deemed a return of capital or net realized gain at fiscal year-end. |
See notes to financial statements.
122
2024
BlackRock Semi-Annual Report to Shareholders
Statements of Changes in Net Assets
(continued)
| | |
| | | | |
INCREASE (DECREASE) IN NET ASSETS | | | | |
| | | | |
Net investment income (loss) | | | | |
| | | | |
Net change in unrealized appreciation (depreciation) | | | | |
Net increase in net assets resulting from operations | | | | |
| | | | |
From net investment income and net realized gain | | | | |
| | | | |
Decrease in net assets resulting from distributions to shareholders | | | | |
CAPITAL SHARE TRANSACTIONS | | | | |
Redemption of shares resulting from share repurchase program (including transaction costs) | | | | |
| | | | |
Total increase (decrease) in net assets | | | | |
| | | | |
| | | | |
| Distributions for annual periods determined in accordance with U.S. federal income tax regulations. |
| A portion of the distributions from net investment income may be deemed a return of capital or net realized gain at fiscal year-end. |
See notes to financial statements.
Statements of Changes in Net Assets
(continued)
| | |
| | | | |
INCREASE (DECREASE) IN NET ASSETS | | | | |
| | | | |
Net investment income (loss) | | | | |
| | | | |
Net change in unrealized appreciation (depreciation) | | | | |
Net increase (decrease) in net assets resulting from operations | | | | |
| | | | |
From net investment income and net realized gain | | | | |
| | | | |
Decrease in net assets resulting from distributions to shareholders | | | | |
CAPITAL SHARE TRANSACTIONS | | | | |
Net proceeds from the issuance of shares | | | | |
Reinvestment of distributions | | | | |
Redemption of shares resulting from share repurchase program (including transaction costs) | | | | |
Net increase (decrease) in net assets derived from capital share transactions | | | | |
| | | | |
Total increase (decrease) in net assets | | | | |
| | | | |
| | | | |
| Distributions for annual periods determined in accordance with U.S. federal income tax regulations. |
| A portion of the distributions from net investment income may be deemed a return of capital or net realized gain at fiscal year-end. |
See notes to financial statements.
124
2024
BlackRock Semi-Annual Report to Shareholders
Statements of Changes in Net Assets
(continued)
| | |
| | | | |
INCREASE (DECREASE) IN NET ASSETS | | | | |
| | | | |
Net investment income (loss) | | | | |
| | | | |
Net change in unrealized appreciation (depreciation) | | | | |
Net increase (decrease) in net assets resulting from operations | | | | |
| | | | |
From net investment income | | | | |
| | | | |
Decrease in net assets resulting from distributions to shareholders | | | | |
CAPITAL SHARE TRANSACTIONS | | | | |
Redemption of shares resulting from share repurchase program (including transaction costs) | | | | |
| | | | |
Total increase (decrease) in net assets | | | | |
| | | | |
| | | | |
| Consolidated Statement of Changes in Net Assets. |
| Distributions for annual periods determined in accordance with U.S. federal income tax regulations. |
| A portion of the distributions from net investment income may be deemed a return of capital or net realized gain at fiscal year-end. |
See notes to financial statements.
Statements of Changes in Net Assets
(continued)
| | |
| | | | |
INCREASE (DECREASE) IN NET ASSETS | | | | |
| | | | |
Net investment income (loss) | | | | |
| | | | |
Net change in unrealized appreciation (depreciation) | | | | |
Net increase in net assets resulting from operations | | | | |
| | | | |
From net investment income and net realized gain | | | | |
| | | | |
Decrease in net assets resulting from distributions to shareholders | | | | |
CAPITAL SHARE TRANSACTIONS | | | | |
Net proceeds from the issuance of shares | | | | |
Reinvestment of distributions | | | | |
Net increase in net assets derived from capital share transactions | | | | |
| | | | |
Total increase (decrease) in net assets | | | | |
| | | | |
| | | | |
| Consolidated Statement of Changes in Net Assets. |
| Distributions for annual periods determined in accordance with U.S. federal income tax regulations. |
| A portion of the distributions from net investment income may be deemed a return of capital or net realized gain at fiscal year-end. |
See notes to financial statements.
126
2024
BlackRock Semi-Annual Report to Shareholders
Statements of Cash Flows
(unaudited)
Six Months Ended June 30, 2024
| | | | |
CASH PROVIDED BY (USED FOR) OPERATING ACTIVITIES | | | | |
Net increase in net assets resulting from operations | | | | |
Adjustments to reconcile net increase in net assets resulting from operations to net cash provided by operating | | | | |
Proceeds from sales of long-term investments and principal paydowns/payups | | | | |
Purchases of long-term investments | | | | |
Net proceeds from sales (purchases) of short-term securities | | | | |
Premiums paid on closing options written | | | | |
Premiums received from options written | | | | |
Net realized gain on investments and options written | | | | |
Net unrealized appreciation on investments, options written and foreign currency translations | | | | |
(Increase) Decrease in Assets | | | | |
| | | | |
| | | | |
| | | | |
Securities lending income — affiliated | | | | |
| | | | |
| | | | |
Increase (Decrease) in Liabilities | | | | |
| | | | |
Collateral on securities loaned | | | | |
| | | | |
| | | | |
| | | | |
Deferred capital gain tax | | | | |
| | | | |
Trustees ’ and Officer ’ s fees | | | | |
| | | | |
| | | | |
| | | | |
Net cash provided by operating activities | | | | |
CASH PROVIDED BY (USED FOR) FINANCING ACTIVITIES | | | | |
Cash dividends paid to shareholders | | | | |
Increase in bank overdraft | | | | |
Net cash used for financing activities | | | | |
CASH IMPACT FROM FOREIGN EXCHANGE FLUCTUATIONS | | | | |
Cash impact from foreign exchange fluctuations | | | | |
CASH AND FOREIGN CURRENCY | | | | |
Net increase (decrease) in restricted and unrestricted cash and foreign currency | | | | |
Restricted and unrestricted cash and foreign currency at beginning of period | | | | |
Restricted and unrestricted cash and foreign currency at end of period | | | | |
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION | | | | |
Cash paid during the period for interest expense | | | | |
RECONCILIATION OF RESTRICTED AND UNRESTRICTED CASH AND FOREIGN CURRENCY PERIOD TO THE STATEMENTS OF ASSETS AND LIABILITIES | | | | |
Foreign currency at value | | | | |
| | | | |
| Consolidated Statement of Cash Flows. |
See notes to financial statements.
Statements of Cash Flows
(unaudited) (continued)
Six Months Ended June 30, 2024
| | | | |
CASH PROVIDED BY (USED FOR) OPERATING ACTIVITIES | | | | |
Net increase (decrease) in net assets resulting from operations | | | | |
Adjustments to reconcile net increase (decrease) in net assets resulting from operations to net cash provided by | | | | |
Proceeds from sales of long-term investments | | | | |
Purchases of long-term investments | | | | |
Net proceeds from sales (purchases) of short-term securities | | | | |
Premiums paid on closing options written | | | | |
Premiums received from options written | | | | |
Net realized (gain) loss on investments and options written | | | | |
Net unrealized (appreciation) depreciation on investments, options written and foreign currency translations | | | | |
(Increase) Decrease in Assets | | | | |
| | | | |
| | | | |
| | | | |
Securities lending income — affiliated | | | | |
| | | | |
| | | | |
Increase (Decrease) in Liabilities | | | | |
Collateral on securities loaned | | | | |
| | | | |
| | | | |
| | | | |
Deferred capital gain tax | | | | |
| | | | |
IRS compliance fee for foreign withholding tax claims | | | | |
Trustees ’ and Officer ’ s fees | | | | |
| | | | |
| | | | |
| | | | |
| | | | |
Net cash provided by operating activities | | | | |
CASH PROVIDED BY (USED FOR) FINANCING ACTIVITIES | | | | |
Cash dividends paid to shareholders | | | | |
Decrease in bank overdraft | | | | |
Net cash used for financing activities | | | | |
CASH IMPACT FROM FOREIGN EXCHANGE FLUCTUATIONS | | | | |
Cash impact from foreign exchange fluctuations | | | | |
CASH AND FOREIGN CURRENCY | | | | |
Net increase (decrease) in restricted and unrestricted cash and foreign currency | | | | |
Restricted and unrestricted cash and foreign currency at beginning of period | | | | |
Restricted and unrestricted cash and foreign currency at end of period | | | | |
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION | | | | |
Cash paid during the period for interest expense | | | | |
RECONCILIATION OF RESTRICTED AND UNRESTRICTED CASH AND FOREIGN CURRENCY PERIOD TO THE STATEMENTS OF ASSETS AND LIABILITIES | | | | |
| | | | |
| | | | |
Collateral — OTC derivatives | | | | |
Foreign currency at value | | | | |
| | | | |
See notes to financial statements.
128
2024
BlackRock Semi-Annual Report to Shareholders
Statements of Cash Flows
(unaudited) (continued)
Six Months Ended June 30, 2024
| | | | |
CASH PROVIDED BY (USED FOR) OPERATING ACTIVITIES | | | | |
Net increase in net assets resulting from operations | | | | |
Adjustments to reconcile net increase in net assets resulting from operations to net cash provided by operating | | | | |
Proceeds from sales of long-term investments | | | | |
Purchases of long-term investments | | | | |
Net proceeds from sales (purchases) of short-term securities | | | | |
Premiums paid on closing options written | | | | |
Premiums received from options written | | | | |
Net realized (gain) loss on investments and options written | | | | |
Net unrealized (appreciation) depreciation on investments, options written and foreign currency translations | | | | |
(Increase) Decrease in Assets | | | | |
| | | | |
| | | | |
| | | | |
| | | | |
Securities lending income — affiliated | | | | |
| | | | |
| | | | |
Increase (Decrease) in Liabilities | | | | |
| | | | |
Collateral on securities loaned | | | | |
| | | | |
| | | | |
| | | | |
Deferred capital gain tax | | | | |
| | | | |
Trustees ’ and Officer ’ s fees | | | | |
| | | | |
| | | | |
| | | | |
| | | | |
Net cash provided by operating activities | | | | |
CASH PROVIDED BY (USED FOR) FINANCING ACTIVITIES | | | | |
Cash dividends paid to shareholders | | | | |
Payments for offering costs | | | | |
Net payments on redemption of capital shares | | | | |
Decrease in bank overdraft | | | | |
Proceeds from issuance of capital shares | | | | |
Net cash used for financing activities | | | | |
CASH IMPACT FROM FOREIGN EXCHANGE FLUCTUATIONS | | | | |
Cash impact from foreign exchange fluctuations | | | | |
CASH AND FOREIGN CURRENCY | | | | |
Net increase (decrease) in restricted and unrestricted cash and foreign currency | | | | |
Restricted and unrestricted cash and foreign currency at beginning of period | | | | |
Restricted and unrestricted cash and foreign currency at end of period | | | | |
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION | | | | |
Cash paid during the period for interest expense | | | | |
NON-CASH FINANCING ACTIVITIES | | | | |
Reinvestment of distributions | | | | |
Statements of Cash Flows
(unaudited) (continued)
Six Months Ended June 30, 2024
| | | | |
RECONCILIATION OF RESTRICTED AND UNRESTRICTED CASH AND FOREIGN CURRENCY PERIOD TO THE STATEMENTS OF ASSETS AND LIABILITIES | | | | |
| | | | |
| | | | |
Collateral — OTC derivatives | | | | |
Foreign currency at value | | | | |
| | | | |
| Consolidated Statement of Cash Flows. |
See notes to financial statements.
130
2024
BlackRock Semi-Annual Report to Shareholders
Financial Highlights
(For a share outstanding throughout each period)
| |
| | | | | | |
|
Net asset value, beginning of period | | | | | | |
| | | | | | |
Net realized and unrealized gain (loss) | | | | | | |
Net increase (decrease) from investment operations | | | | | | |
| | | | | | |
From net investment income | | | | | | |
| | | | | | |
| | | | | | |
Net asset value, end of period | | | | | | |
Market price, end of period | | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
Ratios to Average Net Assets (g) | | | | | | |
| | | | | | |
Total expenses after fees waived and/or reimbursed | | | | | | |
| | | | | | |
| | | | | | |
Net assets, end of period (000) | | | | | | |
| | | | | | |
| Based on average shares outstanding. |
| Distributions for annual periods determined in accordance with U.S. federal income tax regulations. |
| A portion of the distributions from net investment income may be deemed a return of capital or net realized gain at fiscal year-end. |
| Total returns based on market price, which can be significantly greater or less than the net asset value, may result in substantially different returns. Where applicable, excludes the effects of any sales charges and assumes the reinvestment of distributions at actual reinvestment prices. |
| |
| Includes payment from an affiliate, which had no impact on the Trust ’ s total return. |
| Excludes fees and expenses incurred indirectly as a result of investments in underlying funds. |
| |
See notes to financial statements.
Financial Highlights
(continued)
(For a share outstanding throughout each period)
| |
| | | | | | |
|
Net asset value, beginning of period | | | | | | |
| | | | | | |
Net realized and unrealized gain (loss) | | | | | | |
Net increase (decrease) from investment operations | | | | | | |
| | | | | | |
From net investment income | | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
Net asset value, end of period | | | | | | |
Market price, end of period | | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
Ratios to Average Net Assets (f) | | | | | | |
| | | | | | |
Total expenses after fees waived and/or reimbursed | | | | | | |
| | | | | | |
| | | | | | |
Net assets, end of period (000) | | | | | | |
| | | | | | |
| Based on average shares outstanding. |
| Distributions for annual periods determined in accordance with U.S. federal income tax regulations. |
| A portion of the distributions from net investment income may be deemed a return of capital or net realized gain at fiscal year-end. |
| Total returns based on market price, which can be significantly greater or less than the net asset value, may result in substantially different returns. Where applicable, excludes the effects of any sales charges and assumes the reinvestment of distributions at actual reinvestment prices. |
| |
| Excludes fees and expenses incurred indirectly as a result of investments in underlying funds. |
| |
See notes to financial statements.
132
2024
BlackRock Semi-Annual Report to Shareholders
Financial Highlights
(continued)
(For a share outstanding throughout each period)
| |
| | | | | | |
|
Net asset value, beginning of period | | | | | | |
| | | | | | |
Net realized and unrealized gain (loss) | | | | | | |
Net increase (decrease) from investment operations | | | | | | |
| | | | | | |
From net investment income | | | | | | |
| | | | | | |
| | | | | | |
Net asset value, end of period | | | | | | |
Market price, end of period | | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
Ratios to Average Net Assets (h) | | | | | | |
| | | | | | |
Total expenses after fees waived and/or reimbursed | | | | | | |
| | | | | | |
| | | | | | |
Net assets, end of period (000) | | | | | | |
| | | | | | |
| Consolidated Financial Highlights. |
| Based on average shares outstanding. |
| Distributions for annual periods determined in accordance with U.S. federal income tax regulations. |
| A portion of the distributions from net investment income may be deemed a return of capital or net realized gain at fiscal year-end. |
| Total returns based on market price, which can be significantly greater or less than the net asset value, may result in substantially different returns. Where applicable, excludes the effects of any sales charges and assumes the reinvestment of distributions at actual reinvestment prices. |
| Includes payment from an affiliate, which had no impact on the Trust ’ s total return. |
| |
| Excludes fees and expenses incurred indirectly as a result of investments in underlying funds. |
| |
See notes to financial statements.
Financial Highlights
(continued)
(For a share outstanding throughout each period)
| |
| | | | | | |
|
Net asset value, beginning of period | | | | | | |
| | | | | | |
Net realized and unrealized gain (loss) | | | | | | |
Net increase (decrease) from investment operations | | | | | | |
| | | | | | |
From net investment income | | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
Net asset value, end of period | | | | | | |
Market price, end of period | | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
Ratios to Average Net Assets (f) | | | | | | |
| | | | | | |
Total expenses after fees waived and/or reimbursed | | | | | | |
Total expenses after fees waived and/or reimbursed and excluding professional fees for foreign withholding taxes | | | | | | |
| | | | | | |
| | | | | | |
Net assets, end of period (000) | | | | | | |
| | | | | | |
| Based on average shares outstanding. |
| Distributions for annual periods determined in accordance with U.S. federal income tax regulations. |
| A portion of the distributions from net investment income may be deemed a return of capital or net realized gain at fiscal year-end. |
| Total returns based on market price, which can be significantly greater or less than the net asset value, may result in substantially different returns. Where applicable, excludes the effects of any sales charges and assumes the reinvestment of distributions at actual reinvestment prices. |
| |
| Excludes fees and expenses incurred indirectly as a result of investments in underlying funds. |
| |
See notes to financial statements.
134
2024
BlackRock Semi-Annual Report to Shareholders
Financial Highlights
(continued)
(For a share outstanding throughout each period)
| |
| | | | | | |
|
Net asset value, beginning of period | | | | | | |
| | | | | | |
Net realized and unrealized gain (loss) | | | | | | |
Net increase (decrease) from investment operations | | | | | | |
| | | | | | |
From net investment income | | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
Net asset value, end of period | | | | | | |
Market price, end of period | | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
Ratios to Average Net Assets (f) | | | | | | |
| | | | | | |
Total expenses after fees waived and/or reimbursed | | | | | | |
Total expenses after fees waived and/or reimbursed and excluding professional fees for foreign withholding taxes | | | | | | |
| | | | | | |
| | | | | | |
Net assets, end of period (000) | | | | | | |
| | | | | | |
| Based on average shares outstanding. |
| Distributions for annual periods determined in accordance with U.S. federal income tax regulations. |
| A portion of the distributions from net investment income may be deemed a return of capital or net realized gain at fiscal year-end. |
| Total returns based on market price, which can be significantly greater or less than the net asset value, may result in substantially different returns. Where applicable, excludes the effects of any sales charges and assumes the reinvestment of distributions at actual reinvestment prices. |
| |
| Excludes fees and expenses incurred indirectly as a result of investments in underlying funds. |
| |
| Professional fees were not annualized in the calculation of the expense ratios. If this expenses was annualized, the total expenses and total expenses after fees waived and/or reimbursed would have been 1.19% and 1.19%, respectively. |
See notes to financial statements.
Financial Highlights
(continued)
(For a share outstanding throughout each period)
| |
| | | | | |
|
Net asset value, beginning of period | | | | | |
| | | | | |
Net realized and unrealized gain (loss) | | | | | |
Net increase (decrease) from investment operations | | | | | |
| | | | | |
From net investment income | | | | | |
| | | | | |
| | | | | |
| | | | | |
Net asset value, end of period | | | | | |
Market price, end of period | | | | | |
| | | | | |
| | | | | |
| | | | | |
Ratios to Average Net Assets (h) | | | | | |
| | | | | |
Total expenses after fees waived and/or reimbursed | | | | | |
| | | | | |
| | | | | |
Net assets, end of period (000) | | | | | |
| | | | | |
| Commencement of operations. |
| Based on average shares outstanding. |
| Distributions for annual periods determined in accordance with U.S. federal income tax regulations. |
| A portion of the distributions from net investment income may be deemed a return of capital or net realized gain at fiscal year-end. |
| Total returns based on market price, which can be significantly greater or less than the net asset value, may result in substantially different returns. Where applicable, excludes the effects of any sales charges and assumes the reinvestment of distributions at actual reinvestment prices. |
| |
| Includes payment from an affiliate, which had no impact on the Trust ’ s total return. |
| Excludes fees and expenses incurred indirectly as a result of investments in underlying funds. |
| |
| Includes non-recurring expenses of proxy costs. Without these costs, total expenses, total expenses after fees waived and/or reimbursed would have been 1.32% and 1.32%, respectively. |
| The Proxy costs was not annualized in the calculation of the expense ratios. If these expense was annualized, the total expenses and total expenses after fees waived and/or reimbursed would have been 1.47% and 1.47%, respectively. |
| Includes non-recurring expenses of proxy costs. Without these costs, total expenses, total expenses after fees waived and/or reimbursed would have been 1.31% and 1.30%, respectively. |
See notes to financial statements.
136
2024
BlackRock Semi-Annual Report to Shareholders
Financial Highlights
(continued)
(For a share outstanding throughout each period)
| |
| | | | | | |
|
Net asset value, beginning of period | | | | | | |
| | | | | | |
Net realized and unrealized gain (loss) | | | | | | |
Net increase (decrease) from investment operations | | | | | | |
| | | | | | |
From net investment income | | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
Net asset value, end of period | | | | | | |
Market price, end of period | | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
Ratios to Average Net Assets (h) | | | | | | |
| | | | | | |
Total expenses after fees waived and/or reimbursed | | | | | | |
| | | | | | |
| | | | | | |
Net assets, end of period (000) | | | | | | |
| | | | | | |
| Based on average shares outstanding. |
| Distributions for annual periods determined in accordance with U.S. federal income tax regulations. |
| A portion of the distributions from net investment income may be deemed a return of capital or net realized gain at fiscal year-end. |
| Amount is greater than $(0.005) per share. |
| Total returns based on market price, which can be significantly greater or less than the net asset value, may result in substantially different returns. Where applicable, excludes the effects of any sales charges and assumes the reinvestment of distributions at actual reinvestment prices. |
| |
| Includes payment from an affiliate, which had no impact on the Trust ’ s total return. |
| Excludes fees and expenses incurred indirectly as a result of investments in underlying funds. |
| |
See notes to financial statements.
Financial Highlights
(continued)
(For a share outstanding throughout each period)
| |
| | | | |
|
Net asset value, beginning of period | | | | |
| | | | |
Net realized and unrealized gain (loss) | | | | |
Net increase (decrease) from investment operations | | | | |
| | | | |
From net investment income | | | | |
| | | | |
| | | | |
Net asset value, end of period | | | | |
Market price, end of period | | | | |
| | | | |
| | | | |
| | | | |
Ratios to Average Net Assets (h) | | | | |
| | | | |
Total expenses after fees waived and/or reimbursed | | | | |
| | | | |
| | | | |
Net assets, end of period (000) | | | | |
| | | | |
| Commencement of operations. |
| Based on average shares outstanding. |
| Distributions for annual periods determined in accordance with U.S. federal income tax regulations. |
| A portion of the distributions from net investment income may be deemed a return of capital or net realized gain at fiscal year-end. |
| Total returns based on market price, which can be significantly greater or less than the net asset value, may result in substantially different returns. Where applicable, excludes the effects of any sales charges and assumes the reinvestment of distributions at actual reinvestment prices. |
| |
| Includes payment from an affiliate, which had no impact on the Trust ’ s total return. |
| Excludes fees and expenses incurred indirectly as a result of investments in underlying funds. |
| |
| Includes non-recurring expenses of proxy costs. Without these costs, total expenses, total expenses after fees waived and/or reimbursed would have been 1.35% and 1.35%, respectively. |
| The Proxy costs was not annualized in the calculation of the expense ratios. If these expense was annualized, the total expenses and total expenses after fees waived and/or reimbursed would have been 1.55% and 1.55%, respectively. |
| Includes non-recurring expenses of proxy costs. Without these costs, total expenses, total expenses after fees waived and/or reimbursed would have been 1.33% and 1.33%, respectively. |
See notes to financial statements.
138
2024
BlackRock Semi-Annual Report to Shareholders
Financial Highlights
(continued)
(For a share outstanding throughout each period)
| |
| | | | | | |
|
Net asset value, beginning of period | | | | | | |
| | | | | | |
Net realized and unrealized gain (loss) | | | | | | |
Net increase (decrease) from investment operations | | | | | | |
| | | | | | |
From net investment income | | | | | | |
| | | | | | |
| | | | | | |
Net asset value, end of period | | | | | | |
Market price, end of period | | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
Ratios to Average Net Assets (f) | | | | | | |
| | | | | | |
Total expenses after fees waived and/or reimbursed | | | | | | |
Total expenses after fees waived and/or reimbursed and excluding professional fees for foreign withholding taxes | | | | | | |
| | | | | | |
| | | | | | |
Net assets, end of period (000) | | | | | | |
| | | | | | |
| Based on average shares outstanding. |
| Distributions for annual periods determined in accordance with U.S. federal income tax regulations. |
| A portion of the distributions from net investment income may be deemed a return of capital or net realized gain at fiscal year-end. |
| Total returns based on market price, which can be significantly greater or less than the net asset value, may result in substantially different returns. Where applicable, excludes the effects of any sales charges and assumes the reinvestment of distributions at actual reinvestment prices. |
| |
| Excludes fees and expenses incurred indirectly as a result of investments in underlying funds. |
| |
See notes to financial statements.
Financial Highlights
(continued)
(For a share outstanding throughout each period)
| |
| | | | | | |
|
Net asset value, beginning of period | | | | | | |
| | | | | | |
Net realized and unrealized gain (loss) | | | | | | |
Net increase (decrease) from investment operations | | | | | | |
| | | | | | |
From net investment income | | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
Net asset value, end of period | | | | | | |
Market price, end of period | | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
Ratios to Average Net Assets (j) | | | | | | |
| | | | | | |
Total expenses after fees waived and/or reimbursed | | | | | | |
| | | | | | |
| | | | | | |
Net assets, end of period (000) | | | | | | |
| | | | | | |
| Consolidated Financial Highlights. |
| Commencement of operations. |
| Based on average shares outstanding. |
| Distributions for annual periods determined in accordance with U.S. federal income tax regulations. |
| A portion of the distributions from net investment income may be deemed a return of capital or net realized gain at fiscal year-end. |
| Total returns based on market price, which can be significantly greater or less than the net asset value, may result in substantially different returns. Where applicable, excludes the effects of any sales charges and assumes the reinvestment of distributions at actual reinvestment prices. |
| |
| Includes payment from an affiliate, which impacted the Fund’s total return. Excluding the payment from an affiliate, the Fund’s total return would have been 21.68%. |
| Includes payment from an affiliate, which had no impact on the Trust’s total return. |
| Excludes fees and expenses incurred indirectly as a result of investments in underlying funds. |
| The Proxy costs was not annualized in the calculation of the expense ratios. If these expense was annualized, the total expenses and total expenses after fees waived and/or reimbursed would have been 1.53% and 1.53%, respectively. |
| Includes non-recurring expenses of proxy costs. Without these costs, total expenses, total expenses after fees waived and/or reimbursed would have been 1.34% and 1.34%, respectively. |
| |
See notes to financial statements.
140
2024
BlackRock Semi-Annual Report to Shareholders
Financial Highlights
(continued)
(For a share outstanding throughout each period)
| |
| | | | | | |
|
Net asset value, beginning of period | | | | | | |
| | | | | | |
Net realized and unrealized gain (loss) | | | | | | |
Net increase (decrease) from investment operations | | | | | | |
| | | | | | |
From net investment income | | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
Dilutive effect of rights offer (Note 10) | | | | | | |
Net asset value, end of period | | | | | | |
Market price, end of period | | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
Ratios to Average Net Assets (i) | | | | | | |
| | | | | | |
Total expenses after fees waived and/or reimbursed | | | | | | |
Total expenses after fees waived and/or reimbursed and excluding dividend | | | | | | |
| | | | | | |
| | | | | | |
Net assets, end of period (000) | | | | | | |
| | | | | | |
| Consolidated Financial Highlights. |
| Based on average shares outstanding. |
| Distributions for annual periods determined in accordance with U.S. federal income tax regulations. |
| A portion of the distributions from net investment income may be deemed a return of capital or net realized gain at fiscal year-end. |
| Total returns based on market price, which can be significantly greater or less than the net asset value, may result in substantially different returns. Where applicable, excludes the effects of any sales charges and assumes the reinvestment of distributions at actual reinvestment prices. |
| |
| Includes payment from an affiliate, which had no impact on the Trust ’ s total return. |
| For financial reporting purposes, the market value of a certain investment was adjusted as of the report date. Accordingly, the net asset value (NAV) per share and total return performance based on NAV presented herein are different than the information previously published as of December 31, 2020. |
| Excludes fees and expenses incurred indirectly as a result of investments in underlying funds. |
| |
See notes to financial statements.
Financial Highlights
(continued)
(For a share outstanding throughout each period)
| |
| | | | | | |
|
Net asset value, beginning of period | | | | | | |
| | | | | | |
Net realized and unrealized gain (loss) | | | | | | |
Net increase (decrease) from investment operations | | | | | | |
| | | | | | |
From net investment income | | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
Net asset value, end of period | | | | | | |
Market price, end of period | | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
Ratios to Average Net Assets (f) | | | | | | |
| | | | | | |
Total expenses after fees waived and/or reimbursed | | | | | | |
| | | | | | |
| | | | | | |
Net assets, end of period (000) | | | | | | |
| | | | | | |
| Based on average shares outstanding. |
| Distributions for annual periods determined in accordance with U.S. federal income tax regulations. |
| A portion of the distributions from net investment income may be deemed a return of capital or net realized gain at fiscal year-end. |
| Total returns based on market price, which can be significantly greater or less than the net asset value, may result in substantially different returns. Where applicable, excludes the effects of any sales charges and assumes the reinvestment of distributions at actual reinvestment prices. |
| |
| Excludes fees and expenses incurred indirectly as a result of investments in underlying funds. |
| |
See notes to financial statements.
142
2024
BlackRock Semi-Annual Report to Shareholders
Notes to Financial Statements
(unaudited)
The following are registered under the Investment Company Act of 1940, as amended (the “1940 Act”), as closed-end management investment companies and are referred to
herein collectively as the “Trusts”, or individually as a “Trust”:
| | | |
BlackRock Energy and Resources Trust | | | |
BlackRock Enhanced Capital and Income Fund, Inc. | | | |
BlackRock Enhanced Equity Dividend Trust | | | |
BlackRock Enhanced Global Dividend Trust | | | |
BlackRock Enhanced International Dividend Trust | | | |
BlackRock Health Sciences Term Trust | | | |
BlackRock Health Sciences Trust | | | |
BlackRock Innovation and Growth Term Trust | | | |
BlackRock Resources & Commodities Strategy Trust | | | |
BlackRock Science and Technology Term Trust | | | |
BlackRock Science and Technology Trust | | | |
BlackRock Utilities, Infrastructure & Power Opportunities Trust | | | |
| The Trust ’ s classification changed from non-diversified to diversified during the reporting period. |
The Boards of Directors and Boards of Trustees of the Trusts are collectively referred to throughout this report as the “Board,” and the trustees thereof are collectively referred
to throughout this report as “Trustees”. The Trusts determine and make available for publication the net asset values (“NAVs”) of their Common Shares on a daily basis.
The Trusts, together with certain other registered investment companies advised by BlackRock Advisors, LLC (the “Manager”) or its affiliates, are included in a complex of
funds referred to as the BlackRock Fixed-Income Complex.
The accompanying consolidated financial statements of BDJ include the accounts of BDJ Subsidiary, LLC (the “BDJ Taxable Subsidiary”), which is
a wholly-owned taxable subsidiary of BDJ. The BDJ Taxable Subsidiary enables BDJ to hold certain pass-through investments and satisfy regulated investment company tax
requirements. Income earned and gains realized on the investment held by the BDJ Taxable Subsidiary are taxable to such subsidiary. A tax provision for income, if any, is
shown as income tax in the Consolidated Statement of Operations for BDJ. A tax provision for realized and unrealized gains, if any, is included as a reduction of realized and/or
unrealized gain (loss) in the Consolidated Statement of Operations for BDJ. Taxes payable or deferred as of June 30, 2024, if any, are disclosed in the Consolidated
Statements of Assets and Liabilities. BDJ may invest up to 25% of its total assets in the BDJ Taxable Subsidiary. The net assets of the BDJ Taxable Subsidiary as of period end
were $14,661,488, which is 0.9% of BDJ’s consolidated net assets. Intercompany accounts and transactions, if any, have been eliminated. The BDJ Taxable Subsidiary is
subject to the same investment policies and restrictions that apply to BDJ.
The accompanying consolidated financial statements of BSTZ include the accounts of BSTZ Subsidiary, LLC (the “BSTZ Taxable Subsidiary”), which is a wholly-owned taxable
subsidiary of BSTZ. The BSTZ Taxable Subsidiary enables BSTZ to hold certain pass-through investments and satisfy regulated investment company tax requirements.
Income earned and gains realized on the investment held by the BSTZ Taxable Subsidiary are taxable to such subsidiary. A tax provision for income, if any, is shown as income
tax in the Consolidated Statement of Operations for BSTZ. A tax provision for realized and unrealized gains, if any, is included as a reduction of realized and/or unrealized gain
(loss) in the Consolidated Statement of Operations for BSTZ. Taxes payable or deferred as of June 30, 2024, if any, are disclosed in the Consolidated Statements of Assets and
Liabilities. BSTZ may invest up to 25% of its total assets in the BSTZ Taxable Subsidiary. The net assets of the BSTZ Taxable Subsidiary as of period end were $24,240,828,
which is 1.4% of BSTZ’s consolidated net assets. Intercompany accounts and transactions, if any, have been eliminated. The BSTZ Taxable Subsidiary is subject to the same
investment policies and restrictions that apply to BSTZ.
The accompanying consolidated financial statements of BST include the accounts of BST Subsidiary, LLC (the “BST Taxable Subsidiary”), which is a wholly-owned taxable
subsidiary of BST. The BST Taxable Subsidiary enables BST to hold certain pass-through investments and satisfy regulated investment company tax requirements. Income
earned and gains realized on the investment held by the BST Taxable Subsidiary are taxable to such subsidiary. A tax provision for income, if any, is shown as income tax in
the Consolidated Statement of Operations for BST. A tax provision for realized and unrealized gains, if any, is included as a reduction of realized and/or unrealized gain (loss)
in the Consolidated Statement of Operations for BST. Taxes payable or deferred as of June 30, 2024, if any, are disclosed in the Consolidated Statements of Assets and
Liabilities. BST may invest up to 25% of its total assets in the BST Taxable Subsidiary. The net assets of the BST Taxable Subsidiary as of period end were $12,927,479, which
is 1.0% of BST’s consolidated net assets. Intercompany accounts and transactions, if any, have been eliminated. The BST Taxable Subsidiary is subject to the same
investment policies and restrictions that apply to BST.
SIGNIFICANT ACCOUNTING POLICIES
The financial statements are prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”), which may require
management to make estimates and assumptions that affect the reported amounts of assets and liabilities in the financial statements, disclosure of contingent assets and
liabilities at the date of the financial statements and the reported amounts of increases and decreases in net assets from operations during the reporting period. Actual results
could differ from those estimates. Each Trust is considered an investment company under U.S. GAAP and follows the accounting and reporting guidance applicable to
investment companies. Below is a summary of significant accounting policies:
Transactions and Income Recognition:
For financial reporting purposes, investment transactions are recorded on the dates the transactions are executed.
Realized gains and losses on investment transactions are determined using the specific identification method.
Dividend income and capital gain distributions, if any, are
Notes to Financial Statements
143
Notes to Financial Statements
(unaudited) (continued)
recorded on the ex-dividend dates. Non-cash dividends, if any, are recorded on the ex-dividend dates at fair value.
Dividends from foreign securities where the ex-dividend
dates may have passed are subsequently recorded when the Trusts are informed of the ex-dividend dates. Under the applicable foreign tax laws, a withholding tax at various
rates may be imposed on capital gains, dividends and interest.
Upon notification from issuers, a portion of the dividend income received from a real estate investment trust may
be redesignated as a reduction of cost of the related investment and/or realized gain.
Interest income, including amortization and accretion of premiums and discounts on debt
securities, is recognized daily on an accrual basis.
Each Trust’s books and records are maintained in U.S. dollars. Securities and other assets and liabilities denominated in foreign currencies
are translated into U.S. dollars using exchange rates determined as of the close of trading on the New York Stock Exchange (“NYSE”). Purchases and sales of investments are
recorded at the rates of exchange prevailing on the respective dates of such transactions. Generally, when the U.S. dollar rises in value against a foreign currency, the
investments denominated in that currency will lose value; the opposite effect occurs if the U.S. dollar falls in relative value.
Each Trust does not isolate the effect of fluctuations in foreign exchange rates from the effect of fluctuations in the market prices of investments for financial reporting purposes.
Accordingly, the effects of changes in exchange rates on investments are not segregated in the Statements of Operations from the effects of changes in market prices of those
investments, but are included as a component of net realized and unrealized gain (loss) from investments.
Each
Trust reports realized currency gains (losses) on foreign
currency related transactions as components of net realized gain (loss) for financial reporting purposes, whereas such components are generally treated as ordinary income
for U.S. federal income tax purposes.
The Trusts may be subject to foreign taxes (a portion of which may be reclaimable) on income, stock dividends, capital gains on investments, or certain foreign
currency transactions. All foreign taxes are recorded in accordance with the applicable foreign tax regulations and rates that exist in the foreign jurisdictions in which each
Trust
invests. These foreign taxes, if any, are paid by each
Trust and are reflected in its Statements of Operations as follows: foreign taxes withheld at source are presented as a
reduction of income, foreign taxes on securities lending income are presented as a reduction of securities lending income, foreign taxes on stock dividends are presented as
“Foreign taxes withheld”, and foreign taxes on capital gains from sales of investments and foreign taxes on foreign currency transactions are included in their respective net
realized gain (loss) categories. Foreign taxes payable or deferred as of June 30, 2024, if any, are disclosed in the Statements of Assets and Liabilities.
The Trusts file withholding tax reclaims in certain jurisdictions to recover a portion of amounts previously withheld. The Trusts may record a reclaim receivable based on
collectability, which includes factors such as the jurisdiction’s applicable laws, payment history and market convention. The Statements of Operations include tax reclaims
recorded as well as professional and other fees, if any, associated with recovery of foreign withholding taxes.
The
Trusts had outstanding cash disbursements exceeding deposited cash amounts at the custodian during the reporting period. The Trusts
are obligated to
repay the custodian for any overdraft, including any related costs or expenses, where applicable. For financial reporting purposes, overdraft fees, if any, are included in interest
expense in the Statements of Operations.
If required by an exchange or counterparty agreement, the Trusts may be required to deliver/deposit cash and/or securities to/with an exchange, or
broker-dealer or custodian as collateral for certain investments.
Distributions paid by the Trusts are recorded on the ex-dividend dates. Subject to the Trusts
’
managed distribution plan, the Trusts intend to make monthly cash
distributions to shareholders, which may consist of net investment income, and net realized and unrealized gains on investments and/or return of capital.
The character of distributions is determined in accordance with U.S. federal income tax regulations, which may differ from U.S. GAAP. The portion of distributions that exceeds
a Trust’s current and accumulated earnings and profits, which are measured on a tax basis, will constitute a non-taxable return of capital.
Deferred Compensation Plan:
Under the Deferred Compensation Plan (the “Plan”) approved by each Trust
’
s Board, the trustees who are not “interested persons” of the
Trusts, as defined in the 1940 Act (“Independent Trustees”), may defer a portion of their annual complex-wide compensation. Deferred amounts earn an approximate return as
though equivalent dollar amounts had been invested in common shares of certain funds in the BlackRock Fixed-Income Complex selected by the Independent Trustees. This
has the same economic effect for the Independent Trustees as if the Independent Trustees had invested the deferred amounts directly in certain funds in the BlackRock
Fixed-Income Complex.
The Plan is not funded and obligations thereunder represent general unsecured claims against the general assets of each Trust, as applicable. Deferred compensation
liabilities, if any, are included in the Trustees
’
and Officer
’
s fees payable in the Statements of Assets and Liabilities and will remain as a liability of the Trusts until such amounts
are distributed in accordance with the Plan. Net appreciation (depreciation) in the value of participants’ deferral accounts is allocated among the participating funds in the
BlackRock Fixed-Income Complex and reflected as Trustees and Officer expense on the Statements of Operations. The Trustees and Officer expense may be negative as a
result of a decrease in value of the deferred accounts.
In the normal course of business, a Trust enters into contracts that contain a variety of representations that provide general indemnification. A Trust
’
s
maximum exposure under these arrangements is unknown because it involves future potential claims against a Trust, which cannot be predicted with any certainty.
Expenses directly related to a Trust are charged to that Trust. Other operating expenses shared by several funds, including other funds managed by the Manager, are
prorated among those funds on the basis of relative net assets or other appropriate methods.
INVESTMENT VALUATION AND FAIR VALUE MEASUREMENTS
Each
Trust
’
s investments are valued at fair value (also referred to as “market value” within the
financial statements) each day that the Trust
is open for business and, for financial reporting purposes, as of the report date. U.S. GAAP defines fair value as the price a fund would receive to sell an asset or pay to transfer
a liability in an orderly transaction between market participants at the measurement date. The Board has approved the designation of each
Trust’s Manager as the valuation
designee for each
Trust. Each
Trust determines the fair values of its financial instruments using various independent dealers or pricing services under the Manager’s policies.
144
2024
BlackRock Semi-Annual Report to Shareholders
Notes to Financial Statements
(unaudited) (continued)
If a security’s market price is not readily available or does not otherwise accurately represent the fair value of the security, the security will be valued in accordance with the
Manager’s policies and procedures as reflecting fair value. The Manager has formed a committee (the “Valuation Committee”) to develop pricing policies and procedures and
to oversee the pricing function for all financial instruments, with assistance from other BlackRock pricing committees.
Fair Value Inputs and Methodologies:
The following methods and inputs are used to establish the fair value of each Trust
’
s assets and liabilities:
•
Equity investments traded on a recognized securities exchange are valued at that day’s official closing price, as applicable, on the exchange where the stock is primarily
traded. Equity investments traded on a recognized exchange for which there were no sales on that day may be valued at the last available bid (long positions) or ask
(short positions) price.
•
Fixed-income investments for which market quotations are readily available are generally valued using the last available bid price or current market quotations provided
by independent dealers or third-party pricing services. Pricing services generally value fixed-income securities assuming orderly transactions of an institutional round
lot size, but a fund may hold or transact in such securities in smaller, odd lot sizes. Odd lots may trade at lower prices than institutional round lots. The pricing services
may use matrix pricing or valuation models that utilize certain inputs and assumptions to derive values, including transaction data (e.g., recent representative bids and
offers), market data, credit quality information, perceived market movements, news, and other relevant information. Certain fixed-income securities, including asset-backed
and mortgage related securities may be valued based on valuation models that consider the estimated cash flows of each tranche of the entity, establish a
benchmark yield and develop an estimated tranche specific spread to the benchmark yield based on the unique attributes of the tranche. The amortized cost method
of valuation may be used with respect to debt obligations with sixty days or less remaining to maturity unless the Manager determines such method does not represent
fair value.
•
Investments in open-end U.S. mutual funds (including money market funds) are valued at that day’s published NAV.
•
Forward foreign currency exchange contracts are valued at the mean between the bid and ask prices and are determined as of the close of trading on the NYSE based
on that day’s prevailing forward exchange rate for the underlying currencies.
•
Exchange-traded options are valued at the mean between the last bid and ask prices at the close of the options market in which the options trade. An exchange-traded
option for which there is no mean price is valued at the last bid (long positions) or ask (short positions) price. If no bid or ask price is available, the prior day’s price will
be used, unless it is determined that the prior day’s price no longer reflects the fair value of the option. Over-the-counter (“OTC”) options and options on swaps
(“swaptions”) are valued by an independent pricing service using a mathematical model, which incorporates a number of market data factors, such as the trades and
prices of the underlying instruments.
Generally, trading in foreign instruments is substantially completed each day at various times prior to the close of trading on the NYSE. Each business day, the Trusts use
current market factors supplied by independent pricing services to value certain foreign instruments (“Systematic Fair Value Price”). The Systematic Fair Value Price is
designed to value such foreign securities at fair value as of the close of trading on the NYSE, which follows the close of the local markets.
If events (e.g., market volatility, company announcement or a natural disaster) occur that are expected to materially affect the value of such investment, or in the event that
application of these methods of valuation results in a price for an investment that is deemed not to be representative of the market value of such investment, or if a price is not
available, the investment will be valued by the Valuation Committee in accordance with the Manager’s policies and procedures as reflecting fair value (“Fair Valued
Investments”). The fair valuation approaches that may be used by the Valuation Committee include market approach, income approach and cost approach. Valuation
techniques such as discounted cash flow, use of market comparables and matrix pricing are types of valuation approaches and are typically used in determining fair value.
When determining the price for Fair Valued Investments, the Valuation Committee seeks to determine the price that each Trust might reasonably expect to receive or pay from
the current sale or purchase of that asset or liability in an arm’s-length transaction. Fair value determinations shall be based upon all available factors that the Valuation
Committee deems relevant and consistent with the principles of fair value measurement.
For investments in equity or debt issued by privately held companies or funds (“Private Company” or collectively, the “Private Companies”) and other Fair Valued Investments,
the fair valuation approaches that are used by the Valuation Committee and third-party pricing services utilized by the Valuation Committee include one or a combination of, but
not limited to, the following inputs.
| Standard Inputs Generally Considered By The Valuation Committee And Third-Party Pricing Services |
| | recent market transactions, including subsequent rounds of financing, in the underlying investment or comparable issuers; |
| | recapitalizations and other transactions across the capital structure; and |
| | market multiples of comparable issuers. |
| | future cash flows discounted to present and adjusted as appropriate for liquidity, credit, and/or market risks; |
| | quoted prices for similar investments or assets in active markets; and |
| | other risk factors, such as interest rates, yield curves, volatilities, prepayment speeds, loss severities, credit risks, recovery rates, liquidation amounts and/or default rates. |
| | audited or unaudited financial statements, investor communications and financial or operational metrics issued by the Private |
| | changes in the valuation of relevant indices or publicly traded companies comparable to the Private Company; |
| | relevant news and other public sources; and |
| | known secondary market transactions in the Private Company ’ s interests and merger or acquisition activity in companies comparable |
Investments in series of preferred stock issued by Private Companies are typically valued utilizing market approach in determining the enterprise value of the company. Such
investments often contain rights and preferences that differ from other series of preferred and common stock of the same issuer. Enterprise valuation techniques such as an
Notes to Financial Statements
145
Notes to Financial Statements
(unaudited) (continued)
option pricing model (“OPM”), a probability weighted expected return model (“PWERM”), current value method or a hybrid of those techniques are used as deemed appropriate
under the circumstances. The use of these valuation techniques involves a determination of the exit scenarios of the investment in order to appropriately allocate the enterprise
value of the company among the various parts of its capital structure.
The Private Companies are not subject to the public company disclosure, timing, and reporting standards applicable to other investments held by a Trust. Typically, the most
recently available information by a Private Company is as of a date that is earlier than the date a Trust is calculating its NAV. This factor may result in a difference between the
value of the investment and the price a Trust could receive upon the sale of the investment.
Various inputs are used in determining the fair value of financial instruments. These inputs to valuation techniques are categorized into a fair value
hierarchy consisting of three broad levels for financial reporting purposes as follows:
•
Level 1 – Unadjusted price quotations in active markets/exchanges for identical assets or liabilities that each Trust has the ability to access;
•
Level 2 – Other observable inputs (including, but not limited to, quoted prices for similar assets or liabilities in markets that are active, quoted prices for identical or
similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the assets or liabilities (such as interest rates, yield
curves, volatilities, prepayment speeds, loss severities, credit risks and default rates) or other market–corroborated inputs); and
•
Level 3 – Unobservable inputs based on the best information available in the circumstances, to the extent observable inputs are not available (including the Valuation
Committee
’
s assumptions used in determining the fair value of financial instruments).
The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to
unobservable inputs (Level 3 measurements). Accordingly, the degree of judgment exercised in determining fair value is greatest for instruments categorized in Level 3. The
inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the fair value hierarchy classification is
determined based on the lowest level input that is significant to the fair value measurement in its entirety.
Investments classified within Level 3 have significant unobservable
inputs used by the Valuation Committee in determining the price for Fair Valued Investments. Level 3 investments include equity or debt issued by Private Companies that may
not have a secondary market and/or may have a limited number of investors.
The categorization of a value determined for financial instruments is based on the pricing
transparency of the financial instruments and is not necessarily an indication of the risks associated with investing in those securities.
SECURITIES AND OTHER INVESTMENTS
Preferred stock has a preference over common stock in liquidation (and generally in receiving dividends as well), but is subordinated to the liabilities of the
issuer in all respects. As a general rule, the market value of preferred stock with a fixed dividend rate and no conversion element varies inversely with interest rates and
perceived credit risk, while the market price of convertible preferred stock generally also reflects some element of conversion value. Because preferred stock is junior to debt
securities and other obligations of the issuer, deterioration in the credit quality of the issuer will cause greater changes in the value of a preferred stock than in a more senior
debt security with similar stated yield characteristics. Unlike interest payments on debt securities, preferred stock dividends are payable only if declared by the issuer’s board
of directors. Preferred stock also may be subject to optional or mandatory redemption provisions.
Warrants entitle a fund to purchase a specified number of shares of common stock and are non-income producing. The purchase price and number of shares are
subject to adjustment under certain conditions until the expiration date of the warrants, if any. If the price of the underlying stock does not rise above the strike price before the
warrant expires, the warrant generally expires without any value and a fund will lose any amount it paid for the warrant. Thus, investments in warrants may involve more risk
than investments in common stock. Warrants may trade in the same markets as their underlying stock; however, the price of the warrant does not necessarily move with the
price of the underlying stock.
: Commitments are agreements to acquire an investment at a future date (subject to conditions) in connection with a potential public or non-public offering. Such
agreements may obligate a fund to make future cash payments. As of June 30, 2024, BDJ had outstanding commitments of $7,443,073. These commitments are not included
in the net assets of BDJ as of June 30, 2024.
Certain
Trusts may lend their securities to approved borrowers, such as brokers, dealers and other financial institutions. The borrower pledges and
maintains with the Trusts collateral consisting of cash, an irrevocable letter of credit issued by a bank, or securities issued or guaranteed by the U.S. Government. The initial
collateral received by each Trust is required to have a value of at least 102% of the current value of the loaned securities for securities traded on U.S. exchanges and a value
of at least 105% for all other securities. The collateral is maintained thereafter at a value equal to at least 100% of the current market value of the securities on loan. The market
value of the loaned securities is determined at the close of each business day of the Trust and any additional required collateral is delivered to the Trust, or excess collateral
returned by the Trust, on the next business day. During the term of the loan, the Trusts are entitled to all distributions made on or in respect of the loaned securities, but do not
receive interest income on securities received as collateral. Loans of securities are terminable at any time and the borrower, after notice, is required to return borrowed
securities within the standard time period for settlement of securities transactions.
As of period end, any securities on loan were collateralized by cash and/or U.S. Government obligations. Cash collateral invested by the securities lending agent, BlackRock
Investment Management, LLC (“BIM”), if any, is disclosed in the Schedules of Investments. Any non-cash collateral received cannot be sold, re-invested or pledged by the
Trust, except in the event of borrower default. The securities on loan, if any, are disclosed in the Trusts
’
Schedules of Investments. The market value of any securities on loan
and the value of related collateral, if any, are shown separately in the Statements of Assets and Liabilities as a component of investments at value – unaffiliated
and collateral
on securities loaned, respectively.
Securities lending transactions are entered into by the Trusts under Master Securities Lending Agreements (each, an “MSLA”), which provide the right, in the event of default
(including bankruptcy or insolvency), for the non-defaulting party to liquidate the collateral and calculate a net exposure to the defaulting party or request additional collateral.
146
2024
BlackRock Semi-Annual Report to Shareholders
Notes to Financial Statements
(unaudited) (continued)
In the event that a borrower defaults, the Trusts, as lender, would offset the market value of the collateral received against the market value of the securities loaned. When the
value of the collateral is greater than that of the market value of the securities loaned, the lender is left with a net amount payable to the defaulting party. However, bankruptcy
or insolvency laws of a particular jurisdiction may impose restrictions on or prohibitions against such a right of offset in the event of an MSLA counterparty’s bankruptcy or
insolvency. Under the MSLA, absent an event of default, the borrower can resell or re-pledge the loaned securities, and the Trusts can reinvest cash collateral received in
connection with loaned securities. Upon an event of default, the parties’ obligations to return the securities or collateral to the other party are extinguished, and the parties can
resell or re-pledge the loaned securities or the collateral received in connection with the loaned securities in order to satisfy the defaulting party’s net payment obligation for all
transactions under the MSLA. The defaulting party remains liable for any deficiency.
As of period end, the following table is a summary of the Trusts
’
securities on loan by counterparty which are subject to offset under an MSLA:
| | | | |
| | | | |
SG Americas Securities LLC | | | | |
| | | | |
| | | | |
| | | | |
| | | | |
Citigroup Global Markets, Inc. | | | | |
| | | | |
| | | | |
| | | | |
National Financial Services LLC | | | | |
State Street Bank & Trust Co. | | | | |
| | | | |
| | | | |
| | | | |
Citigroup Global Markets, Inc. | | | | |
| | | | |
National Financial Services LLC | | | | |
State Street Bank & Trust Co. | | | | |
| | | | |
| | | | |
| | | | |
| | | | |
Citigroup Global Markets, Inc. | | | | |
| | | | |
National Financial Services LLC | | | | |
State Street Bank & Trust Co. | | | | |
| | | | |
| | | | |
| | | | |
| | | | |
Citigroup Global Markets, Inc. | | | | |
| | | | |
J.P. Morgan Securities LLC | | | | |
| | | | |
State Street Bank & Trust Co. | | | | |
| | | | |
| | | | |
Goldman Sachs International | | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| Collateral received, if any, in excess of the market value of securities on loan is not presented in this table. The total cash collateral received by each Trust is disclosed in the Trust’s Statements of Assets and Liabilities. |
| The market value of the loaned securities is determined as of June 30, 2024. Additional collateral is delivered to each Trust on the next business day in accordance with the MSLA. The net amount would be subject to the borrower default indemnity in the event of default by the counterparty. |
Notes to Financial Statements
147
Notes to Financial Statements
(unaudited) (continued)
The risks of securities lending include the risk that the borrower may not provide additional collateral when required or may not return the securities when due. To mitigate these
risks, the Trusts benefit from a borrower default indemnity provided by BIM. BIM’s indemnity allows for full replacement of the securities loaned to the extent the collateral
received does not cover the value on the securities loaned in the event of borrower default. Each
Trust could incur a loss if the value of an investment purchased with cash
collateral falls below the market value of loaned securities or if the value of an investment purchased with cash collateral falls below the value of the original cash collateral
received. Such losses are borne entirely by the Trusts.
DERIVATIVE FINANCIAL INSTRUMENTS
The Trusts engage in various portfolio investment strategies using derivative contracts both to increase the returns of the Trusts and/or to manage their exposure to certain
risks such as credit risk, equity risk, interest rate risk, foreign currency exchange rate risk, commodity price risk or other risks (e.g., inflation risk). Derivative financial
instruments categorized by risk exposure are included in the Schedules of Investments. These contracts may be transacted on an exchange or OTC.
Forward Foreign Currency Exchange Contracts
: Forward foreign currency exchange contracts are entered into to gain or reduce exposure to foreign currencies (foreign
currency exchange rate risk).
A forward foreign currency exchange contract is an agreement between two parties to buy and sell a currency at a set exchange rate on a specified date. These contracts help
to manage the overall exposure to the currencies in which some of the investments held by the Trusts are denominated and in some cases, may be used to obtain exposure
to a particular market. The contracts are traded OTC and not on an organized exchange.
The contract is marked-to-market daily and the change in market value is recorded as unrealized appreciation (depreciation) in the Statements
of Assets and Liabilities. When
a contract is closed, a realized gain or loss is recorded in the Statements
of Operations equal to the difference between the value at the time it was opened and the value at the
time it was closed. Non-deliverable forward foreign currency exchange contracts are settled with the counterparty in cash without the delivery of foreign currency. The use of
forward foreign currency exchange contracts involves the risk that the value of a forward foreign currency exchange contract changes unfavorably due to movements in the
value of the referenced foreign currencies, and such value may exceed the amount(s)
reflected in the Statements of Assets and Liabilities. Cash amounts pledged for forward
foreign currency exchange contracts are considered restricted and are included in cash pledged as collateral for OTC derivatives in the Statements of Assets and Liabilities.
The Trust
’
s
risk of loss from counterparty credit risk on OTC derivatives is generally limited to the aggregate unrealized gain netted against any collateral held by the Trust.
The Trusts may purchase and write call and put options to increase or decrease their exposure to the risks of underlying instruments, including equity risk, interest
rate risk and/or commodity price risk and/or, in the case of options written, to generate gains from options premiums.
A call option gives the purchaser (holder) of the option the right (but not the obligation) to buy, and obligates the seller (writer) to sell (when the option is exercised) the
underlying instrument at the exercise or strike price at any time or at a specified time during the option period. A put option gives the holder the right to sell and obligates the
writer to buy the underlying instrument at the exercise or strike price at any time or at a specified time during the option period.
Premiums paid on options purchased and premiums received on options written, as well as the daily fluctuation in market value, are included in investments at value –
unaffiliated and options written at value, respectively, in the Statements of Assets and Liabilities. When an instrument is purchased or sold through the exercise of an option,
the premium is offset against the cost or proceeds of the underlying instrument. When an option expires, a realized gain or loss is recorded in the Statements of Operations to
the extent of the premiums received or paid. When an option is closed or sold, a gain or loss is recorded in the Statements of Operations to the extent the cost of the closing
transaction exceeds the premiums received or paid. When the Trusts write a call option, such option is typically “covered,” meaning that they hold the underlying instrument
subject to being called by the option counterparty. When the Trusts write a put option, cash is segregated in an amount sufficient to cover the obligation. These amounts, which
are considered restricted, are included in cash pledged as collateral for options written in the Statements of Assets and Liabilities.
In purchasing and writing options, the Trusts bear the risk of an unfavorable change in the value of the underlying instrument or the risk that they may not be able to enter into
a closing transaction due to an illiquid market. Exercise of a written option could result in the Trusts purchasing or selling a security when they otherwise would not, or at a price
different from the current market value.
Master Netting Arrangements:
In order to define its contractual rights and to secure rights that will help it mitigate its counterparty risk, a Trust may enter into an International
Swaps and Derivatives Association, Inc. Master Agreement (“ISDA Master Agreement”) or similar agreement with its derivative contract counterparties. An ISDA Master
Agreement is a bilateral agreement between a
Trust and a counterparty that governs certain OTC derivatives and typically contains, among other things, collateral posting
terms and netting provisions in the event of a default and/or termination event. Under an ISDA Master Agreement, a
Trust may, under certain circumstances, offset with the
counterparty certain derivative financial instruments’ payables and/or receivables with collateral held and/or posted and create one single net payment. The provisions of the
ISDA Master Agreement typically permit a single net payment in the event of default including the bankruptcy or insolvency of the counterparty. However, bankruptcy or
insolvency laws of a particular jurisdiction may impose restrictions on or prohibitions against the right of offset in bankruptcy, insolvency or other events.
For derivatives traded under an ISDA Master Agreement, the collateral requirements are typically calculated by netting the mark-to-market amount
for each transaction under such agreement and comparing that amount to the value of any collateral currently pledged by the Trusts
and the counterparty.
Cash collateral that has been pledged to cover obligations of the Trusts
and cash collateral received from the counterparty, if any, is reported separately in the Statements
of
Assets and Liabilities as cash pledged as collateral and cash received as collateral, respectively. Non-cash collateral pledged by the Trusts, if any, is noted in the Schedules
of
Investments. Generally, the amount of collateral due from or to a counterparty is subject to a certain minimum transfer amount threshold before a transfer is required, which is
determined at the close of business of the Trusts. Any additional required collateral is delivered to/pledged by the Trusts
on the next business day. Typically, the counterparty
is not permitted to sell, re-pledge or use cash and non-cash collateral it receives. A
Trust
generally agrees not to use non-cash collateral that it receives but may, absent default
or certain other circumstances defined in the underlying ISDA Master Agreement, be permitted to use cash collateral received. In such cases, interest may be paid pursuant
to the collateral arrangement with the counterparty. To the extent amounts due to the Trusts
from the counterparties are not fully collateralized, each
Trust
bears the risk of loss
148
2024
BlackRock Semi-Annual Report to Shareholders
Notes to Financial Statements
(unaudited) (continued)
from counterparty non-performance. Likewise, to the extent the
Trusts
have
delivered collateral to a counterparty and stand
ready to perform under the terms of
their
agreement with such counterparty, each
Trust
bears the risk of loss from a counterparty in the amount of the value of the collateral in the event the counterparty fails to
return such collateral. Based on the terms of agreements, collateral may not be required for all derivative contracts.
For financial reporting purposes, the Trusts do
not offset derivative assets and derivative liabilities that are subject to netting arrangements, if any, in the Statements of Assets
and Liabilities.
INVESTMENT ADVISORY AGREEMENT AND OTHER TRANSACTIONS WITH AFFILIATES
Each Trust entered into an Investment Advisory Agreement with the Manager, the Trusts
’
investment adviser and an indirect, wholly-owned subsidiary
of BlackRock, Inc. (“BlackRock”), to provide investment advisory and administrative services. The Manager is responsible for the management of each Trust
’
s portfolio and
provides the personnel, facilities, equipment and certain other services necessary to the operations of each Trust.
For such services, each Trust, except BCX, pays the Manager a monthly fee at the following annual rates:
Average weekly value of each Trust’s net assets:
Average daily value of each Trust’s net assets, plus the proceeds of any outstanding debt securities or borrowings for leverage:
Average daily value of each Trust’s net assets:
Average daily value of each Trust’s managed assets:
For such services, BCX pays the Manager a monthly fee at an annual rate equal to 1.00% of the sum of the average daily value of the net assets of the Trust (excluding the
value of the Trust
’
s interest in the BCX Subsidiary, LLC (the "BCX Taxable Subsidiary"), which is a wholly-owned taxable subsidiary of BCX) and the average daily value of the
net assets of its subsidiary, which fee is allocated pro rata between the Trust and the BCX Taxable Subsidiary based on the average daily value of their respective net assets
(excluding, in the case of the Trust, the value of the Trust
’
s interest in the BCX Taxable Subsidiary). The BCX Taxable Subsidiary had no net assets or activity during the period
ended June 30, 2024.
For purposes of calculating these fees, “net assets” mean the total assets of BGR, CII, BDJ, BOE, BGY, BME, BCX and BUI minus the sum of its accrued liabilities.
For purposes of calculating these fees, “managed assets” are determined as total assets of BMEZ, BIGZ, BSTZ and BST (including any assets attributable to money borrowed
for investment purposes) less the sum of its accrued liabilities (other than money borrowed for investment purposes).
The Manager provides investment management and other services to BDJ Taxable Subsidiary, BSTZ Taxable Subsidiary and BST Taxable Subsidiary. The Manager does not
receive separate compensation from the BDJ Taxable Subsidiary, BSTZ Taxable Subsidiary or BST Taxable Subsidiary for providing investment management or administrative
services. However, BDJ pays the Manager based on the Trust’s net assets, which includes the assets of the BDJ Taxable Subsidiary, and BSTZ and BST pay the Manager
based on the Trust
’
s managed assets, which includes the assets of the BSTZ Taxable Subsidiary and BST Taxable Subsidiary, respectively.
With respect to BGR, BOE, BGY, BCX and BUI, the Manager entered into separate sub-advisory agreements with BlackRock International Limited (“BIL”), an affiliate of the
Manager. The Manager pays BIL for services it provides for that portion of each Trust for which BIL acts as sub-adviser, a monthly fee that is equal to a percentage of the
investment advisory fees paid by each Trust to the Manager.
BDJ, BME, BST and BUI have each entered into Distribution Agreements with BlackRock Investments, LLC (“BRIL”), an affiliate of the Manager, to provide
for distribution of BDJ
’
s, BME’s, BST’s and BUI’s common shares on a reasonable best efforts basis through an equity shelf offering (a “Shelf Offering”) (the “Distribution
Agreement”). Pursuant to the Distribution Agreement, BRIL will receive commissions with respect to sales of common shares at a commission rate of 1.00% of the gross
proceeds of the sale of BDJ
’
s, BME’s, BST’s and BUI’s common shares and a portion of such commission is re-allowed to broker-dealers engaged by BRIL. The commissions
retained by BRIL during the six months ended June 30, 2024 amounted to $0, $0, $17,451 and $0 for each of BDJ, BME, BST and BUI, respectively.
Expense Limitations, Waivers and Reimbursements:
The Manager voluntarily agreed to waive a portion of the investment advisory fees on the following Trusts as a
percentage of their average weekly net assets, as follows:
Notes to Financial Statements
149
Notes to Financial Statements
(unaudited) (continued)
These voluntary waivers may be reduced or discontinued at any time without notice.
For the six months ended June 30, 2024, the investment advisory fees waived, which are included in fees waived and/or reimbursed by the Manager in the Statements of
Operations, were as follows:
| Fees Waived and/or Reimbursed |
| |
| |
With respect to each Trust, the Manager contractually agreed to waive its investment advisory fees by the amount of investment advisory fees each Trust pays to the Manager
indirectly through its investment in affiliated money market funds (the “affiliated money market fund waiver") through June 30, 2025. The contractual agreement may be
terminated upon 90 days’ notice by a majority of the Independent Trustees, or by a vote of a majority of the outstanding voting securities of a
Trust. These amounts are included
in fees waived and/or reimbursed by the Manager in the Statements of Operations. For the six months ended June 30, 2024, the amounts waived were as follows:
| Fees Waived and/or Reimbursed |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
The Manager contractually agreed to waive its investment advisory fee with respect to any portion of each
Trust
’
s assets invested in affiliated equity and fixed-income mutual
funds and affiliated exchange-traded funds that have a contractual management fee through June 30, 2025. The agreement can be renewed for annual periods thereafter, and
may be terminated on 90 days’ notice, each subject to approval by a majority of the Trusts
’
Independent Trustees. For the six months ended June 30, 2024, there were no fees
waived by the Manager pursuant to this arrangement.
The U.S. Securities and Exchange Commission (“SEC”) has issued an exemptive order which permits BIM, an affiliate of the Manager, to serve as
securities lending agent for the Trusts, subject to applicable conditions. As securities lending agent, BIM bears all operational costs directly related to securities lending.
The Trusts
are responsible for fees in connection with the investment of cash collateral received for securities on loan (the “collateral investment fees”). The cash collateral is
invested in a money market fund, BlackRock Cash Funds: Institutional, managed by the Manager or its affiliates. However, BIM has agreed to reduce the amount of securities
lending income it receives in order to effectively limit the collateral investment fees the Trusts bear to an annual rate of 0.04%. The SL Agency Shares of such money market
fund will not be subject to a sales load, redemption fee, distribution fee or service fee. The money market fund in which the cash collateral has been reinvested may impose a
discretionary liquidity fee of up to 2% of the value redeemed, if such fee, is determined to be in the best interests of such money market fund.
Securities lending income is generally equal to the total of income earned from the reinvestment of cash collateral (and excludes collateral investment fees), and any fees or
other payments to and from borrowers of securities. Each
Trust retains a portion of the securities lending income and remits the remaining portion to BIM as compensation for
its services as securities lending agent.
Pursuant to the current securities lending agreement, each of CII, BDJ, BMEZ, BME, BIGZ and BST retains 81% of securities lending income (which excludes collateral
investment expenses), and this amount retained can never be less than 70% of the total of securities lending income plus the collateral investment expenses.
In addition, commencing the business day following the date that the aggregate securities lending income earned across the BlackRock Fixed-Income Complex in a calendar
year exceeds a specified threshold, each of CII, BDJ, BMEZ, BME, BIGZ and BST, pursuant to the securities lending agreement, will retain for the remainder of that calendar
year securities lending income in an amount equal to 81% of securities lending income (which excludes collateral investment expenses), and this amount retained can never
be less than 70% of the total of securities lending income plus the collateral investment expenses.
Pursuant to the current securities lending agreement, each
of BGR, BOE, BGY, BCX, BSTZ and BUI retains 82% of securities lending income (which excludes collateral
investment expenses), and this amount retained can never be less than 70% of the total of securities lending income plus the collateral investment expenses.
In addition, commencing the business day following the date that the aggregate securities lending income earned across the BlackRock Fixed-Income Complex in a calendar
year exceeds a specified threshold, each
of BGR, BOE, BGY, BCX, BSTZ and BUI, pursuant to the securities lending agreement, will retain for the remainder of that calendar
year securities lending income in an amount equal to 85% of securities lending income (which excludes collateral investment expenses), and this amount retained can never
be less than 70% of the total of securities lending income plus the collateral investment expenses.
150
2024
BlackRock Semi-Annual Report to Shareholders
Notes to Financial Statements
(unaudited) (continued)
The share of securities lending income earned by each Trust is shown as securities lending income — affiliated — net in the Statements of Operations. For the six months
ended June 30, 2024, each Trust paid BIM the following amounts for securities lending agent services:
Certain trustees and/or officers of the Trusts are directors and/or officers of BlackRock or its affiliates. The Trusts reimburse the Manager for a portion
of the compensation paid to the Trusts
’
Chief Compliance Officer, which is included in Trustees and Officer in the Statements of Operations.
During the period ended June 30, 2024, BDJ received a reimbursement of $3,800, from an affiliate, which is included in payment by affiliate
in the Statements of Operations, related to an operating event.
For the six months ended June 30, 2024, purchases and sales of investments,
excluding short-term securities, were as follows:
It is each
Trust
’
s policy to comply with the requirements of the Internal Revenue Code of 1986, as amended, applicable to regulated investment companies, and to distribute
substantially all of its taxable income to its shareholders. Therefore, no U.S. federal income tax provision is required.
Each Trust files U.S. federal and various state and local tax returns. No income tax returns are currently under examination. The statute of limitations on each Trust’s
U.S. federal tax returns generally remains open for a period of three years after they are filed. The statutes of limitations on each Trust’s state and local tax returns may remain
open for an additional year depending upon the jurisdiction.
Management has analyzed tax laws and regulations and their application to the Trusts as of June 30, 2024, inclusive of the open tax return years, and does not believe that
there are any uncertain tax positions that require recognition of a tax liability in the Trusts
’
financial statements.
As of December 31, 2023, the Trusts had non-expiring capital loss carryforwards available to offset future realized capital gains and qualified late-year losses as follows:
Notes to Financial Statements
151
Notes to Financial Statements
(unaudited) (continued)
As of June 30, 2024, gross unrealized appreciation and depreciation based on cost of investments (including short positions and derivatives, if any) for U.S. federal income tax
purposes were as follows:
In the normal course of business, the Trusts
invest in securities or other instruments and may enter into certain transactions, and such activities subject each
Trust to various
risks, including among others, fluctuations in the market (market risk) or failure of an issuer to meet all of its obligations. The value of securities or other instruments may also
be affected by various factors, including, without limitation: (i) the general economy; (ii) the overall market as well as local, regional or global political and/or social instability;
(iii) regulation, taxation or international tax treaties between various countries; or (iv) currency, interest rate and price fluctuations. Local, regional or global events such as war,
acts of terrorism, the spread of infectious illness or other public health issues, recessions, or other events could have a significant impact on the Trusts and their
investments.
BDJ
’
s, BME’s, BST’s and BUI’s prospectuses provide details of the risks to which each
Trust is subject.
The
Trusts
may be exposed to additional risks when reinvesting cash collateral in money market funds that do not seek to maintain a stable NAV per share of $1.00, which may
be subject to discretionary liquidity fees under certain circumstances.
Each Trust may invest without limitation in illiquid or less liquid investments or investments in which no secondary market is readily available or which are
otherwise illiquid, including private placement securities. A Trust may not be able to readily dispose of such investments at prices that approximate those at which a Trust could
sell such investments if they were more widely traded and, as a result of such illiquidity, a Trust may have to sell other investments or engage in borrowing transactions if
necessary to raise funds to meet its obligations. Limited liquidity can also affect the market price of investments, thereby adversely affecting a Trust’s NAV and ability to make
dividend distributions. Privately issued debt securities are often of below investment grade quality, frequently are unrated and present many of the same risks as investing in
below investment grade public debt securities.
The market values of equities, such as common stocks and preferred securities or equity related investments, such as futures and options, may decline due
to general market conditions which are not specifically related to a particular company. They may also decline due to factors which affect a particular industry or industries.
A
Trust may invest in illiquid investments. An illiquid investment is any investment that a
Trust reasonably expects cannot be sold or disposed of in current market conditions
in seven calendar days or less without the sale or disposition significantly changing the market value of the investment. A
Trust may experience difficulty in selling illiquid
investments in a timely manner at the price that it believes the investments are worth. Prices may fluctuate widely over short or extended periods in response to company,
market or economic news. Markets also tend to move in cycles, with periods of rising and falling prices. This volatility may cause each
Trust’s NAV to experience significant
increases or decreases over short periods of time. If there is a general decline in the securities and other markets, the NAV of a
Trust may lose value, regardless of the
individual results of the securities and other instruments in which a
Trust invests.
The price a Trust could receive upon the sale of any particular portfolio investment may differ from a Trust
’
s valuation of the investment, particularly for securities that trade in
thin or volatile markets or that are valued using a fair valuation technique or a price provided by an independent pricing service. Changes to significant unobservable inputs and
assumptions (i.e., publicly traded company multiples, growth rate, time to exit) due to the lack of observable inputs may significantly impact the resulting fair value and therefore
a Trust
’
s results of operations. As a result, the price received upon the sale of an investment may be less than the value ascribed by a Trust, and a Trust could realize a greater
than expected loss or lesser than expected gain upon the sale of the investment. A Trust
’
s ability to value its investments may also be impacted by technological issues and/or
errors by pricing services or other third-party service providers.
Counterparty Credit Risk:
The Trusts may be exposed to counterparty credit risk, or the risk that an entity may fail to or be unable to perform on its commitments related to
unsettled or open transactions, including making timely interest and/or principal payments or otherwise honoring its obligations. The Trusts manage counterparty credit risk by
entering into transactions only with counterparties that the Manager believes have the financial resources to honor their obligations and by monitoring the financial stability of
those counterparties. Financial assets, which potentially expose the Trusts to market, issuer and counterparty credit risks, consist principally of financial instruments and
receivables due from counterparties. The extent of the Trusts
’
exposure to market, issuer and counterparty credit risks with respect to these financial assets is approximately
their value recorded in the Statements of Assets and Liabilities, less any collateral held by the Trusts.
A derivative contract may suffer a mark-to-market loss if the value of the contract decreases due to an unfavorable change in the market rates or values of the underlying
instrument. Losses can also occur if the counterparty does not perform under the contract.
152
2024
BlackRock Semi-Annual Report to Shareholders
Notes to Financial Statements
(unaudited) (continued)
For OTC options purchased, each
Trust bears the risk of loss in the amount of the premiums paid plus the positive change in market values net of any collateral held by the
Trusts should the counterparty fail to perform under the contracts. Options written by the Trusts do not typically give rise to counterparty credit risk, as options written generally
obligate the Trusts, and not the counterparty, to perform. The Trusts may be exposed to counterparty credit risk with respect to options written to the extent each
Trust
deposits
collateral with its counterparty to a written option.
With exchange-traded options purchased, there is less counterparty credit risk to the Trusts since the exchange or clearinghouse, as counterparty to such instruments,
guarantees against a possible default. The clearinghouse stands between the buyer and the seller of the contract; therefore, credit risk is limited to failure of the clearinghouse.
While offset rights may exist under applicable law, a Trust does not have a contractual right of offset against a clearing broker or clearinghouse in the event of a default
(including the bankruptcy or insolvency).
Geographic/Asset Class Risk:
A diversified portfolio, where this is appropriate and consistent with a fund’s objectives, minimizes the risk that a price change of a particular
investment will have a material impact on the NAV of a fund. The investment concentrations within each
Trust’s portfolio are disclosed in its Schedule of Investments.
As of period end, the Trusts listed below invested a significant portion of their assets in securities in the following sectors:
Changes in economic conditions affecting such sectors would have a greater impact on the Trusts and could affect the value, income and/or liquidity of positions in such
securities.
Certain
Trusts
invest a significant portion of their assets in securities within a single or limited number of market sectors. When a fund concentrates its investments in this
manner, it assumes the risk that economic, regulatory, political and social conditions affecting such sectors may have a significant impact on the Trust and could affect the
income from, or the value or liquidity of, the Trust’s portfolio. Investment percentages in specific sectors are presented in the Schedules of Investments.
Certain
Trusts
invest a substantial amount of their assets in issuers located in a single country or a limited number of countries. When a fund concentrates its investments in
this manner, it assumes the risk that economic, regulatory, political and social conditions in those countries may have a significant impact on their investment performance and
could affect the income from, or the value or liquidity of, the Trust
’
s portfolio. Unanticipated or sudden political or social developments may cause uncertainty in the markets and
as a result adversely affect the Trust’s investments. Foreign issuers may not be subject to the same uniform accounting, auditing and financial reporting standards and
practices as used in the United States. Foreign securities markets may also be more volatile and less liquid than U.S. securities and may be less subject to governmental
supervision not typically associated with investing in U.S. securities. Investment percentages in specific countries are presented in the Schedules of Investments.
Certain
Trusts invest a significant portion of their assets in securities of issuers located in the United States.
A decrease in imports or exports, changes in trade regulations,
inflation and/or an economic recession in the United States may have a material adverse effect on the U.S. economy and the securities listed on U.S. exchanges. Proposed
and adopted policy and legislative changes in the United States may also have a significant effect on U.S. markets generally, as well as on the value of certain securities.
Governmental agencies project that the United States will continue to maintain elevated public debt levels for the foreseeable future which may constrain future economic
growth. Circumstances could arise that could prevent the timely payment of interest or principal on U.S. government debt, such as reaching the legislative “debt ceiling.” Such
non-payment would result in substantial negative consequences for the U.S. economy and the global financial system. If U.S. relations with certain countries deteriorate, it
could adversely affect issuers that rely on the United States for trade. The United States has also experienced increased internal unrest and discord. If these trends were to
continue, they may have an adverse impact on the U.S. economy and the issuers in which the Trusts invest.
Certain
Trusts invest a significant portion of their assets in securities of issuers located in Europe or with significant exposure to European issuers or countries. The European
financial markets have recently experienced volatility and adverse trends due to concerns about economic downturns in, or rising government debt levels of, several European
countries as well as acts of war in the region. These events may spread to other countries in Europe and may affect the value and liquidity of certain of the Trusts
’
investments.
Responses to the financial problems by European governments, central banks and others, including austerity measures and reforms, may not work, may result in social unrest
and may limit future growth and economic recovery or have other unintended consequences. Further defaults or restructurings by governments and others of their debt could
have additional adverse effects on economies, financial markets and asset valuations around the world. The United Kingdom has withdrawn from the European Union, and one
or more other countries may withdraw from the European Union and/or abandon the Euro, the common currency of the European Union. These events and actions have
adversely affected, and may in the future adversely affect, the value and exchange rate of the Euro and may continue to significantly affect the economies of every country in
Europe, including countries that do not use the Euro and non-European Union member states. The impact of these actions, especially if they occur in a disorderly fashion, is
not clear but could be significant and far reaching. In addition, Russia launched a large-scale invasion of Ukraine on February 24, 2022. The extent and duration of the military
action, resulting sanctions and resulting future market disruptions in the region are impossible to predict, but have been, and may continue to be, significant and have a severe
adverse effect on the region, including significant negative impacts on the economy and the markets for certain securities and commodities, such as oil and natural gas, as well
as other sectors.
Notes to Financial Statements
153
Notes to Financial Statements
(unaudited) (continued)
CAPITAL SHARE TRANSACTIONS
Each
Trust is authorized to issue an unlimited number of shares, with the exception of CII, all of which were initially classified as Common Shares. CII is authorized to issue
200 million Common Shares. The par value for each Trust’s Common Shares is $0.001, except for CII, which is $0.10. The Board is authorized, however, to reclassify any
unissued Common Shares to Preferred Shares without the approval of Common Shareholders.
BDJ, BME, BST and BUI have each filed a prospectus with the SEC allowing them to issue an additional 40,000,000, 4,000,000, 18,000,000 and 8,000,000 Common Shares,
respectively, through an equity Shelf Offering.
Under the Shelf Offerings, BDJ, BME, BST and BUI, subject to market conditions, may raise additional equity capital from time
to time in varying amounts and utilizing various offering methods at a net price at or above each Trust’s NAV per Common Share (calculated within 48 hours of pricing). As of
period end, 40,000,000, 3,332,695, 15,661,664 and 7,658,406 Common Shares, respectively, remain available for issuance under the Shelf Offerings. During the period ended
June 30, 2024, BDJ, BME, BST and BUI issued 0, 0, 236,917 and 0 shares, respectively, under the Trust
’
s respective current Shelf Offering and the Trust
’
s prior Shelf Offering.
See Additional Information — Shelf Offering Program for additional information.
Initial costs incurred by each of BDJ, BME, BST and BUI in connection with their Shelf Offerings are recorded as “Deferred offering costs” in the Statements of Assets and
Liabilities. As shares are sold, a portion of the costs attributable to the shares sold will be charged against paid-in-capital. Any remaining deferred charges at the end of the
Shelf Offering period will be charged to expense.
For the periods shown, shares issued and outstanding increased by the following amounts as a result of shares issued through the Shelf Offering:
For the periods shown, shares issued and outstanding increased by the following amounts as a result of dividend reinvestment:
The Trusts participate in an open market share repurchase program (the “Repurchase Program”). From December 1, 2022 through November 30, 2023, each Trust may
repurchase up to 5% of its outstanding common shares under the Repurchase Program, based on common shares outstanding as of the close of business on November 30,
2022, subject to certain conditions. From December 1, 2023 through November 30, 2024, each Trust may repurchase up to 5% of its outstanding common shares under the
Repurchase Program, based on common shares outstanding as of the close of business on November 30, 2023, subject to certain conditions. The Repurchase Program has
an accretive effect as shares are purchased at a discount to the Trust’s NAV. There is no assurance that the Trusts will purchase
shares
in
any
particular amounts. For the six
months ended June 30, 2024, the Trusts did not repurchase any shares.
The total cost of the shares repurchased is reflected in the Trusts’ Statements of Changes in Net Assets. For the periods shown, shares repurchased and cost, including
transaction costs, were as follows:
| |
| | |
Six Months Ended June 30, 2024 | | |
Year Ended December 31, 2023 | | |
| |
| | |
Six Months Ended June 30, 2024 | | |
Year Ended December 31, 2023 | | |
| |
| | |
Six Months Ended June 30, 2024 | | |
Year Ended December 31, 2023 | | |
| |
| | |
Six Months Ended June 30, 2024 | | |
Year Ended December 31, 2023 | | |
154
2024
BlackRock Semi-Annual Report to Shareholders
Notes to Financial Statements
(unaudited) (continued)
| |
| | |
Six Months Ended June 30, 2024 | | |
Year Ended December 31, 2023 | | |
| |
| | |
Six Months Ended June 30, 2024 | | |
Year Ended December 31, 2023 | | |
| |
| | |
Six Months Ended June 30, 2024 | | |
Year Ended December 31, 2023 | | |
| |
| | |
Six Months Ended June 30, 2024 | | |
Year Ended December 31, 2023 | | |
On May 3, 2024, the Board approved each Trust’s adoption of a one-year discount management program (the “Program”) that is comprised of four 3-month measurement
periods, expiring with the measurement period ending March 31, 2025, unless continued by the Board. Under the Program, each Trust intends to offer to repurchase a portion
of its common shares via tender offer if the Trust’s common shares trade at an average daily discount to NAV of more than 7.5% during a 3-month measurement period. The
Board approved each Trust (excluding BST and BUI) offering to repurchase 2.5% of its outstanding common shares for the first measurement period, which began on April 1,
2024 and ended on June 30, 2024, as the discount trigger was met for each Trust other than BST and BUI. The results of the second, third and fourth measurement periods,
and any action approved by the Board as a result, will be announced promptly after the end of each applicable measurement period. There is no guarantee that shareholders
will be able to sell all of the shares that they desire to sell in any particular tender offer that is executed and there can be no assurances as to the effect that the Program will
have on the market for a Trust’s shares or the discount at which a Trust’s shares may trade relative to its NAV.
As of June 30, 2024, BlackRock Financial Management, Inc., an affiliate of the Trust, owned 5,000 Shares of BIGZ.
FOREIGN WITHHOLDINGS TAX CLAIMS
BGY is seeking a closing agreement with the IRS to address any prior years’ U.S. income tax liabilities attributable to Trust shareholders resulting from the recovery of foreign
taxes. The closing agreement would result in the Trust paying a compliance fee to the IRS, on behalf of its shareholders, representing the estimated tax savings generated from
foreign tax credits claimed by Trust shareholders on their tax returns in prior years. The Trust has accrued a liability for the estimated IRS compliance fee related to foreign
withholding tax claims, which is disclosed in the Statements of Assets and Liabilities. The actual IRS compliance fee may differ from the estimate and that difference may be
material.
Management’s evaluation of the impact of all subsequent events on the Trusts
’
financial statements was completed through the date the financial statements were issued and
the following items were noted:
The Trusts declared and paid or will pay distributions to Common Shareholders as follows:
Notes to Financial Statements
155
Notes to Financial Statements
(unaudited) (continued)
As a result of the discount trigger being met during the first measurement period under the discount management program, BGR, CII and BDJ each conducted a tender offer
for 2.5% of its outstanding common shares, at a price equal to 98% of the NAV per share, determined on the business day after the tender offer expired. The tender offers
expired on August 16, 2024 and the results of the tender offers were as follows:
| Date the tender offer period began. |
As a result of the discount trigger being met during the first measurement period under the discount management program, BGY, BMEZ and BME each conducted a tender
offer for 2.5% of its outstanding common shares, at a price equal to 98% of the NAV per share, determined on the business day after the tender offer expired. The tender offers
expired on August 19, 2024 and the results of the tender offers were as follows:
156
2024
BlackRock Semi-Annual Report to Shareholders
Notes to Financial Statements
(unaudited) (continued)
| Date the tender offer period began. |
On July 19, 2024, BOE, BCX and BSTZ each commenced a tender offer for 2.5% of its outstanding common shares as a result of the discount trigger being met during the first
measurement period under the discount management program. The tender offers expired on August 20, 2024 and the results are pending at the time of release of this report.
On July 22, 2024, BIGZ commenced a tender offer for 2.5% of its outstanding common shares as a result of the discount trigger being met during the first measurement period
under the discount management program. The tender offer expired on August 21, 2024 and the results are pending at the time of release of this report.
Notes to Financial Statements
157
Disclosure of Investment Advisory Agreements and Sub-Advisory Agreements
The Boards of Directors/Trustees, as applicable (collectively, the “Board,” the members of which are referred to as “Board Members”) of BlackRock Energy and Resources
Trust (“BGR”), BlackRock Enhanced Capital and Income Fund, Inc. (“CII”), BlackRock Enhanced Equity Dividend Trust (“BDJ”), BlackRock Enhanced Global Dividend Trust
(“BOE”), BlackRock Enhanced International Dividend Trust (“BGY”), BlackRock Health Sciences Trust (“BME”), BlackRock Health Sciences Term Trust (“BMEZ”), BlackRock
Innovation and Growth Term Trust (“BIGZ”), BlackRock Resources & Commodities Strategy Trust (“BCX”), BlackRock Science and Technology Trust (“BST”), BlackRock
Science and Technology Term Trust (“BSTZ”) and BlackRock Utilities, Infrastructure & Power Opportunities Trust (“BUI”) (collectively, the “Funds” and each, a “Fund”) met on
May 3, 2024 (the “May Meeting”) and June 6-7, 2024 (the “June Meeting”) to consider the approval to continue the investment advisory agreements (the “Advisory
Agreements”) between each Fund and BlackRock Advisors, LLC (the “Manager”), each Fund’s investment advisor. The Board also considered the approval to continue the
sub-advisory agreements (the “Sub-Advisory Agreements”) between the Manager, BlackRock International Limited (the “Sub-Advisor”) and each of BGR, BOE, BGY, BCX and
BUI. The Manager and the Sub-Advisor are referred to herein as “BlackRock.” The Advisory Agreements and the Sub-Advisory Agreements are referred to herein as the
“Agreements.”
Consistent with the requirements of the Investment Company Act of 1940 (the “1940 Act”), the Board considers the approval of the continuation of the Agreements for each
Fund on an annual basis. The Board members who are not “interested persons” of each Fund, as defined in the 1940 Act, are considered independent Board members (the
“Independent Board Members”). The Board’s consideration entailed a year-long deliberative process during which the Board and its committees assessed BlackRock’s various
services to each Fund, including through the review of written materials and oral presentations, and the review of additional information provided in response to requests from
the Independent Board Members. The Board had four quarterly meetings per year, each of which extended over a two-day period, as well as additional ad hoc meetings and
executive sessions throughout the year, as needed. The committees of the Board similarly met throughout the year. The Board also had an additional one-day meeting to
consider specific information regarding the renewal of the Agreements. In considering the renewal of the Agreements, the Board assessed, among other things, the nature,
extent and quality of the services provided to each Fund by BlackRock, BlackRock’s personnel and affiliates, including (as applicable): investment management services;
accounting oversight; administrative and shareholder services; oversight of each Fund’s service providers; risk management and oversight; and legal, regulatory and
compliance services. Throughout the year, including during the contract renewal process, the Independent Board Members were advised by independent legal counsel, and
met with independent legal counsel in various executive sessions outside of the presence of BlackRock’s management.
During the year, the Board, acting directly and through its committees, considered information that was relevant to its annual consideration of the renewal of the Agreements,
including the services and support provided by BlackRock to each Fund and its shareholders. BlackRock also furnished additional information to the Board in response to
specific questions from the Board. Among the matters the Board considered were: (a) investment performance for one-year, three-year, five-year, and/or since inception
periods, as applicable, against peer funds, relevant benchmarks, and other performance metrics, as applicable, as well as BlackRock senior management’s and portfolio
managers’ investment performance analyses, and the reasons for any outperformance or underperformance relative to its peers, benchmarks, and other performance metrics,
as applicable; (b) leverage management, as applicable; (c) fees, including advisory, administration, if applicable, and other amounts paid to BlackRock and its affiliates by each
Fund for services; (d) Fund operating expenses and how BlackRock allocates expenses to each Fund; (e) the resources devoted to risk oversight of, and compliance reports
relating to, implementation of each Fund’s investment objective, policies and restrictions, and meeting regulatory requirements; (f) BlackRock’s and each Fund’s adherence to
applicable compliance policies and procedures; (g) the nature, character and scope of non-investment management services provided by BlackRock and its affiliates and the
estimated cost of such services, as available; (h) BlackRock’s and other service providers’ internal controls and risk and compliance oversight mechanisms; (i) BlackRock’s
implementation of the proxy voting policies approved by the Board; (j) the use of brokerage commissions and execution quality of portfolio transactions; (k) BlackRock’s
implementation of each Fund’s valuation and liquidity procedures; (l) an analysis of management fees paid to BlackRock for products with similar investment mandates across
the open-end fund, closed-end fund, sub-advised mutual fund, collective investment trust and institutional separate account product channels, as applicable, and the
similarities and differences between these products and the services provided as compared to each Fund; (m) BlackRock’s compensation methodology for its investment
professionals and the incentives and accountability it creates, along with investment professionals’ investments in the fund(s) they manage; (n) periodic updates on
BlackRock’s business; and (o) each Fund’s market discount/premium compared to peer funds.
Prior to and in preparation for the May Meeting, the Board received and reviewed materials specifically relating to the renewal of the Agreements. The Independent Board
Members continuously engaged in a process with their independent legal counsel and BlackRock to review the nature and scope of the information provided to the Board to
better assist its deliberations. The materials provided in connection with the May Meeting included, among other things: (a) information independently compiled and prepared
by Broadridge Financial Solutions, Inc. (“Broadridge”), based on either a Lipper classification or Morningstar category, regarding each Fund’s fees and expenses as compared
with a peer group of funds as determined by Broadridge (“Expense Peers”) and the investment performance of each Fund as compared with a peer group of funds
(“Performance Peers”); (b) information on the composition of the Expense Peers and Performance Peers and a description of Broadridge’s methodology; (c) information on the
estimated profits realized by BlackRock and its affiliates pursuant to the Agreements and a discussion of fall-out benefits to BlackRock and its affiliates; (d) a general analysis
provided by BlackRock concerning investment management fees received in connection with other types of investment products, such as institutional accounts, sub-advised
mutual funds, closed-end funds, and open-end funds, under similar investment mandates, as applicable; (e) a review of non-management fees; (f) the existence, impact and
sharing of potential economies of scale, if any, with each Fund; (g) a summary of aggregate amounts paid by each Fund to BlackRock; and (h) various additional information
requested by the Board as appropriate regarding BlackRock’s and each Fund’s operations.
At the May Meeting, the Board reviewed materials relating to its consideration of the Agreements and the Independent Board Members presented BlackRock with questions
and requests for additional information. BlackRock responded to these questions and requests with additional written information in advance of the June Meeting, and such
responses were reviewed by the Board Members.
At the June Meeting, the Board concluded its assessment of, among other things: (a) the nature, extent and quality of the services provided by BlackRock; (b) the investment
performance of each Fund as compared to its Performance Peers and to other metrics, as applicable; (c) the advisory fee and the estimated cost of the services and estimated
profits realized by BlackRock and its affiliates from their relationship with each Fund; (d) each Fund’s fees and expenses compared to its Expense Peers; (e) the existence and
sharing of potential economies of scale; (f) any fall-out benefits to BlackRock and its affiliates as a result of BlackRock’s relationship with each Fund; and (g) other factors
deemed relevant by the Board Members.
158
2024
BlackRock Semi-Annual Report to Shareholders
Disclosure of Investment Advisory Agreements and Sub-Advisory Agreements
(continued)
The Board also considered other matters it deemed important to the approval process, such as other payments made to BlackRock or its affiliates relating to securities lending
and cash management, and BlackRock’s services related to the valuation and pricing of Fund portfolio holdings. The Board noted the willingness of BlackRock’s personnel to
engage in open, candid discussions with the Board. The Board evaluated the information available to it on a fund-by-fund basis. The following paragraphs provide more
information about some of the primary factors that were relevant to the Board’s decision. The Board Members did not identify any particular information, or any single factor as
determinative, and each Board Member may have attributed different weights to the various items and factors considered.
A. Nature, Extent and Quality of the Services
The Board, including the Independent Board Members, reviewed the nature, extent and quality of services provided by BlackRock, including the investment advisory services,
and the resulting performance of each Fund. Throughout the year, the Board compared Fund performance to the performance of a comparable group of closed-end funds,
relevant benchmarks, and performance metrics, as applicable. The Board met with BlackRock’s senior management personnel responsible for investment activities, including
the senior investment officers. The Board also reviewed the materials provided by each Fund’s portfolio management team discussing each Fund’s performance, investment
strategies and outlook.
The Board considered, among other factors, with respect to BlackRock: the experience of each Fund’s portfolio management team; research capabilities; investments by
portfolio managers in the funds they manage; portfolio trading capabilities; use of technology; commitment to compliance; credit analysis capabilities; risk analysis and
oversight capabilities; and the approach to training and retaining portfolio managers and other research, advisory and management personnel. The Board also considered
BlackRock’s overall risk management program, including the continued efforts of BlackRock and its affiliates to address cybersecurity risks and the role of BlackRock’s Risk &
Quantitative Analysis Group. The Board engaged in a review of BlackRock’s compensation structure with respect to each Fund’s portfolio management team and BlackRock’s
ability to attract and retain high-quality talent and create performance incentives.
In addition to investment advisory services, the Board considered the nature and quality of the administrative and other non-investment advisory services provided to each
Fund. BlackRock and its affiliates provide each Fund with certain administrative, shareholder and other services (in addition to any such services provided to each Fund by
third parties) and officers and other personnel as are necessary for the operations of each Fund. In particular, BlackRock and its affiliates provide each Fund with administrative
services including, among others: (i) responsibility for disclosure documents, registration statements in connection with BDJ’s, BME’s, BST’s and BUI’s equity shelf program,
and periodic shareholder reports; (ii) preparing communications with analysts to support secondary market trading of each Fund; (iii) oversight of daily accounting and pricing;
(iv) responsibility for periodic filings with regulators and stock exchanges; (v) overseeing and coordinating the activities of third-party service providers including, among others,
each Fund’s custodian, fund accountant, transfer agent, and auditor; (vi) organizing Board meetings and preparing the materials for such Board meetings; (vii) providing legal
and compliance support; (viii) furnishing analytical and other support to assist the Board in its consideration of strategic issues such as the merger, consolidation or repurposing
of certain closed-end funds; and (ix) performing or managing administrative functions necessary for the operation of each Fund, such as tax reporting, expense management,
fulfilling regulatory filing requirements, and shareholder call center and other services. The Board reviewed the structure and duties of BlackRock’s fund administration,
shareholder services, and legal and compliance departments and considered BlackRock’s policies and procedures for assuring compliance with applicable laws and
regulations. The Board considered the operation of BlackRock’s business continuity plans.
The Board noted that the engagement of the Sub-Advisor with respect to BGR, BOE, BGY, BCX, and BUI facilitates the provision of investment advice and trading by
investment personnel out of non-U.S. jurisdictions. The Board considered that this arrangement provides additional flexibility to the portfolio management team, which may
benefit each Fund and its shareholders.
B. The Investment Performance of each Fund
The Board, including the Independent Board Members, reviewed and considered the performance history of each Fund throughout the year and at the May Meeting. In
preparation for the May Meeting, the Board was provided with reports independently prepared by Broadridge, which included an analysis of each Fund’s performance as of
December 31, 2023, as compared to its Performance Peers. The performance information is based on net asset value (“NAV”), and utilizes Lipper data. Lipper’s methodology
calculates a fund’s total return assuming distributions are reinvested on the ex-date at a fund’s ex-date NAV. Broadridge ranks funds in quartiles, ranging from first to fourth,
where first is the most desirable quartile position and fourth is the least desirable. In connection with its review, the Board received and reviewed information regarding the
investment performance of each Fund as compared to its Performance Peers and certain performance metrics (“Performance Metrics”). The Board and its Performance
Oversight Committee regularly review and meet with Fund management to discuss the performance of each Fund throughout the year.
In evaluating performance, the Board focused particular attention on funds with less favorable performance records. The Board also noted that while it found the data provided
by Broadridge generally useful, it recognized the limitations of such data, including in particular, that notable differences may exist between a fund and its Performance Peers
(for example, the investment objectives and strategies). Further, the Board recognized that the performance data reflects a snapshot of a period as of a particular date and that
selecting a different performance period could produce significantly different results. The Board also acknowledged that long-term performance could be impacted by even one
period of significant outperformance or underperformance, and that a single investment theme could have the ability to disproportionately affect long-term performance.
The Board reviewed and considered BGR’s performance relative to BGR’s Performance Metrics. Based on an overall rating relative to the Performance Metrics, BGR
generally performed above expectations. The Board noted that BlackRock believes that the Performance Metrics are an appropriate performance comparison for BGR, and
that BlackRock has explained its rationale for this belief to the Board.
The Board reviewed and considered CII’s performance relative to CII’s Performance Metrics. Based on an overall rating relative to the Performance Metrics, CII generally
performed above expectations. The Board noted that BlackRock believes that the Performance Metrics are an appropriate performance comparison for CII, and that
BlackRock has explained its rationale for this belief to the Board.
The Board reviewed and considered BDJ’s performance relative to BDJ’s Performance Metrics. Based on an overall rating relative to the Performance Metrics, BDJ generally
performed above expectations. The Board noted that BlackRock believes that the Performance Metrics are an appropriate performance comparison for BDJ, and that
BlackRock has explained its rationale for this belief to the Board.
Disclosure of Investment Advisory Agreements and Sub-Advisory Agreements
159
Disclosure of Investment Advisory Agreements and Sub-Advisory Agreements
(continued)
The Board reviewed and considered BOE’s performance relative to BOE’s Performance Metrics. Based on an overall rating relative to the Performance Metrics, BOE generally
performed in line with expectations. The Board noted that BlackRock believes that the Performance Metrics are an appropriate performance comparison for BOE, and that
BlackRock has explained its rationale for this belief to the Board.
The Board reviewed and considered BGY’s performance relative to BGY’s Performance Metrics. Based on an overall rating relative to the Performance Metrics, BGY generally
performed above expectations. The Board noted that BlackRock believes that the Performance Metrics are an appropriate performance comparison for BGY, and that
BlackRock has explained its rationale for this belief to the Board.
The Board reviewed and considered BME’s performance relative to BME’s Performance Metrics. Based on an overall rating relative to the Performance Metrics, BME
generally performed above expectations. The Board noted that BlackRock believes that the Performance Metrics are an appropriate performance comparison for BME, and
that BlackRock has explained its rationale for this belief to the Board.
The Board reviewed and considered BMEZ’s performance relative to BMEZ’s Performance Metrics. Based on an overall rating relative to the Performance Metrics, BMEZ
generally performed in line with expectations. The Board noted that BlackRock believes that the Performance Metrics are an appropriate performance comparison for BMEZ,
and that BlackRock has explained its rationale for this belief to the Board.
The Board reviewed and considered BIGZ’s performance relative to BIGZ’s Performance Metrics. Based on an overall rating relative to the Performance Metrics, BIGZ
generally performed below expectations. The Board noted that BlackRock believes that the Performance Metrics are an appropriate performance comparison for BIGZ, and
that BlackRock has explained its rationale for this belief to the Board. The Board and BlackRock reviewed BIGZ’s underperformance relative to the Performance Metrics.
The Board reviewed and considered BCX’s performance relative to BCX’s Performance Metrics. Based on an overall rating relative to the Performance Metrics, BCX generally
performed above expectations. The Board noted that BlackRock believes that the Performance Metrics are an appropriate performance comparison for BCX, and that
BlackRock has explained its rationale for this belief to the Board.
The Board reviewed and considered BST’s performance relative to BST’s Performance Metrics. Based on an overall rating relative to the Performance Metrics, BST generally
performed below expectations. The Board noted that BlackRock believes that the Performance Metrics are an appropriate performance comparison for BST, and that
BlackRock has explained its rationale for this belief to the Board. The Board and BlackRock reviewed BST’s underperformance relative to the Performance Metrics.
The Board reviewed and considered BSTZ’s performance relative to BSTZ’s Performance Metrics. Based on an overall rating relative to the Performance Metrics, BSTZ
generally performed below expectations. The Board noted that BlackRock believes that the Performance Metrics are an appropriate performance comparison for BSTZ, and
that BlackRock has explained its rationale for this belief to the Board. The Board and BlackRock reviewed BSTZ’s underperformance relative to the Performance Metrics.
The Board reviewed and considered BUI’s performance relative to BUI’s Performance Metrics. Based on an overall rating relative to the Performance metrics, BUI generally
performed above expectations. The Board noted that BlackRock believes that the Performance Metrics are an appropriate performance comparison for BUI, and that
BlackRock has explained its rationale for this belief to the Board.
C. Consideration of the Advisory/Management Fees and the Estimated Cost of the Services and Estimated Profits Realized by BlackRock and its Affiliates from
their Relationship with each Fund
The Board, including the Independent Board Members, reviewed each Fund’s contractual management fee rate compared with those of its Expense Peers. The contractual
management fee rate represents a combination of the advisory fee and any administrative fees, before taking into account any reimbursements or fee waivers. The Board also
compared each Fund’s total expense ratio, as well as its actual management fee rate as a percentage of managed assets, which is the total assets of each Fund (including any
assets attributable to money borrowed for investment purposes) minus the sum of each Fund’s accrued liabilities (other than money borrowed for investment purposes) to
those of its Expense Peers. The total expense ratio represents a fund’s total net operating expenses, excluding any investment related expenses. The total expense ratio gives
effect to any expense reimbursements or fee waivers, and the actual management fee rate gives effect to any management fee reimbursements or waivers. The Board
considered that the fee and expense information in the Broadridge report for each Fund reflected information for a specific period and that historical asset levels and expenses
may differ from current levels, particularly in a period of market volatility. The Board considered the services provided and the fees charged by BlackRock and its affiliates to
other types of clients with similar investment mandates, as applicable, including institutional accounts and sub-advised mutual funds (including mutual funds sponsored by third
parties).
The Board received and reviewed statements relating to BlackRock’s financial condition. The Board reviewed BlackRock’s profitability methodology and was also provided
with an estimated profitability analysis that detailed the revenues earned and the expenses incurred by BlackRock for services provided to each Fund. The Board reviewed
BlackRock’s estimated profitability with respect to each Fund and other funds the Board currently oversees for the year ended December 31, 2023 compared to available
aggregate estimated profitability data provided for the prior two years. The Board reviewed BlackRock’s estimated profitability with respect to certain other U.S. fund complexes
managed by the Manager and/or its affiliates. The Board reviewed BlackRock’s assumptions and methodology of allocating expenses in the estimated profitability analysis,
noting the inherent limitations in allocating costs among various advisory products. The Board recognized that profitability may be affected by numerous factors including,
among other things, fee waivers and expense reimbursements by the Manager, the types of funds managed, precision of expense allocations and business mix. The Board
thus recognized that calculating and comparing profitability at the individual fund level is difficult.
The Board noted that, in general, individual fund or product line profitability of other advisors is not publicly available. The Board reviewed BlackRock’s overall operating
margin, in general, compared to that of certain other publicly traded asset management firms. The Board considered the differences between BlackRock and these other firms,
including the contribution of technology at BlackRock, BlackRock’s expense management, and the relative product mix.
The Board considered whether BlackRock has the financial resources necessary to attract and retain high quality investment management personnel to perform its obligations
under the Agreements and to continue to provide the high quality of services that is expected by the Board. The Board further considered factors including but not limited to
160
2024
BlackRock Semi-Annual Report to Shareholders
Disclosure of Investment Advisory Agreements and Sub-Advisory Agreements
(continued)
BlackRock’s commitment of time and resources, assumption of risk, and liability profile in servicing each Fund, including in contrast to what is required of BlackRock with
respect to other products with similar investment mandates across the open-end fund, closed-end fund, sub-advised mutual fund, collective investment trust, and institutional
separate account product channels, as applicable.
The Board noted that BGR’s contractual management fee rate ranked in the fourth quartile, and that the actual management fee rate and total expense ratio ranked in the
second and first quartiles, respectively, relative to the Expense Peers. The Board and BlackRock agreed to a lower contractual advisory fee rate, and in connection determined
to eliminate a voluntary advisory fee waiver. These changes were effective July 1, 2024.
The Board noted that CII’s contractual management fee rate ranked in the first quartile, and that the actual management fee rate and total expense ratio ranked in the second
and first quartiles, respectively, relative to the Expense Peers.
The Board noted that BDJ’s contractual management fee rate ranked in the first quartile, and that the actual management fee rate and total expense ratio each ranked in the
first quartile relative to the Expense Peers.
The Board noted that BOE’s contractual management fee rate ranked in the third quartile, and that the actual management fee rate and total expense ratio each ranked in the
first quartile relative to the Expense Peers. In addition, the Board noted that BlackRock had agreed to voluntarily waive a portion of the advisory fee payable by BOE. After
discussion between the Board, including the Independent Board Members, and BlackRock, the Board and BlackRock agreed to a continuation of the current 17.5 basis points
voluntary advisory fee waiver.
The Board noted that BGY’s contractual management fee rate ranked in the second quartile, and that the actual management fee rate and total expense ratio ranked in the
third and second quartiles, respectively, relative to the Expense Peers.
The Board noted that BME’s contractual management fee rate ranked in the first quartile, and that the actual management fee rate and total expense ratio each ranked in the
first quartile relative to the Expense Peers.
The Board noted that BMEZ’s contractual management fee rate ranked in the second quartile, and that the actual management fee rate and total expense ratio ranked in the
third and second quartiles, respectively, relative to the Expense Peers.
The Board noted that BIGZ’s contractual management fee rate ranked in the fourth quartile, and that the actual management fee rate and total expense ratio ranked in the
fourth and second quartiles, respectively, relative to the Expense Peers.
The Board noted that BCX’s contractual management fee rate ranked in the first quartile, and that the actual management fee rate and total expense ratio ranked in the second
and first quartiles, respectively, relative to the Expense Peers.
The Board noted that BST’s contractual management fee rate ranked in the first quartile, and that the actual management fee rate and total expense ratio each ranked in the
first quartile relative to the Expense Peers.
The Board noted that BSTZ’s contractual management fee rate ranked in the second quartile, and that the actual management fee rate and total expense ratio ranked in the
third and second quartiles, respectively, relative to the Expense Peers.
The Board noted that BUI’s contractual management fee rate ranked in the second quartile, and that the actual management fee rate and total expense ratio ranked in the third
and first quartiles, respectively, relative to the Expense Peers.
The Board, including the Independent Board Members, considered the extent to which any economies of scale might benefit each Fund in a variety of ways as the assets of
each Fund increase. The Board considered multiple factors, including the advisory fee rate and breakpoints, and fee waivers, as applicable. The Board considered each
Fund’s asset levels and whether the current fee was appropriate.
Based on the Board’s review and consideration of the issue, the Board concluded that most closed-end funds do not have fund level breakpoints because closed-end funds
generally do not experience substantial growth after the initial public offering. Closed-end funds are typically priced at scale at a fund’s inception. The Board noted that although
each of BDJ, BME, BST and BUI may from time-to-time make additional share offerings pursuant to its equity shelf program, the growth of each BDJ’s, BME’s, BST’s and BUI’s
assets will occur primarily through the appreciation of its investment portfolio.
E. Other Factors Deemed Relevant by the Board Members
The Board, including the Independent Board Members, also took into account other ancillary or “fall-out” benefits that BlackRock or its affiliates may derive from BlackRock’s
respective relationships with each Fund, both tangible and intangible, such as BlackRock’s ability to leverage its investment professionals who manage other portfolios and its
risk management personnel, an increase in BlackRock’s profile in the investment advisory community, and the engagement of BlackRock’s affiliates as service providers to
each Fund, including for administrative, securities lending and cash management services. With respect to securities lending, during the year the Board also considered
information provided by independent third-party consultants related to the performance of each BlackRock affiliate as securities lending agent. The Board also considered
BlackRock’s overall operations and its efforts to expand the scale of, and improve the quality of, its operations. The Board also noted that, subject to applicable law, BlackRock
may use and benefit from third-party research obtained by soft dollars generated by certain registered fund transactions to assist in managing all or a number of its other client
accounts.
In connection with its consideration of the Agreements, the Board also received information regarding BlackRock’s brokerage and soft dollar practices. The Board received
reports from BlackRock which included information on brokerage commissions and trade execution practices throughout the year.
Disclosure of Investment Advisory Agreements and Sub-Advisory Agreements
161
Disclosure of Investment Advisory Agreements and Sub-Advisory Agreements
(continued)
The Board also considered the various notable initiatives and projects BlackRock performed in connection with its closed-end fund product line. These initiatives included
developing equity shelf programs; efforts to eliminate product overlap with fund mergers; ongoing services to manage leverage that has become increasingly complex; periodic
evaluation of share repurchases and other support initiatives for certain BlackRock funds; and efforts to reduce fund discounts, including continued communication efforts with
shareholders, fund analysts and financial advisers. With respect to the latter, the Independent Board Members noted BlackRock’s continued commitment to supporting the
secondary market for the common shares of its closed-end funds through a comprehensive secondary market communication program designed to raise investor and analyst
awareness and understanding of closed-end funds. BlackRock’s support services included, among other things: sponsoring and participating in conferences; communicating
with closed-end fund analysts covering the BlackRock funds throughout the year; providing marketing and product updates for the closed-end funds; and maintaining and
enhancing its closed-end fund website.
At the June Meeting, in a continuation of the discussions that occurred during the May Meeting, and as a culmination of the Board’s year-long deliberative process, the Board,
including the Independent Board Members, unanimously approved the continuation of the Advisory Agreements between the Manager and each Fund for a one-year term
ending June 30, 2025, and the Sub-Advisory Agreements among the Manager, the Sub-Advisor and each of BGR, BOE, BGY, BCX and BUI for a one-year term ending
June 30, 2025. Based upon its evaluation of all of the aforementioned factors in their totality, as well as other information, the Board, including the Independent Board
Members, was satisfied that the terms of the Agreements were fair and reasonable and in the best interest of each Fund and its shareholders. In arriving at its decision to
approve the Agreements, the Board did not identify any single factor or group of factors as all-important or controlling, but considered all factors together, and different Board
Members may have attributed different weights to the various factors considered. The Independent Board Members were advised by independent legal counsel throughout the
deliberative process.
162
2024
BlackRock Semi-Annual Report to Shareholders
The Annual Meeting of Shareholders of BMEZ (the “Meeting”) was held on June 25, 2024 for shareholders of record on April 3, 2024 to consider and vote on the election of
three Class II Trustees and to consider and vote on a shareholder proposal submitted by an activist hedge fund to terminate the investment management agreement between
BMEZ and BlackRock Advisors, LLC. There were no broker non-votes.
The vote results in the election of Class II Trustees were as follows:
No nominee received the required number of votes to be re-elected or elected to the Board of BMEZ. The vote standard to elect Board members is described in BMEZ
’
s most
recent proxy statement. R. Glenn Hubbard, W. Carl Kester and John M. Perlowski, incumbent Class II Trustees, will continue to serve as Class II Trustees until their successors
have been duly elected and qualified.
The Trustees of BMEZ whose term of office continued after the Meeting because they were not up for election are Cynthia L. Egan, Robert Fairbairn, Lorenzo A. Flores, Stayce
D. Harris, J. Phillip Holloman, Catherine A. Lynch and Arthur P. Steinmetz.
The shareholder proposal to terminate the investment management agreement between BMEZ and BlackRock Advisors, LLC was not approved by shareholders:
The vote standard to approve the shareholder proposal is described in BMEZ
’
s most recent proxy statement.
The Annual Meeting of Shareholders of BIGZ (the “Meeting”) was held on June 25, 2024 for shareholders of record on April 3, 2024 to consider and vote on the election of four
Class I Trustees and three Class II Trustees and to consider and vote on a shareholder proposal submitted by an activist hedge fund to terminate the investment management
agreement between BIGZ and BlackRock Advisors, LLC. There were no broker non-votes.
The vote results in the election of Class I Trustees were as follows:
The vote results in the election of Class II Trustees were as follows:
Additional Information
163
Additional Information
(continued)
No nominee received the required number of votes to be re-elected or elected to the Board of BIGZ. The vote standard to elect Board members is described in BIGZ
’
s most
recent proxy statement. Cynthia L. Egan, Lorenzo A. Flores, Stayce D. Harris, and Catherine A. Lynch, incumbent Class I Trustees, will continue to serve as Class I Trustees
and R. Glenn Hubbard, W. Carl Kester and John M. Perlowski, incumbent Class II Trustees, will continue to serve as Class II Trustees until their successors have been duly
elected and qualified.
The Trustees of BIGZ whose term of office continued after the Meeting because they were not up for election are Robert Fairbairn, J. Phillip Holloman and Arthur P. Steinmetz.
The shareholder proposal to terminate the investment management agreement between BIGZ and BlackRock Advisors, LLC was not approved by shareholders:
The vote standard to approve the shareholder proposal is described in BIGZ
’
s most recent proxy statement.
The Annual Meeting of Shareholders of BSTZ (the “Meeting”) was held on June 18, 2024 and adjourned to July 16, 2024 for shareholders of record on April 22, 2024 to
consider and vote on the election of three Class II Trustees and to consider and vote on a shareholder proposal submitted by an activist hedge fund to terminate the investment
management agreement between BSTZ and BlackRock Advisors, LLC. The Meeting was initially called for June 18, 2024, but adjourned to July 16, 2024 to seek additional
shareholder participation. There were no broker non-votes.
The vote results in the election of Class II Trustees were as follows:
No nominee received the required number of votes to be re-elected or elected to the Board of BSTZ. The vote standard to elect Board members is described in BSTZ
’
s most
recent proxy statement. R. Glenn Hubbard, W. Carl Kester and John M. Perlowski, incumbent Class II Trustees, will continue to serve as Class II Trustees until their successors
have been duly elected and qualified.
The Trustees of BSTZ whose term of office continued after the Meeting because they were not up for election are Cynthia L. Egan, Robert Fairbairn, Lorenzo A. Flores, Stayce
D. Harris, J. Phillip Holloman, Catherine A. Lynch and Arthur P. Steinmetz.
The shareholder proposal to terminate the investment management agreement between BSTZ and BlackRock Advisors, LLC was not approved by shareholders:
The vote standard to approve the shareholder proposal is described in BSTZ
’
s most recent proxy statement.
The Trusts
are listed for trading on the NYSE and have filed with the NYSE their annual chief executive officer certification regarding compliance with the NYSE’s listing
standards. The Trusts filed with the SEC the certification of its chief executive officer and chief financial officer required by Section 302 of the Sarbanes-Oxley Act.
Environmental, Social and Governance (“ESG”) Integration
Although the Trusts do not seek to implement a specific sustainability objective, strategy or process unless otherwise disclosed, Trust management will consider ESG factors
as part of the investment process for the Trusts. Trust management views ESG integration as the practice of incorporating financially material ESG data or information into
investment processes with the objective of enhancing risk-adjusted returns. These ESG considerations will vary depending on the Trusts
’
particular investment strategies and
may include consideration of third-party research as well as consideration of proprietary BlackRock research across the ESG risks and opportunities regarding an issuer. The
ESG characteristics utilized in the Trusts
’
investment process are anticipated to evolve over time and one or more characteristics may not be relevant with respect to all issuers
that are eligible for investment. Certain of these considerations may affect the Trusts
’
exposure to certain companies or industries. While Trust management views ESG
considerations as having the potential to contribute to the Trusts
’
long-term performance, there is no guarantee that such results will be achieved.
164
2024
BlackRock Semi-Annual Report to Shareholders
Additional Information
(continued)
Each Trust’s policy is to make monthly distributions to shareholders. In order to provide shareholders with a more stable level of dividend distributions, each Trust employs a
managed distribution plan (the "Plan"), the goal of which is to provide shareholders with consistent and predictable cash flows by setting distribution rates based on expected
long-term returns of each Trust.
The distributions paid by each Trust for any particular month may be more or less than the amount of net investment income earned by each Trust during such month.
Furthermore, the final tax characterization of distributions is determined after the year-end of each Trust and is reported in each Trust’s annual report to shareholders.
Distributions can be characterized as ordinary income, capital gains and/or return of capital. Each Trust’s taxable net investment income and net realized capital gains
(“taxable income”) may not be sufficient to support the level of distributions paid. To the extent that distributions exceed the Trust’s current and accumulated earnings and
profits, the excess may be treated as a non-taxable return of capital.
A return of capital is a return of a portion of an investor’s original investment. A return of capital is not expected to be taxable, but it reduces a shareholder’s tax basis in his or
her shares, thus reducing any loss or increasing any gain on a subsequent disposition by the shareholder of his or her shares. It is possible that a substantial portion of the
distributions paid during a calendar year may ultimately be classified as return of capital for U.S. federal income tax purposes when the final determination of the source and
character of the distributions is made.
Such distributions, under certain circumstances, may exceed a Trust’s total return performance. When total distributions exceed total return performance for the period, the
difference reduces the Trust’s total assets and net asset value (“NAV”) per share and, therefore, could have the effect of increasing the Trust’s expense ratio and reducing the
amount of assets the Trust has available for long term investment.
The Trusts, other than BDJ, BME, BST and BUI, do not make available copies of their Statements of Additional Information because the Trusts
’
shares, other than BDJ, BME,
BST and BUI, are not continuously offered, which means that the Statement of Additional Information of each Trust, other than BDJ, BME, BST and BUI, has not been updated
after completion of the respective Trust’s offerings and the information contained in each Trust’s Statement of Additional Information may have become outdated.
BDJ
’
s, BME
’
s, BST
’
s and BUI
’
s Statements of Additional Information include additional information about the Board and are available, without charge upon request by
calling (800)882-0052.
The following information is a summary of certain changes since December 31, 2023. This information may not reflect all of the changes that have occurred since you
purchased the relevant Trust.
Except if noted otherwise herein, there were no changes to the Trusts
’
charters or by-laws that would delay or prevent a change of control of the Trusts that were not approved
by the shareholders.
In accordance with Section 23(c) of the Investment Company Act of 1940, each Trust may from time to time purchase shares of its common stock in the open market or in
private transactions.
Quarterly performance, semi-annual and annual reports, current net asset value and other information regarding the Trusts may be found on BlackRock’s website, which can
be accessed at
. Any reference to BlackRock’s website in this report is intended to allow investors public access to information regarding the Trusts and does
not, and is not intended to, incorporate BlackRock’s website in this report.
Shareholders can sign up for e-mail notifications of quarterly statements, annual and semi-annual shareholder reports and, for BDJ, BME, BST and BUI only, prospectuses, by
enrolling in the electronic delivery program. Electronic copies of shareholder reports and, for BDJ, BME, BST and BUI only, prospectuses, are available on BlackRock’s
website.
To enroll in electronic delivery:
Shareholders Who Hold Accounts with Investment Advisers, Banks or Brokerages:
Please contact your financial adviser. Please note that not all investment advisers, banks or brokerages may offer this service.
The Trusts will mail only one copy of shareholder documents, including for BDJ, BME, BST and BUI only, prospectuses, annual and semi-annual reports, Rule 30e-3 notices
and proxy statements, to shareholders with multiple accounts at the same address. This practice is commonly called “householding” and is intended to reduce expenses and
eliminate duplicate mailings of shareholder documents. Mailings of your shareholder documents may be householded indefinitely unless you instruct us otherwise. If you do
not want the mailing of these documents to be combined with those for other members of your household, please call the Trusts
at (800) 882-0052.
Additional Information
165
Additional Information
(continued)
Availability of Quarterly Schedule of Investments
The Trusts file their complete schedules of portfolio holdings with the SEC for the first and third quarters of each fiscal year as an exhibit to their reports on Form N-PORT. The
Trusts
’
Forms N-PORT are available on the SEC’s website at
. Additionally, each Trust makes its portfolio holdings for the first and third quarters of each fiscal year
available at
blackrock.com/fundreports
.
Availability of Proxy Voting Policies, Procedures and Voting Records
A description of the policies and procedures that the Trusts use to determine how to vote proxies relating to portfolio securities and information about how the Trusts voted
proxies relating to securities held in the Trusts
’
portfolios during the most recent 12-month period ended June 30 is available without charge, upon request (1) by calling (800)
882-0052; (2) on the BlackRock website at
; and (3) on the SEC’s website at
.
Availability of Trust Updates
BlackRock will update performance and certain other data for the Trusts on a monthly basis on its website in the “Closed-end Funds” section of
as well as
certain other material information as necessary from time to time. Investors and others are advised to check the website for updated performance information and the release
of other material information about the Trusts. This reference to BlackRock’s website is intended to allow investors public access to information regarding the Trusts and does
not, and is not intended to, incorporate BlackRock’s website in this report.
From time to time, BDJ, BME, BST and BUI may seek to raise additional equity capital through a Shelf Offering. In a Shelf Offering, BDJ, BME, BST and BUI may, subject to
market conditions, raise additional equity capital by issuing new Common Shares from time to time in varying amounts at a net price at or above BDJ
’
s, BME
’
s, BST
’
s and BUI
’
s
net asset value (“NAV”) per Common Share (calculated within 48 hours of pricing). While any such Shelf Offering may allow BDJ, BME, BST and BUI to pursue additional
investment opportunities without the need to sell existing portfolio investments, it could also entail risks – including that the issuance of additional Common Shares may limit
the extent to which the Common Shares are able to trade at a premium to NAV in the secondary market.
BDJ, BME, BST and BUI filed final prospectuses with the SEC in connection with its Shelf Offering on June 2, 2023, April 26, 2022, May 10, 2022 and March 10, 2022,
respectively. This report and the prospectuses of BDJ, BME, BST and BUI are not offers to sell BDJ, BME, BST and BUI Common Shares or solicitations of an offer to buy BDJ,
BME, BST and BUI Common Shares in any jurisdiction where such offers or sales are not permitted. The prospectuses of BDJ, BME, BST and BUI contains important
information about BDJ, BME, BST and BUI, including their investment objectives, risks, charges and expenses. Investors are urged to read the prospectuses of BDJ, BME,
BST and BUI carefully and in their entirety before investing. Copies of the final prospectuses for BDJ, BME, BST and BUI can be obtained from BlackRock at
.
BlackRock Privacy Principles
BlackRock is committed to maintaining the privacy of its current and former fund investors and individual clients (collectively, “Clients”) and to safeguarding their non-public
personal information. The following information is provided to help you understand what personal information BlackRock collects, how we protect that information and why in
certain cases we share such information with select parties.
If you are located in a jurisdiction where specific laws, rules or regulations require BlackRock to provide you with additional or different privacy-related rights beyond what is set
forth below, then BlackRock will comply with those specific laws, rules or regulations.
BlackRock obtains or verifies personal non-public information from and about you from different sources, including the following: (i) information we receive from you or, if
applicable, your financial intermediary, on applications, forms or other documents; (ii) information about your transactions with us, our affiliates, or others; (iii) information we
receive from a consumer reporting agency; and (iv) from visits to our websites.
BlackRock does not sell or disclose to non-affiliated third parties any non-public personal information about its Clients, except as permitted by law or as is necessary to respond
to regulatory requests or to service Client accounts. These non-affiliated third parties are required to protect the confidentiality and security of this information and to use it only
for its intended purpose.
We may share information with our affiliates to service your account or to provide you with information about other BlackRock products or services that may be of interest to
you. In addition, BlackRock restricts access to non-public personal information about its Clients to those BlackRock employees with a legitimate business need for the
information. BlackRock maintains physical, electronic and procedural safeguards that are designed to protect the non-public personal information of its Clients, including
procedures relating to the proper storage and disposal of such information.
Trust and Service Providers
BlackRock Advisors, LLC
Wilmington, DE 19809
BlackRock International Limited
(a)
Edinburgh, EH3 8BL
United Kingdom
166
2024
BlackRock Semi-Annual Report to Shareholders
Additional Information
(continued)
Trust and Service Providers (continued)
Accounting Agent and Custodian
State Street Bank and Trust Company
Boston, MA 02114
Computershare Trust Company, N.A.
Canton, MA 02021
BlackRock Investments, LLC
(b)
New York, NY 10001
(a)
For BGR, BOE, BGY, BCX and BUI.
(b)
For BDJ, BME, BST and BUI.
Independent Registered Public Accounting Firm
Deloitte & Touche LLP
Boston, MA 02116
Willkie Farr & Gallagher LLP
New York, NY 10019
100 Bellevue Parkway
Wilmington, DE 19809
Additional Information
167
Glossary of Terms Used in this Report
|
| American Depositary Receipt |
| |
| |
| |
| Private Investment in Public Equity |
| Public Joint Stock Company |
| Real Estate Investment Trust |
| |
| |
168
2024
BlackRock Semi-Annual Report to Shareholders
THIS PAGE INTENTIONALLY LEFT BLANK.
THIS PAGE INTENTIONALLY LEFT BLANK.
THIS PAGE INTENTIONALLY LEFT BLANK.
blackrock.com
|
800-882-0052
This report is intended for current holders. It is not a prospectus. Past performance results shown in this report should not be
considered a representation of future performance. Statements and other information herein are as dated and are subject to
change.
(b) Not Applicable
| Item 2 – | Code of Ethics – Not Applicable to this semi-annual report |
| Item 3 – | Audit Committee Financial Expert – Not Applicable to this semi-annual report |
| Item 4 – | Principal Accountant Fees and Services – Not Applicable to this semi-annual report |
| Item 5 – | Audit Committee of Listed Registrant – Not Applicable to this semi-annual report |
(a) The registrant’s Schedule of Investments is included as part of the Report to Stockholders filed under Item 1(a) of this Form.
(b) Not Applicable due to no such divestments during the semi-annual period covered since the previous Form N-CSR filing.
| Item 7 – | Financial Statements and Financial Highlights for Open-End Management Investment Companies – Not Applicable |
| Item 8 – | Changes in and Disagreements with Accountants for Open-End Management Investment Companies – Not Applicable |
| Item 9 – | Proxy Disclosures for Open-End Management Investment Companies – Not Applicable |
| Item 10 – | Remuneration Paid to Directors, Officers, and Others of Open-End Management Investment Companies – Not Applicable |
| Item 11 – | Statement Regarding Basis for Approval of Investment Advisory Contract – The registrant’s statement regarding the basis for approval of the investment advisory contract is included as part of the Report to Stockholders filed under Item 1(a) of this Form. |
| Item 12 – | Disclosure of Proxy Voting Policies and Procedures for Closed-End Management Investment Companies – Not Applicable to this semi-annual report |
| Item 13 – | Portfolio Managers of Closed-End Management Investment Companies |
(a) Not Applicable to this semi-annual report
(b) As of the date of this filing, there have been no changes in any of the portfolio managers identified in the most recent annual report on Form N-CSR.
| Item 14 – | Purchases of Equity Securities by Closed-End Management Investment Company and Affiliated Purchasers – Not Applicable due to no such purchases during the period covered by this report. |
| Item 15 – | Submission of Matters to a Vote of Security Holders – There have been no material changes to these procedures. |
| Item 16 – | Controls and Procedures |
(a) The registrant’s principal executive and principal financial officers, or persons performing similar functions, have concluded that the registrant’s disclosure controls and procedures (as defined in Rule 30a-3(c) under the Investment Company Act of 1940, as amended (the “1940 Act”)) are effective as of a date within 90 days of the filing date of this report based on the evaluation of these controls and procedures required by Rule 30a-3(b) under the 1940 Act and Rule 13a-15(b) or 15d-15(b) under the Securities Exchange Act of 1934, as amended.
(b) There were no changes in the registrant’s internal control over financial reporting (as defined in Rule 30a-3(d) under the 1940 Act) that occurred during the period covered by this report that have materially affected, or are reasonably likely to materially affect, the registrant’s internal control over financial reporting.
| Item 17 – | Disclosure of Securities Lending Activities for Closed-End Management Investment Companies – Not Applicable to this semi-annual report |
| Item 18 – | Recovery of Erroneously Awarded Compensation – Not Applicable |
| Item 19 – | Exhibits attached hereto |
(a)(1) Code of Ethics – Not Applicable to this semi-annual report
(a)(2) Any policy required by the listing standards adopted pursuant to Rule 10D-1 under the Exchange Act (17 CFR 240.10D-1) by the registered national securities exchange or registered national securities association upon which the registrant’s securities are listed – Not Applicable
(a)(3) Section 302 Certifications are attached
(a)(4) Any written solicitation to purchase securities under Rule 23c-1 – Not Applicable
(a)(5) Change in Registrant’s independent public accountant – Not Applicable
(b) Section 906 Certifications are attached
(c) Notices to the registrant’s common shareholders in accordance with the order under Section 6(c) of the 1940 Act granting an exemption from Section 19(b) of the 1940 Act and Rule 19b-1 under the 1940 Act, dated May 9, 20091
| 1 | | The Fund has received exemptive relief from the Securities and Exchange Commission permitting it to make periodic distributions of long-term capital gains with respect to its outstanding common stock as frequently as twelve times each year, and as frequently as distributions are specified by or in accordance with the terms of its outstanding preferred stock. This relief is conditioned, in part, on an undertaking by the Fund to make the disclosures to the holders of the Fund’s common shares, in addition to the information required by Section 19(a) of the 1940 Act and Rule 19a-1 thereunder. The Fund is likewise obligated to file with the SEC the information contained in any such notice to shareholders and, in that regard, has attached hereto copies of each such notice made during the period. |
Pursuant to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
BlackRock Enhanced Equity Dividend Trust
| | | | |
| | By: | | /s/ John M. Perlowski |
| | | | John M. Perlowski |
| | | | Chief Executive Officer (principal executive officer) of |
| | | | BlackRock Enhanced Equity Dividend Trust |
Date: August 23, 2024
Pursuant to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| | | | |
| | By: | | /s/ John M. Perlowski |
| | | | John M. Perlowski |
| | | | Chief Executive Officer (principal executive officer) of |
| | | | BlackRock Enhanced Equity Dividend Trust |
Date: August 23, 2024
| | | | |
| | By: | | /s/ Trent Walker |
| | | | Trent Walker |
| | | | Chief Financial Officer (principal financial officer) of |
| | | | BlackRock Enhanced Equity Dividend Trust |
Date: August 23, 2024
